1
00:00:07,875 --> 00:00:11,612
>> SO, WELCOME BACK,
EVERYBODY. 

2
00:00:11,612 --> 00:00:14,481
IT IS MY ABSOLUTE PLEASURE TO 

3
00:00:14,481 --> 00:00:17,951
INTRODUCE OUR NEXT SPEAKER 

4
00:00:17,951 --> 00:00:22,055
MONICA BER TIG NOELI.  AS MANY 

5
00:00:22,055 --> 00:00:24,224
KNOW SHE PREVIOUSLY SERVED AS 

6
00:00:24,224 --> 00:00:27,461
DIRECTOR OF NATIONAL CANCER 

7
00:00:27,461 --> 00:00:28,428
INSTITUTE BEFORE STARTING ROLE 

8
00:00:28,428 --> 00:00:31,131
AS NIH DIRECTOR THIS PAST 

9
00:00:31,131 --> 00:00:33,200
NOVEMBER.  SHE HAS BEEN A CANCER

10
00:00:33,200 --> 00:00:35,202
SURGEON FOR MORE THAN 35 YEARS 

11
00:00:35,202 --> 00:00:40,440
BRAND JOINING NCI SHE JOINED IN 

12
00:00:40,440 --> 00:00:44,611
SURGERY AND ONCOLOGY AT HARVARD 

13
00:00:44,611 --> 00:00:46,313
MEDICAL SCHOOL. 

14
00:00:46,313 --> 00:00:50,417
AND SAR COMA CENTERS AT DANA 

15
00:00:50,417 --> 00:00:53,120
FARM INSTITUTE THROUGHOUT CAREER

16
00:00:53,120 --> 00:00:55,255
SHE HAS LED TRANSLATIONAL 

17
00:00:55,255 --> 00:00:59,393
SCIENCE INITIATIVES WITHIN 

18
00:00:59,393 --> 00:01:02,462
NCI-FUNDED COOPERATIVE GROUPS 

19
00:01:02,462 --> 00:01:04,298
PROGRAMS AND HAS WAY TOO MANY 

20
00:01:04,298 --> 00:01:07,267
ACCOMPLISHMENTS AND CREDENTIALS 

21
00:01:07,267 --> 00:01:10,537
TOE GO THROUGH THIS SHORT TIME. 

22
00:01:10,537 --> 00:01:13,473
I COULD SPEND NEXT HOUR 

23
00:01:13,473 --> 00:01:14,374
DESCRIBING THESE.  YOU WOULD 

24
00:01:14,374 --> 00:01:16,443
LOVE TO HEAR FROM HER.  I WILL 

25
00:01:16,443 --> 00:01:19,947
TURN IT OVER TO LOOK FOR DR. 

26
00:01:19,947 --> 00:01:21,748
BERTAGNOLLI.  I WILL UPLOAD YOUR

27
00:01:21,748 --> 00:01:21,982
SLIDES. 

28
00:01:21,982 --> 00:01:24,151
>> HOW ARE WE DOING?  YES,

29
00:01:24,151 --> 00:01:25,319
PLEASE, THE SLIDES. 

30
00:01:25,319 --> 00:01:29,089
THANK YOU SO MUCH FOR THE KIND 

31
00:01:29,089 --> 00:01:31,992
INTRODUCTION.  THIS IS AN 

32
00:01:31,992 --> 00:01:33,827
INVITATION I ACCEPTED AFTER 

33
00:01:33,827 --> 00:01:36,129
BECOMING NIH DIRECTOR IN 

34
00:01:36,129 --> 00:01:38,999
NOVEMBER.  I'M EXCITED ABOUT 

35
00:01:38,999 --> 00:01:39,866
POTENTIAL PARTNERSHIP BETWEEN 

36
00:01:39,866 --> 00:01:43,804
NIH AND INDUSTRY AND HAVE TO SAY

37
00:01:43,804 --> 00:01:46,239
THROUGHOUT MY CAREER I HAVE BEEN

38
00:01:46,239 --> 00:01:47,708
ABLE TO PARTICIPATE IN 

39
00:01:47,708 --> 00:01:50,277
PARTNERSHIPS OF THIS TYPE THAT 

40
00:01:50,277 --> 00:01:52,112
HAVE BEEN INCREDIBLY VALUABLE. 

41
00:01:52,112 --> 00:01:53,113
NEXT SLIDE. 

42
00:01:53,113 --> 00:01:56,249
I WILL HAVE SOMEBODY RUN -- 

43
00:01:56,249 --> 00:01:56,550
THANK YOU. 

44
00:01:56,550 --> 00:01:58,185
BEFORE BECOMING NIH DIRECTOR I 

45
00:01:58,185 --> 00:02:00,520
WAS A CANCER SURGEON AND 

46
00:02:00,520 --> 00:02:02,389
RESEARCHER AND YOU SEE FROM THE 

47
00:02:02,389 --> 00:02:04,558
PHOTOS I GREW UP FROM 

48
00:02:04,558 --> 00:02:06,126
INTERMOUNTAIN WEST AND STILL 

49
00:02:06,126 --> 00:02:07,327
RETURN THERE. 

50
00:02:07,327 --> 00:02:10,597
THIS HAS GIVEN ME A PASSION FOR 

51
00:02:10,597 --> 00:02:13,967
ENSURING THAT INNOVATION IN 

52
00:02:13,967 --> 00:02:15,202
HEALTH REACHES EVERYONE WHO CAN 

53
00:02:15,202 --> 00:02:16,737
BENEFIT INCLUDING THOSE WHO LIVE

54
00:02:16,737 --> 00:02:20,540
IN RURAL COMMUNITIES FAR FROM 

55
00:02:20,540 --> 00:02:26,513
MAJOR HUBS OF ACADEMIC LIFE. 

56
00:02:26,513 --> 00:02:29,316
THESE ARE TOPICS I WILL DISCUSS 

57
00:02:29,316 --> 00:02:29,683
TODAY. 

58
00:02:29,683 --> 00:02:30,684
NEXT SLIDE. 

59
00:02:30,684 --> 00:02:32,786
LY HELP INTRODUCE YOU TO NIH. 

60
00:02:32,786 --> 00:02:34,087
YOU KNOW NIH. 

61
00:02:34,087 --> 00:02:37,391
THIS IS A BIG AND VERY COMPLEX 

62
00:02:37,391 --> 00:02:38,992
PLACE AND WITH THIS CONFERENCE 

63
00:02:38,992 --> 00:02:40,994
HOPE TO MAKE IT EASIER FOR YOU 

64
00:02:40,994 --> 00:02:42,329
TO NAVIGATE. 

65
00:02:42,329 --> 00:02:44,831
AT NIH WE SEEK FUNDAMENTAL 

66
00:02:44,831 --> 00:02:46,566
KNOWLEDGE ABOUT NATURE AND 

67
00:02:46,566 --> 00:02:48,368
BEHAVIOR OF LIVING SYSTEMS AND 

68
00:02:48,368 --> 00:02:50,370
TO APPLY THAT KNOWLEDGE IN WAYS 

69
00:02:50,370 --> 00:02:54,441
THAT IMPROVE HEALTH FOR ALL. 

70
00:02:54,441 --> 00:02:55,809
TODAY'S DISCUSSIONS WILL REVOLVE

71
00:02:55,809 --> 00:02:58,078
AROUND TRANSLATIONAL PART OF OUR

72
00:02:58,078 --> 00:02:59,980
MISSION AND ACTUAL APPLICATION 

73
00:02:59,980 --> 00:03:02,349
OF KNOWLEDGE TO IMPROVE HEALTH. 

74
00:03:02,349 --> 00:03:04,251
NEXT SLIDE. 

75
00:03:04,251 --> 00:03:06,686
NIH TODAY SUPPORTS RESEARCH 

76
00:03:06,686 --> 00:03:09,389
AROUND THE COUNTRY AND INDEED 

77
00:03:09,389 --> 00:03:12,325
THROUGHOUT THE WORLD AND TRAINS 

78
00:03:12,325 --> 00:03:13,193
INVESTIGATORS CONDUCTING 

79
00:03:13,193 --> 00:03:15,896
RESEARCH IN ITS OWN 

80
00:03:15,896 --> 00:03:16,229
LABORATORIES. 

81
00:03:16,229 --> 00:03:17,531
NEXT SLIDE. 

82
00:03:17,531 --> 00:03:21,001
NIH BUDGET IN FISCAL YEAR 2023 

83
00:03:21,001 --> 00:03:24,938
WAS $47.3 BILLION AND LARGE 

84
00:03:24,938 --> 00:03:27,007
MAJORITY OF NIH SPENDING IS MADE

85
00:03:27,007 --> 00:03:29,976
UP OF GRANTS TO RESEARCHERS AT 

86
00:03:29,976 --> 00:03:31,611
UNIVERSITIES, MEDICAL SCHOOLS 

87
00:03:31,611 --> 00:03:33,213
AND SCIENTIFIC INSTITUTIONS 

88
00:03:33,213 --> 00:03:35,282
OUTSIDE OF THE NIH WALLS. 

89
00:03:35,282 --> 00:03:39,186
IN FUTURE YEARS WE HOPE TO 

90
00:03:39,186 --> 00:03:40,854
INCORPORATE MORE INFORMATION ON 

91
00:03:40,854 --> 00:03:42,522
THIS VERY LARGE EXTRAMURAL 

92
00:03:42,522 --> 00:03:44,925
RESEARCH PROGRAM INTO THIS 

93
00:03:44,925 --> 00:03:45,225
CONFERENCE. 

94
00:03:45,225 --> 00:03:47,828
TODAY, WE ARE FOCUSING ON THE 

95
00:03:47,828 --> 00:03:50,630
NIH INTRAMURAL RESEARCH PROGRAM 

96
00:03:50,630 --> 00:03:54,768
TO WHICH WE DEVOTE ABOUT 11% OF 

97
00:03:54,768 --> 00:03:56,203
NIH'S TOTAL BUDGET. 

98
00:03:56,203 --> 00:03:57,971
NEXT SLIDE. 

99
00:03:57,971 --> 00:03:59,406
INTRAMURAL RESEARCH PROGRAM 

100
00:03:59,406 --> 00:04:02,142
LARGELY LOCATED IN MARYLAND 

101
00:04:02,142 --> 00:04:05,445
INCLUDES MORE THAN 3,000 ACTIVE 

102
00:04:05,445 --> 00:04:07,514
PROJECTS AND MORE THAN 6,000 

103
00:04:07,514 --> 00:04:10,217
SCIENTISTS ENGAGED IN 

104
00:04:10,217 --> 00:04:12,319
COLLABORATIVE RESEARCH AND 

105
00:04:12,319 --> 00:04:14,821
ACTIVE IN PATENTING AND 

106
00:04:14,821 --> 00:04:16,123
LICENSING OUR WORK. 

107
00:04:16,123 --> 00:04:18,625
NIH IS MADE UP OF 27 INSTITUTES 

108
00:04:18,625 --> 00:04:21,628
AND CENTERS AND EACH HAS ITS OWN

109
00:04:21,628 --> 00:04:25,499
SPECIFIC RESEARCH AGENDA. 

110
00:04:25,499 --> 00:04:26,967
EACH ADMINISTERS ITS OWN BUDGET.

111
00:04:26,967 --> 00:04:29,569
23 OF INSTITUTES AND CENTERS 

112
00:04:29,569 --> 00:04:31,605
ARE INVOLVED IN FUNDING AND 

113
00:04:31,605 --> 00:04:35,142
DIRECTING INTRAMURAL RESEARCH. 

114
00:04:35,142 --> 00:04:35,976
NEXT SLIDE. 

115
00:04:35,976 --> 00:04:39,212
AT NIH, WE TRY TO KEEP OUR 

116
00:04:39,212 --> 00:04:41,815
ULTIMATE GOALS IN THE FOREGROUND

117
00:04:41,815 --> 00:04:43,283
ALWAYS WHEN WE THINK ABOUT 

118
00:04:43,283 --> 00:04:47,521
DELIVERING ON NIH'S MISSION, WE 

119
00:04:47,521 --> 00:04:52,592
KNOW THAT INCLUDES MAKING SURE 

120
00:04:52,592 --> 00:04:54,561
INSIGHTS AND DISCOVERIES 

121
00:04:54,561 --> 00:04:55,629
EMERGING INTO RESEARCH GET OUT 

122
00:04:55,629 --> 00:04:58,532
INTO THE WORLD AND IMPROVE NIH'S

123
00:04:58,532 --> 00:05:01,234
LIVE AND IS NOT DONE WHEN 

124
00:05:01,234 --> 00:05:03,236
INVESTIGATORS PUBLISH A PAPER. 

125
00:05:03,236 --> 00:05:05,305
PEOPLE'S LIVES CAN ONLY GET 

126
00:05:05,305 --> 00:05:07,274
BETTER IF THEY CAN ACCESS 

127
00:05:07,274 --> 00:05:09,876
PRODUCTS AND SERVICES THAT ARE 

128
00:05:09,876 --> 00:05:11,645
BUILT UPON OUR WORK. 

129
00:05:11,645 --> 00:05:13,847
NIH DOES NOT BRING NEW PRODUCTS 

130
00:05:13,847 --> 00:05:15,782
AND SERVICES TO MARKET. 

131
00:05:15,782 --> 00:05:18,718
AGENCY AND NATION RELY ON 

132
00:05:18,718 --> 00:05:21,555
PRODUCTIVE INDUSTRY PARTNERSHIPS

133
00:05:21,555 --> 00:05:24,191
TO ACHIEVE THIS NEXT SLIDE. 

134
00:05:24,191 --> 00:05:26,393
THERE ARE UNIQUE BENEFITS FROM 

135
00:05:26,393 --> 00:05:29,229
NIH INDUSTRY PARTNERSHIPS. 

136
00:05:29,229 --> 00:05:31,231
CHANCE TO WORK TOGETHER TO 

137
00:05:31,231 --> 00:05:32,732
IMPROVE HUMAN HEALTH IS AT THE 

138
00:05:32,732 --> 00:05:34,301
TOP OF THE LIST. 

139
00:05:34,301 --> 00:05:38,572
TO THAT END AGENCY'S INTRAMURAL 

140
00:05:38,572 --> 00:05:39,806
PROGRAM DELIVERS TOP-NOTCH 

141
00:05:39,806 --> 00:05:41,541
SCIENCE AND INDUSTRY PARTNERS 

142
00:05:41,541 --> 00:05:43,343
HAVE OPPORTUNITY TO TURN THOSE 

143
00:05:43,343 --> 00:05:45,178
DISCOVERIES INTO NEW PRODUCTS 

144
00:05:45,178 --> 00:05:48,181
AND SERVICES AND INTRAMURAL 

145
00:05:48,181 --> 00:05:49,850
PROGRAM IS SPECIAL IN THAT IT 

146
00:05:49,850 --> 00:05:53,220
FOCUSES PRIMARILY ON WORK THAT 

147
00:05:53,220 --> 00:05:58,158
IS NOT OR WILL NOT BE DONE 

148
00:05:58,158 --> 00:05:58,925
ELSEWHERE. 

149
00:05:58,925 --> 00:06:01,261
ADVANCING TECHNOLOGIES CRYO-EM 

150
00:06:01,261 --> 00:06:05,365
AND DATA INITIATIVES AND 

151
00:06:05,365 --> 00:06:06,032
SUPERCOMPUTING FACILITIES 

152
00:06:06,032 --> 00:06:08,535
DEPARTMENT OF DEFENSE RARE 

153
00:06:08,535 --> 00:06:09,135
DISEASE CHARACTERIZATION AND 

154
00:06:09,135 --> 00:06:10,170
THERAPY DEVELOPMENT WORK AGO 

155
00:06:10,170 --> 00:06:13,673
CROSS THE WORLD AND ACROSS ALL 

156
00:06:13,673 --> 00:06:19,246
OF GOVERNMENT TO IDENTIFY 

157
00:06:19,246 --> 00:06:20,647
EMERGING INFECTIOUS DISEASE 

158
00:06:20,647 --> 00:06:23,116
THREATS TARGETING FOR PREVENTION

159
00:06:23,116 --> 00:06:25,218
AND TO IDENTIFY A VERY FEW 

160
00:06:25,218 --> 00:06:27,687
ASPECTS OF NIH INTRAMURAL 

161
00:06:27,687 --> 00:06:30,323
RESEARCH THAT WE RELY ON. 

162
00:06:30,323 --> 00:06:32,759
THESE FRUITFUL INDEAFORS SPIN 

163
00:06:32,759 --> 00:06:35,095
OFF FUNDAMENTAL KNOWLEDGE THAT 

164
00:06:35,095 --> 00:06:36,896
APPLIES TO EVERYTHING IN HEALTH 

165
00:06:36,896 --> 00:06:39,165
AND BROAD PARTNERSHIP IS 

166
00:06:39,165 --> 00:06:44,571
ENCOURAGED AND PRODUCED MANY 

167
00:06:44,571 --> 00:06:45,138
SUCCESSES. 

168
00:06:45,138 --> 00:06:47,073
PUBLIC HEALTH CHALLENGE WE FACE 

169
00:06:47,073 --> 00:06:50,143
IS [INDISCERNIBLE] AND 10,000 

170
00:06:50,143 --> 00:06:51,978
DISEASES WE KNOW, 5% HAVE 

171
00:06:51,978 --> 00:06:53,213
TREATMENTS OR CURES AND 

172
00:06:53,213 --> 00:06:55,148
TYPICALLY TAKES MORE THAN 10 

173
00:06:55,148 --> 00:06:58,451
YEARS TO GO FROM AN IDEA FOR 

174
00:06:58,451 --> 00:07:00,987
DRUG FROM TESTING PROCESS TO 

175
00:07:00,987 --> 00:07:04,424
BRING IT TO MARKET AND LARGE 

176
00:07:04,424 --> 00:07:06,326
MAJORITY CANDIDATE THERAPIES 

177
00:07:06,326 --> 00:07:08,962
FAIL AND FOSTERING PUBLIC 

178
00:07:08,962 --> 00:07:10,997
PRIVATE COLLABORATION REMAINS 

179
00:07:10,997 --> 00:07:11,331
CRITICAL. 

180
00:07:11,331 --> 00:07:13,333
WE HAVE LOTS OF WORK TO DO. 

181
00:07:13,333 --> 00:07:14,301
NEXT SLIDE. 

182
00:07:14,301 --> 00:07:17,170
THE OPPORTUNITIES FOR NIH 

183
00:07:17,170 --> 00:07:18,838
INDUSTRY COLLABORATION TAKE A 

184
00:07:18,838 --> 00:07:19,973
VARIETY OF FORMS. 

185
00:07:19,973 --> 00:07:24,210
FOR EXAMPLE, NIH LICENSES ARE 

186
00:07:24,210 --> 00:07:25,912
PATENTS AND TECHNOLOGY AND 

187
00:07:25,912 --> 00:07:28,148
SUPPORTS COLLABORATIVE RESEARCH 

188
00:07:28,148 --> 00:07:33,653
THROUGH CREDICE AND AGENCY 

189
00:07:33,653 --> 00:07:36,890
SUPPORTS PUBLIC AND PRIVATE 

190
00:07:36,890 --> 00:07:38,958
PARTNERSHIPS AND EXAMPLE I LIKE 

191
00:07:38,958 --> 00:07:40,960
TO HIGHLIGHT ACCELERATING 

192
00:07:40,960 --> 00:07:42,462
MEDICINE PARTNERSHIPS IF YOU 

193
00:07:42,462 --> 00:07:45,799
DON'T KNOW AMP IS A PARTNERSHIP 

194
00:07:45,799 --> 00:07:49,235
AMONGST NIHFDA BIOPHARMA 

195
00:07:49,235 --> 00:07:51,037
COMPANIES AND NON-PROFIT 

196
00:07:51,037 --> 00:07:52,906
INSTITUTIONS AND GOAL IS TO 

197
00:07:52,906 --> 00:07:55,075
TRANSFORM CURRENT MODEL 

198
00:07:55,075 --> 00:07:57,077
DEVELOPING NEW DIAGNOSTICS AND 

199
00:07:57,077 --> 00:07:59,346
CURES AND PARTNER EXPERTISE AND 

200
00:07:59,346 --> 00:08:01,414
RESOURCES AIMING TO IMPROVE 

201
00:08:01,414 --> 00:08:02,982
UNDERSTANDING OF BIOLOGICAL 

202
00:08:02,982 --> 00:08:04,384
PATHWAYS AND TO VALIDATE 

203
00:08:04,384 --> 00:08:05,585
INFORMATION THAT COULD BE 

204
00:08:05,585 --> 00:08:08,621
RELEVANT TO DEVELOPING MULTIPLE 

205
00:08:08,621 --> 00:08:08,955
THERAPEUTICS. 

206
00:08:08,955 --> 00:08:11,424
WE ARE VERY APPRECIATIVE OF OUR 

207
00:08:11,424 --> 00:08:14,027
PRODUCTIVE RELATIONSHIP WITH THE

208
00:08:14,027 --> 00:08:16,629
-- THE INSTITUTE FOR THE -- THE 

209
00:08:16,629 --> 00:08:20,300
FOUNDATION FOR THE NIH IN 

210
00:08:20,300 --> 00:08:24,671
ACHIEVING THE AMP ACTIVITIES. 

211
00:08:24,671 --> 00:08:26,506
NCAPS, NATIONAL CENTER FOR 

212
00:08:26,506 --> 00:08:27,907
ADVANCING TRANSLATIONAL SCIENCE 

213
00:08:27,907 --> 00:08:30,910
IS NIH INSTITUTION THAT IS 

214
00:08:30,910 --> 00:08:33,480
DEVOTE ENTIRELY TO TRANSLATIONAL

215
00:08:33,480 --> 00:08:34,914
ACTIVITIES THAT IS ANOTHER HUB 

216
00:08:34,914 --> 00:08:38,084
OF THE PUBLIC AND PRIVATE 

217
00:08:38,084 --> 00:08:39,386
PARTNERSHIPS AND SUPPORT SMALL 

218
00:08:39,386 --> 00:08:40,820
BUSINESSES DEVELOPING TECHNOLOGY

219
00:08:40,820 --> 00:08:42,489
WITH COMMERCIAL POTENTIAL 

220
00:08:42,489 --> 00:08:45,625
THROUGH SBIR PROGRAM. 

221
00:08:45,625 --> 00:08:47,260
WE HAVE INNOVATION 

222
00:08:47,260 --> 00:08:49,729
ENTREPRENEURSHIP TRAINING 

223
00:08:49,729 --> 00:08:52,165
PROGRAMS LIKE ICORE AND 

224
00:08:52,165 --> 00:08:53,700
INVESTIGATORS CAN ACCESS TOOLS 

225
00:08:53,700 --> 00:08:56,302
TO BRING TREATMENTS TO PATIENTS.

226
00:08:56,302 --> 00:08:58,037
NIH DOESN'T LOOK FOR 

227
00:08:58,037 --> 00:08:59,239
COLLABORATIONS TO BE ARM'S 

228
00:08:59,239 --> 00:09:01,141
LENGTH TRANSACTIONS AND LOOK FOR

229
00:09:01,141 --> 00:09:02,642
TRUE COLLABORATIONS AND 

230
00:09:02,642 --> 00:09:04,477
OPPORTUNITIES TO SHARE 

231
00:09:04,477 --> 00:09:06,579
SCIENTIFIC AND REGULATORY 

232
00:09:06,579 --> 00:09:08,381
EXPERTISE, SHARE MATERIALS AND 

233
00:09:08,381 --> 00:09:12,318
OTHER RESOURCES THAT WE CAN 

234
00:09:12,318 --> 00:09:14,587
CONTRIBUTE FROM THE PUBLIC END. 

235
00:09:14,587 --> 00:09:17,724
NIH HAS MANY TOOLS TO ENABLE 

236
00:09:17,724 --> 00:09:19,993
INDUSTRY PARTNERSHIPS MEETING 

237
00:09:19,993 --> 00:09:23,263
NEEDS OF ALL PARTIES ADVANCING 

238
00:09:23,263 --> 00:09:23,930
PUBLIC HEALTH. 

239
00:09:23,930 --> 00:09:26,933
AS A GOVERNMENT AGENCY, WE HAVE 

240
00:09:26,933 --> 00:09:28,835
TO OPERATE WITHIN CERTAIN 

241
00:09:28,835 --> 00:09:30,270
STATUTORY FRAMEWORKS AND HAVE A 

242
00:09:30,270 --> 00:09:33,039
DIVERSITY OF OPTIONS HELPING US 

243
00:09:33,039 --> 00:09:35,708
BE CREATIVE AND FLEXIBLE AND 

244
00:09:35,708 --> 00:09:37,911
ULTIMATELY DELIVER WIN, WIN, WIN

245
00:09:37,911 --> 00:09:41,514
APPROACHES FOR THE AGENCY, OUR 

246
00:09:41,514 --> 00:09:44,284
PARTNERS, AND THE US TAXPAYER. 

247
00:09:44,284 --> 00:09:44,584
NEXT SLIDE. 

248
00:09:44,584 --> 00:09:46,653
I WOULD LIKE TO TOUCH ON 

249
00:09:46,653 --> 00:09:48,621
EXAMPLES OF SUCCESS STORIES AND 

250
00:09:48,621 --> 00:09:51,191
THIS SLIDE SHOWS JUST A FEW OF 

251
00:09:51,191 --> 00:09:53,293
THE VACCINES AND THERAPEUTIC 

252
00:09:53,293 --> 00:09:55,261
PRODUCTS ON THE MARKET THAT USE 

253
00:09:55,261 --> 00:09:57,163
SOME FORM OF TECHNOLOGY LICENSED

254
00:09:57,163 --> 00:10:00,233
FROM NIH'S INTRAMURAL PROGRAM 

255
00:10:00,233 --> 00:10:02,869
INCLUDING VACCINES FOR COVID-19 

256
00:10:02,869 --> 00:10:08,007
AND RSV AND TREATMENT FOR 

257
00:10:08,007 --> 00:10:11,244
PROGERIA AND ABILITY TO CLIFR 

258
00:10:11,244 --> 00:10:13,279
COVID-19 VACCINES IN RECORD TIME

259
00:10:13,279 --> 00:10:16,382
REFLECTS YEARS OF COLLABORATIVE 

260
00:10:16,382 --> 00:10:18,184
RESEARCH STARTING WELL BEFORE 

261
00:10:18,184 --> 00:10:21,855
THE PANDEMIC NIH INDUSTRY 

262
00:10:21,855 --> 00:10:24,691
ANDACDEMIA WORK TOGETHER ON 

263
00:10:24,691 --> 00:10:28,495
DEVELOPMENT OF MRNA VACCINES FOR

264
00:10:28,495 --> 00:10:32,765
CORONAVIRUSES HPV VACCINE GUARDO

265
00:10:32,765 --> 00:10:34,501
SIL AND [INDISCERNIBLE] NCI 

266
00:10:34,501 --> 00:10:36,503
SCIENTISTS ARE THOUGHT TO HAVE 

267
00:10:36,503 --> 00:10:42,275
AVERTED OVER 80,000 CASES AND 

268
00:10:42,275 --> 00:10:43,843
NEARLY 27,000 DEATHS FROM 

269
00:10:43,843 --> 00:10:47,247
CERVICAL CANCER IN THE UNITED 

270
00:10:47,247 --> 00:10:50,149
STATES ALONE PREVENTING NEARLY 

271
00:10:50,149 --> 00:10:51,918
600,000 FUTURE YEARS OF LIFE 

272
00:10:51,918 --> 00:10:59,859
LOST FROM 2008 TO 2019 A DECADE 

273
00:10:59,859 --> 00:11:07,200
ONLY. 

274
00:11:07,200 --> 00:11:12,605
 -- INCLUDING LOXTERNA TO TREAT 

275
00:11:12,605 --> 00:11:13,740
RETINAL DISEASE AND 

276
00:11:13,740 --> 00:11:20,747
[INDISCERNIBLE] AND ROCTAVIAN TO

277
00:11:20,747 --> 00:11:24,651
TREAT HEMOPHILIA RNA MORE TO 

278
00:11:24,651 --> 00:11:25,451
COME. 

279
00:11:25,451 --> 00:11:27,620
EXPERTISE THAT ARE 27 INSTITUTES

280
00:11:27,620 --> 00:11:31,457
AND CENTERS THAT BRING TO 

281
00:11:31,457 --> 00:11:33,192
PARTNERSHIPS AND SPANS 

282
00:11:33,192 --> 00:11:35,562
DIAGNOSTICS DEVICES AND 

283
00:11:35,562 --> 00:11:38,197
APPLICATIONS FOR ARTIFICIAL 

284
00:11:38,197 --> 00:11:41,367
INTELLIGENCE AND POTENTIAL 

285
00:11:41,367 --> 00:11:42,835
APPLICATIONS INCLUDE MED TECH 

286
00:11:42,835 --> 00:11:46,205
WEARABLES AND TECHNOLOGY FOR 

287
00:11:46,205 --> 00:11:48,041
HEALTH AND INTRAMURAL PROGRAM 

288
00:11:48,041 --> 00:11:49,642
COLLABORATOR DEVELOPED A SLEEP 

289
00:11:49,642 --> 00:11:51,844
MONITORING DEVICE CONNECTING 

290
00:11:51,844 --> 00:11:53,246
COMPREHENSIVE SLEEP DATA WORKING

291
00:11:53,246 --> 00:11:58,151
WITH NIH ON CLINICAL VALIDATION 

292
00:11:58,151 --> 00:12:04,123
OF THE DEVICE THIS COMPANY 

293
00:12:04,123 --> 00:12:06,759
SONOLOGY CAN SERVE AS A CASE 

294
00:12:06,759 --> 00:12:07,827
STUDY FOR THIS. 

295
00:12:07,827 --> 00:12:11,264
COLLABORATED WITH NIH IN 2017 TO

296
00:12:11,264 --> 00:12:13,666
STUDY THE EFFECT OF DIET AND 

297
00:12:13,666 --> 00:12:14,634
ENVIRONMENT ON SLEEP. 

298
00:12:14,634 --> 00:12:17,637
IN 2019, THE COMPANY PARTNERED 

299
00:12:17,637 --> 00:12:22,008
ALSO WITH THE VA TO EVALUATE 

300
00:12:22,008 --> 00:12:24,143
VETERANS ACROSS THE COMPANY 

301
00:12:24,143 --> 00:12:26,579
HELPING TO REDUCE VA COST FOR 

302
00:12:26,579 --> 00:12:29,082
SLEEP TESTING OF ITS PATIENTS. 

303
00:12:29,082 --> 00:12:34,420
IN 2021 SONOLOGY WON A MED TECH 

304
00:12:34,420 --> 00:12:36,155
BREAKTHROUGH AWARD FOR ITS 

305
00:12:36,155 --> 00:12:36,389
DEVICE. 

306
00:12:36,389 --> 00:12:40,159
I ENCOURAGE YOU TO VISIT NIH'S 

307
00:12:40,159 --> 00:12:41,594
OFFICE FOR TECH TRANSFER 

308
00:12:41,594 --> 00:12:41,961
WEBSITE. 

309
00:12:41,961 --> 00:12:46,099
YOU CAN SEE THE URL HERE. 

310
00:12:46,099 --> 00:12:48,001
SITE LISTS NIH TECHNOLOGIES 

311
00:12:48,001 --> 00:12:49,402
AVAILABLE FOR LICENSING. 

312
00:12:49,402 --> 00:12:51,404
THESE NUMBERS ARE UPDATED DAILY.

313
00:12:51,404 --> 00:12:58,878
YOU CAN SEE AREAS THAT THESE 

314
00:12:58,878 --> 00:13:00,680
CURRENTLY AVAILABLE TECHNOLOGIES

315
00:13:00,680 --> 00:13:01,648
ENCOMPASS. 

316
00:13:01,648 --> 00:13:02,715
NEXT SLIDE. 

317
00:13:02,715 --> 00:13:04,283
INDUSTRY COLLABORATION OFFERS 

318
00:13:04,283 --> 00:13:07,553
UNIQUE BENEFITS AND AGENCY HAS 

319
00:13:07,553 --> 00:13:10,790
ROBUST IN-HOUSE EXPERTISE 

320
00:13:10,790 --> 00:13:12,392
HELPING COMPANIES COMMERCIALIZE 

321
00:13:12,392 --> 00:13:14,560
PRODUCTS EXPERTISE ON TECHNOLOGY

322
00:13:14,560 --> 00:13:15,728
TRANSFER AND BUSINESS 

323
00:13:15,728 --> 00:13:17,330
DEVELOPMENT WITHIN INDUSTRY 

324
00:13:17,330 --> 00:13:19,599
EXPERIENCE AND ENTREPRENEURS IN 

325
00:13:19,599 --> 00:13:22,101
RESIDENCE AND INNOVATION-FOCUSED

326
00:13:22,101 --> 00:13:24,003
TRAINING AND NETWORKING 

327
00:13:24,003 --> 00:13:24,671
OPPORTUNITIES. 

328
00:13:24,671 --> 00:13:26,906
IN-HOUSE EXPERTS CAN BE 

329
00:13:26,906 --> 00:13:27,907
PARTICULARLY VALUABLE FOR 

330
00:13:27,907 --> 00:13:29,409
START-UPS AND EMERGING COMPANIES

331
00:13:29,409 --> 00:13:30,977
WE WORK WITH. 

332
00:13:30,977 --> 00:13:36,015
INDEED, 1/3 OF NIH'S MOST 

333
00:13:36,015 --> 00:13:39,719
SUCCESSFUL TECHNOLOGIES WERE 

334
00:13:39,719 --> 00:13:41,320
LICENSED TO EARLY-STAGE 

335
00:13:41,320 --> 00:13:41,688
COMPANIES. 

336
00:13:41,688 --> 00:13:42,889
NEXT SLIDE. 

337
00:13:42,889 --> 00:13:47,260
I SAID EARLIER THAT NIH IS 

338
00:13:47,260 --> 00:13:49,729
ALMOST 2S DO XEN INSTITUTE AND 

339
00:13:49,729 --> 00:13:50,963
CENTERS CONDUCTING INTRAMURAL 

340
00:13:50,963 --> 00:13:53,032
RESEARCH AND HUNDREDS OF LABS 

341
00:13:53,032 --> 00:13:55,201
CONDUCTING WIDE VARIETY OF 

342
00:13:55,201 --> 00:13:57,203
RESEARCH AND TRUE HEART OF 

343
00:13:57,203 --> 00:14:01,274
PROGRAM IS NIH CLINICAL CENTER 

344
00:14:01,274 --> 00:14:06,045
THAT IS A WORLD CLASS 

345
00:14:06,045 --> 00:14:08,147
INSTITUTION WHERE WE ROUTINELY 

346
00:14:08,147 --> 00:14:10,183
CONDUCT SMALL FIRST IN HUMAN 

347
00:14:10,183 --> 00:14:12,251
HIGH RISK CLINICAL TRIALS THAT 

348
00:14:12,251 --> 00:14:14,487
IS THE NATION'S ONLY 

349
00:14:14,487 --> 00:14:16,556
FULL-SERVICE HOSPITAL THAT IS 

350
00:14:16,556 --> 00:14:18,891
DEVOTED ENTIRELY TO BIOMEDICAL 

351
00:14:18,891 --> 00:14:19,292
RESEARCH. 

352
00:14:19,292 --> 00:14:21,027
NEXT SLIDE. 

353
00:14:21,027 --> 00:14:23,162
COLLABORATION HAS BENEFITS TO 

354
00:14:23,162 --> 00:14:25,164
INDUSTRY AND NIH. 

355
00:14:25,164 --> 00:14:27,934
AND NIH OFFERS ACCESS TO CUTTING

356
00:14:27,934 --> 00:14:30,103
EDGE BASIC TRANSLATIONAL AND 

357
00:14:30,103 --> 00:14:32,038
CLINICAL RESEARCH AND ACCESS TO 

358
00:14:32,038 --> 00:14:35,742
OUR UNIQUE RESOURCES AND 

359
00:14:35,742 --> 00:14:37,009
EXPERTISE. 

360
00:14:37,009 --> 00:14:38,978
WE OFFER THE OPTION TO LICENSE 

361
00:14:38,978 --> 00:14:41,614
NIH TECHNOLOGIES FOR RESEARCH, 

362
00:14:41,614 --> 00:14:42,448
DEVELOPMENT AND 

363
00:14:42,448 --> 00:14:43,683
COMMERCIALIZATION AND PARTNERING

364
00:14:43,683 --> 00:14:47,386
WITH INDUSTRY CAN GIVE US AT NIH

365
00:14:47,386 --> 00:14:49,956
ACCESS TO ADDITIONAL INNOVATIONS

366
00:14:49,956 --> 00:14:52,725
AND COMMERCIAL DEVELOPMENT 

367
00:14:52,725 --> 00:14:53,025
EXPERTISE. 

368
00:14:53,025 --> 00:14:55,161
MOST OF ALL CAN SERVE OUR 

369
00:14:55,161 --> 00:14:56,562
MANDATE TO GET MEDICAL SOLUTIONS

370
00:14:56,562 --> 00:14:58,798
TO PATIENTS THAT NEED THEM. 

371
00:14:58,798 --> 00:15:02,702
WE VIEW INDUSTRY AS OUR PARTNERS

372
00:15:02,702 --> 00:15:05,071
RATHER THAN REVENUE RESOURCES. 

373
00:15:05,071 --> 00:15:07,507
AND SEE COLLABORATION AS A TRUE 

374
00:15:07,507 --> 00:15:10,777
EXCHANGE OF IDEAS AND EFFORTS. 

375
00:15:10,777 --> 00:15:14,213
THIS HAS -- IT IS WHAT HAS 

376
00:15:14,213 --> 00:15:16,149
ALWAYS LED TO SUCCESS AND WE 

377
00:15:16,149 --> 00:15:18,785
DON'T LOOK FOR SPONSORED FOR 

378
00:15:18,785 --> 00:15:19,819
FEE-FOR-SERVICE RESEARCH. 

379
00:15:19,819 --> 00:15:21,287
ROYALTIES ARE USED TO 

380
00:15:21,287 --> 00:15:24,757
REINVESTORS AND REINVEST NOT 

381
00:15:24,757 --> 00:15:27,493
TOWARDS A PROFIT MARGIN FOR NIH.

382
00:15:27,493 --> 00:15:29,495
WE ALSO HAVE A STATUTORY 

383
00:15:29,495 --> 00:15:32,198
PREFERENCE FOR WORKING WITH 

384
00:15:32,198 --> 00:15:33,933
SMALLER BUSINESSES. 

385
00:15:33,933 --> 00:15:37,136
ULTIMATELY, NIH SUPPORT CAN FREE

386
00:15:37,136 --> 00:15:40,873
UP OTHER CAPITAL FOR BUSINESSES 

387
00:15:40,873 --> 00:15:42,308
AND EXTEND THE RUNWAY FOR 

388
00:15:42,308 --> 00:15:44,076
DEVELOPING PRODUCTS. 

389
00:15:44,076 --> 00:15:46,612
WHEN SUCCESSFUL PARTNERSHIPS 

390
00:15:46,612 --> 00:15:49,549
DELIVER PRODUCTS TO BENEFIT OF 

391
00:15:49,549 --> 00:15:52,885
PATIENTS, WE AT NIH WIN. 

392
00:15:52,885 --> 00:15:53,586
NEXT SLIDE. 

393
00:15:53,586 --> 00:15:56,856
I WOULD BE REMISED NOT TO 

394
00:15:56,856 --> 00:15:58,291
MENTION NATIONAL CENTER 

395
00:15:58,291 --> 00:15:59,892
ADVANCING TRANSLATIONAL 

396
00:15:59,892 --> 00:16:01,527
SCIENCES. 

397
00:16:01,527 --> 00:16:04,263
NCATS FOCUSES IMPROVING PROCESS 

398
00:16:04,263 --> 00:16:05,798
OF TURNING OBSERVATIONS INTO 

399
00:16:05,798 --> 00:16:07,133
INTERVENTIONS THAT IMPROVE 

400
00:16:07,133 --> 00:16:07,867
HEALTH. 

401
00:16:07,867 --> 00:16:09,402
CENTER CAN PROVIDE 

402
00:16:09,402 --> 00:16:11,637
COLLABORATORS WITH ACCESS TO 

403
00:16:11,637 --> 00:16:13,005
TRANSLATIONAL SCIENCE WORKFORCE 

404
00:16:13,005 --> 00:16:15,174
TO STATE OF THE ART FACILITIES 

405
00:16:15,174 --> 00:16:18,144
AND INFORMATICS CAPABILITIES. 

406
00:16:18,144 --> 00:16:19,612
STRONG COMMITMENT TO TEAM 

407
00:16:19,612 --> 00:16:23,216
SCIENCE AND ACCESS TO INNOVATIVE

408
00:16:23,216 --> 00:16:31,624
PARTNERSHIPS. 

409
00:16:32,158 --> 00:16:36,896
 N CATS INTRAMURAL PROGRAM AND 

410
00:16:36,896 --> 00:16:38,998
INDUSTRY PARTNERS LED TO 

411
00:16:38,998 --> 00:16:46,172
APPROVED TREATMENTS FOR MUSCULAR

412
00:16:46,172 --> 00:16:56,682
DISTROPHY -- POMPEI DISEASE, 

413
00:17:00,019 --> 00:17:03,689
FRAGILE X SYNDROME, BETA 

414
00:17:03,689 --> 00:17:05,791
THAT'LLCEMIA AND MANY OTHER 

415
00:17:05,791 --> 00:17:06,125
CONDITIONS. 

416
00:17:06,125 --> 00:17:07,560
NEXT SLIDE. 

417
00:17:07,560 --> 00:17:10,997
FINALLY NIH AIMS FOR A BALANCED 

418
00:17:10,997 --> 00:17:12,899
RESEARCH PORTFOLIO AND POLICIES 

419
00:17:12,899 --> 00:17:14,901
PROMOTING HIGH RETURN ON 

420
00:17:14,901 --> 00:17:17,470
INVESTMENT FOR US TAXPAYERS. 

421
00:17:17,470 --> 00:17:19,538
RETURN ON INVESTMENT INCLUDES 

422
00:17:19,538 --> 00:17:21,641
THE LAUNCH OF NEW PRODUCTS BASED

423
00:17:21,641 --> 00:17:24,577
ON NIH-FUNDED RESEARCH AND, OF 

424
00:17:24,577 --> 00:17:27,280
COURSE, IMPROVEMENTS IN HUMAN 

425
00:17:27,280 --> 00:17:27,680
HEALTH. 

426
00:17:27,680 --> 00:17:29,649
WE LOOK ALSO AT RETURN ON 

427
00:17:29,649 --> 00:17:32,585
INVESTMENT AND PUBLIC BENEFITS 

428
00:17:32,585 --> 00:17:34,754
THROUGH OTHER LENS THROUGH 

429
00:17:34,754 --> 00:17:36,656
ECONOMIC GROWTH, JOB CREATION 

430
00:17:36,656 --> 00:17:38,391
AND BOOSTING FOLLOW-ON 

431
00:17:38,391 --> 00:17:41,928
INNOVATION AND IN PAST DECADES 

432
00:17:41,928 --> 00:17:44,263
TECHNOLOGY LICENSED FROM NIH HAS

433
00:17:44,263 --> 00:17:48,234
BEEN INTEGRATED IN OVER 1,000 

434
00:17:48,234 --> 00:17:50,236
PRODUCTS BROUGHT TO MARKET THAT 

435
00:17:50,236 --> 00:17:53,105
PRODUCE REPORTED SALES EXCEEDING

436
00:17:53,105 --> 00:17:57,510
$130 BILLION AND THOSE SALES IN 

437
00:17:57,510 --> 00:18:01,714
TURN SUPPORTED AVERAGE OF 74,500

438
00:18:01,714 --> 00:18:05,484
EMPLOYMENT POSITIONS IN THE PAST

439
00:18:05,484 --> 00:18:08,354
20 YEARS ALONE AND NIH WORKS 

440
00:18:08,354 --> 00:18:11,023
TOWARDS CREATION SCORES OF NEW 

441
00:18:11,023 --> 00:18:12,124
START-UP COMPANIES THAT ARE 

442
00:18:12,124 --> 00:18:14,193
OUTSIDE OF CONTRIBUTIONS TO THE 

443
00:18:14,193 --> 00:18:14,794
ECONOMY. 

444
00:18:14,794 --> 00:18:17,630
A LOT OF THE AGENCY'S WORK IS 

445
00:18:17,630 --> 00:18:19,699
FOCUSED ALSO ON SPURRING FURTHER

446
00:18:19,699 --> 00:18:22,268
RESEARCH AND DEVELOPMENT. 

447
00:18:22,268 --> 00:18:24,503
NIH-FUNDED RESEARCH CAN AND DOES

448
00:18:24,503 --> 00:18:26,973
LEAD TO NEW RESEARCH TOOLS FOR 

449
00:18:26,973 --> 00:18:30,109
IDENTIFICATION OF NEW APPROACHES

450
00:18:30,109 --> 00:18:32,878
TO APPROVING WAYS THAT WE DO 

451
00:18:32,878 --> 00:18:34,447
SCIENCE. 

452
00:18:34,447 --> 00:18:36,515
FINALLY, RESEARCH TOOLS LIKE 

453
00:18:36,515 --> 00:18:41,020
REAGENTS AND CELL LINES, FOR 

454
00:18:41,020 --> 00:18:44,523
EXAMPLE, THEY MAKE UP LARGEST 

455
00:18:44,523 --> 00:18:46,859
PORTION OF INTRAMURAL PATENT 

456
00:18:46,859 --> 00:18:50,129
LICENSING PORTFOLIO AND 

457
00:18:50,129 --> 00:18:53,366
INVESTIGATORS ARE CONTINUALLY 

458
00:18:53,366 --> 00:18:55,201
CONTRIBUTING TOOLS AND RESEARCH 

459
00:18:55,201 --> 00:18:57,269
THAT SCIENCE HAS DONE AND ARE 

460
00:18:57,269 --> 00:18:58,537
LICENSING TECHNOLOGY OUT SO 

461
00:18:58,537 --> 00:18:59,905
OTHERS CAN USE IT. 

462
00:18:59,905 --> 00:19:00,906
NEXT SLIDE. 

463
00:19:00,906 --> 00:19:03,175
YOU HAVE HEARD AND WILL CONTINUE

464
00:19:03,175 --> 00:19:05,644
TO HEAR ME TALK ABOUT THE 

465
00:19:05,644 --> 00:19:07,546
CRITICAL IMPORTANCE OF EQUITY 

466
00:19:07,546 --> 00:19:09,382
AND ACCESS. 

467
00:19:09,382 --> 00:19:11,050
PROMOTING EQUITABLE ACCESS TO 

468
00:19:11,050 --> 00:19:15,788
THE PRODUCTS OF NIH RESEARCH IS 

469
00:19:15,788 --> 00:19:16,789
COMPLEX. 

470
00:19:16,789 --> 00:19:19,658
WITHOUT A DOUBT, AGENCY WANTS TO

471
00:19:19,658 --> 00:19:23,062
SEE MORE INNOVATION AND WORKING 

472
00:19:23,062 --> 00:19:24,563
PARTNERSHIP TO DELIVER MORE 

473
00:19:24,563 --> 00:19:30,169
PRODUCTS AND SERVICES THAT PATI 

474
00:19:30,169 --> 00:19:31,971
WANT AND NEED AND DOING THAT 

475
00:19:31,971 --> 00:19:34,807
HAVING A MEANINGFUL POSITIVE 

476
00:19:34,807 --> 00:19:36,342
IMPACT ON HUMAN HEALTH. 

477
00:19:36,342 --> 00:19:38,944
WE NEED PROMISING INDUSTRY 

478
00:19:38,944 --> 00:19:40,546
PARTNERS WORKING HAND IN HAND 

479
00:19:40,546 --> 00:19:43,349
WITH NIH AND I HOPE THAT TODAY'S

480
00:19:43,349 --> 00:19:45,184
MEETING IS VERY HELPFUL TO YOU 

481
00:19:45,184 --> 00:19:47,486
AND HOPE IT SEEKS YOU TO INQUIRE

482
00:19:47,486 --> 00:19:50,056
MORE ABOUT THE POSSIBILITIES FOR

483
00:19:50,056 --> 00:19:51,791
YOUR PARTICULAR COMPANIES ON 

484
00:19:51,791 --> 00:19:54,226
WHAT NIH MAY HAVE TO OFFER YOU. 

485
00:19:54,226 --> 00:19:57,663
I HOPE THAT IT ENGENDERS MANY 

486
00:19:57,663 --> 00:20:00,066
FOLLOWUP CONVERSATIONS LEADING 

487
00:20:00,066 --> 00:20:03,602
TO SUCCESSFUL PARTNERSHIPS. 

488
00:20:03,602 --> 00:20:13,946
THANK YOU SO MUCH. 

489
00:20:14,280 --> 00:20:17,483
>> OKAY.  I'M DOING MY
BEST TO 

490
00:20:17,483 --> 00:20:21,120
MANAGE TECHNOLOGY HERE. 

491
00:20:21,120 --> 00:20:26,292
SO, THERE ARE -- ONE QUESTION I 

492
00:20:26,292 --> 00:20:28,227
CAN SEE IN THE CHAT, FIRST OF 

493
00:20:28,227 --> 00:20:31,530
ALL, THANKS SO MUCH FOR THAT 

494
00:20:31,530 --> 00:20:32,665
SPECTACULAR TALK HIGHLIGHTING 

495
00:20:32,665 --> 00:20:34,834
ALL THINGS I LOVE ABOUT NIH. 

496
00:20:34,834 --> 00:20:36,535
>> YOU HAVE TO STOP RIGHT
THERE 

497
00:20:36,535 --> 00:20:36,836
THOUGH. 

498
00:20:36,836 --> 00:20:40,206
YOU HAVE TO TELL EVERYONE WHAT 

499
00:20:40,206 --> 00:20:43,809
OUR ASSOCIATION IS. 

500
00:20:43,809 --> 00:20:47,246
>> MONICA AND I WERE
COLLEGE 

501
00:20:47,246 --> 00:20:47,546
ROOMMATES. 

502
00:20:47,546 --> 00:20:49,248
>> WE WERE COLLEGE
ROOMMATES AND

503
00:20:49,248 --> 00:20:51,484
IT IS A WONDERFUL CHANCE FOR ME 

504
00:20:51,484 --> 00:20:54,553
TO BE ABLE TO WORK WITH AMY ON 

505
00:20:54,553 --> 00:20:57,089
THIS REALLY IMPORTANT EFFORT 

506
00:20:57,089 --> 00:21:00,459
ACROSS NIH AND REALLY FIRST 

507
00:21:00,459 --> 00:21:02,194
INTERACTION SINCE I CAME ON AS 

508
00:21:02,194 --> 00:21:04,196
NIH DIRECTOR AND PLEASED THAT 

509
00:21:04,196 --> 00:21:06,198
THIS IS WHERE BOTH CAREERS HAVE 

510
00:21:06,198 --> 00:21:07,032
BROUGHT US. 

511
00:21:07,032 --> 00:21:08,467
>> ME AS WELL.  

512
00:21:08,467 --> 00:21:11,170
I WAS TRYING IT KEEP IT 

513
00:21:11,170 --> 00:21:13,139
PROFESSIONAL BUT ON A PERSONAL 

514
00:21:13,139 --> 00:21:16,108
NOTE IT IS A PLEASURE TO 

515
00:21:16,108 --> 00:21:18,978
INTRODUCE MONICA TO ALL OF YOU 

516
00:21:18,978 --> 00:21:19,779
THROUGH THIS VENUE. 

517
00:21:19,779 --> 00:21:22,448
THERE IS A QUESTION IN THE CHAT.

518
00:21:22,448 --> 00:21:24,783
CAN YOU COMMENT -- YOU PROBABLY 

519
00:21:24,783 --> 00:21:25,117
CAN'T. 

520
00:21:25,117 --> 00:21:29,221
CAN YOU COMMENT ON PROPOSED 

521
00:21:29,221 --> 00:21:33,058
CHANGES TO THE BAIL DOLE ACT AND

522
00:21:33,058 --> 00:21:36,262
INFLUENCING FUTURE NIH INDUSTRY 

523
00:21:36,262 --> 00:21:36,662
COLLABORATIONS?  

524
00:21:36,662 --> 00:21:39,098
>> HAPPY TO TAKE THAT ON
AND 

525
00:21:39,098 --> 00:21:41,467
HAPPY FOR THAT QUESTION. 

526
00:21:41,467 --> 00:21:42,868
THERE HAS BEEN INTEREST ON PART 

527
00:21:42,868 --> 00:21:45,304
OF THE LEGISLATORS IN MAKING 

528
00:21:45,304 --> 00:21:46,772
SURE THAT AMERICAN PEOPLE 

529
00:21:46,772 --> 00:21:50,509
RECEIVE A FAIR RETURN ON 

530
00:21:50,509 --> 00:21:52,511
INVESTMENT FOR THE PUBLIC DOLLAR

531
00:21:52,511 --> 00:21:55,014
AND CONTRIBUTION TO BIOMEDICAL 

532
00:21:55,014 --> 00:21:55,414
RESEARCH. 

533
00:21:55,414 --> 00:21:57,750
WE KNOW AND YOU HEARD ME SAY TO 

534
00:21:57,750 --> 00:22:01,187
REALLY WANT TO SEE THE FRUITS OF

535
00:22:01,187 --> 00:22:03,189
NIH-FUNDING TO TURN INTO 

536
00:22:03,189 --> 00:22:04,790
MARKETABLE PRODUCTS AND 

537
00:22:04,790 --> 00:22:05,057
SERVICES. 

538
00:22:05,057 --> 00:22:07,393
WE ARE BEING ASKED ACROSS ALL OF

539
00:22:07,393 --> 00:22:08,994
THE FEDERAL GOVERNMENT AND NOT 

540
00:22:08,994 --> 00:22:12,298
JUST NIH BUT ALL OF GOVERNMENT 

541
00:22:12,298 --> 00:22:14,900
TO TAKE A LOOK AT 

542
00:22:14,900 --> 00:22:16,268
GOVERNMENT-INVESTMENT IN HEALTH 

543
00:22:16,268 --> 00:22:19,638
AND EVALUATE HOW WE CAN MAKE 

544
00:22:19,638 --> 00:22:22,274
SURE THAT THE -- THE PRODUCTS OF

545
00:22:22,274 --> 00:22:25,511
PUBLIC FUNDING REALLY ARE 

546
00:22:25,511 --> 00:22:27,513
ACCESSIBLE AND AVAILABLE TO THE 

547
00:22:27,513 --> 00:22:29,481
AMERICAN PEOPLE. 

548
00:22:29,481 --> 00:22:30,950
THAT IS WHAT THE DISCUSSION IS 

549
00:22:30,950 --> 00:22:31,383
ABOUT. 

550
00:22:31,383 --> 00:22:33,352
IT WILL TAKE PLACE ON ALL OF 

551
00:22:33,352 --> 00:22:34,486
GOVERNMENT LEVEL. 

552
00:22:34,486 --> 00:22:35,988
FINALLY, ONE THING THAT I CAN'T 

553
00:22:35,988 --> 00:22:39,959
THINK OF A BETTER WAY TO MAKE 

554
00:22:39,959 --> 00:22:43,128
SURE NIH-FUNDING ACTUALLY 

555
00:22:43,128 --> 00:22:45,431
PRODUCES GOODS AND SERVICES 

556
00:22:45,431 --> 00:22:46,665
BENEFITING PEOPLE THAT ENGAGE 

557
00:22:46,665 --> 00:22:49,835
WITH INDUSTRY PARTNERS LIKE WE 

558
00:22:49,835 --> 00:22:52,938
CHAMPION WITH THIS MEETING 

559
00:22:52,938 --> 00:22:54,006
TODAY. 

560
00:22:54,006 --> 00:22:55,875
>> IF -- I ONLY SEE THAT
ONE 

561
00:22:55,875 --> 00:22:58,310
QUESTION IN THE CHAT. 

562
00:22:58,310 --> 00:23:00,212
IF OTHER PEOPLE HAVE QUESTIONS, 

563
00:23:00,212 --> 00:23:02,348
PLEASE PUT THEM IN -- IT IS NOT 

564
00:23:02,348 --> 00:23:04,416
CALLED THE CHAT BUT QUESTIONS IN

565
00:23:04,416 --> 00:23:06,619
THE -- IN THE FORMAT THAT YOU 

566
00:23:06,619 --> 00:23:06,952
HAVE. 

567
00:23:06,952 --> 00:23:10,222
I'M HAPPY TO POSE THEM TO 

568
00:23:10,222 --> 00:23:10,456
MONICA. 

569
00:23:10,456 --> 00:23:12,992
ONE QUESTION THAT IS:  WILL 

570
00:23:12,992 --> 00:23:15,661
THERE BE SLIDES AVAILABLE?  

571
00:23:15,661 --> 00:23:17,496
THIS ENTIRE PROGRAM IS BEING 

572
00:23:17,496 --> 00:23:19,465
RECORDED AND WILL BE MADE 

573
00:23:19,465 --> 00:23:19,965
AVAILABLE. 

574
00:23:19,965 --> 00:23:24,336
IT IS AVAILABLE FOR THE NEXT 

575
00:23:24,336 --> 00:23:25,971
FOUR WEEKS FOR THE FORMAT YOU 

576
00:23:25,971 --> 00:23:26,472
HAVE. 

577
00:23:26,472 --> 00:23:28,607
YOU CAN GO INTO SWAP CARD AND BE

578
00:23:28,607 --> 00:23:31,677
ABLE TO ACCESS ALL TALKS AND IN 

579
00:23:31,677 --> 00:23:33,178
TERMS WHETHER SPECIFIC SLIDES 

580
00:23:33,178 --> 00:23:34,813
FROM THE SESSION WILL BE 

581
00:23:34,813 --> 00:23:38,183
AVAILABLE, I WILL LEAVE TO 

582
00:23:38,183 --> 00:23:39,151
MONICA TO ANSWER THAT. 

583
00:23:39,151 --> 00:23:41,487
>> OH, YEAH.  OF COURSE
YOU CAN 

584
00:23:41,487 --> 00:23:42,121
SHARE THEM WIDELY. 

585
00:23:42,121 --> 00:23:44,490
>> THAT IS THE ANSWER TO
THE 

586
00:23:44,490 --> 00:23:44,757
QUESTION. 

587
00:23:44,757 --> 00:23:46,425
I GUESS SINCE THERE ARE NO OTHER

588
00:23:46,425 --> 00:23:47,926
QUESTIONS IN THE CHAT, MY 

589
00:23:47,926 --> 00:23:49,795
QUESTION TO YOU WOULD BE DO YOU 

590
00:23:49,795 --> 00:23:50,763
HAVE SUGGESTIONS?  

591
00:23:50,763 --> 00:23:52,464
I KNOW YOU HAVE LOTS OF 

592
00:23:52,464 --> 00:23:54,300
EXPERIENCE WITH WORKING WITH 

593
00:23:54,300 --> 00:23:56,001
INDUSTRY ON THE OUTSIDE. 

594
00:23:56,001 --> 00:23:58,470
NOW YOU ARE ON THE INSIDE. 

595
00:23:58,470 --> 00:24:00,639
HOW -- DO YOU HAVE SUGGESTIONS 

596
00:24:00,639 --> 00:24:03,676
FOR WAYS TO INCREASE OUR -- OUR 

597
00:24:03,676 --> 00:24:05,944
INTERACTION WITH INDUSTRY OR 

598
00:24:05,944 --> 00:24:07,246
SIMPLIFY THE -- THE INTERACTIONS

599
00:24:07,246 --> 00:24:09,214
WE HAVE TO MAKE THEM -- MAKE 

600
00:24:09,214 --> 00:24:10,916
THEM HAPPEN MORE QUICKLY?  

601
00:24:10,916 --> 00:24:13,752
THAT IS ALWAYS AN ISSUE IN 

602
00:24:13,752 --> 00:24:14,053
GOVERNMENT. 

603
00:24:14,053 --> 00:24:16,555
>> YEAH.  YOU KNOW, THE
FIRST 

604
00:24:16,555 --> 00:24:18,090
REALLY KEY PRINCIPLE THAT I WILL

605
00:24:18,090 --> 00:24:19,758
SAY THAT THE THING THAT MAKES 

606
00:24:19,758 --> 00:24:21,894
THINGS GOT QUICKEST IS WHEN 

607
00:24:21,894 --> 00:24:24,296
THERE IS VERY CLEAR THERE IS 

608
00:24:24,296 --> 00:24:26,398
MUTUAL BENEFIT AND FINDING SWEET

609
00:24:26,398 --> 00:24:28,667
SPOTS WE ARE VERY CLEAR THIS SAY

610
00:24:28,667 --> 00:24:30,135
COLLABORATION THAT THIS NEEDS TO

611
00:24:30,135 --> 00:24:30,502
HAPPEN. 

612
00:24:30,502 --> 00:24:32,204
I THINK WE DON'T DO AS MANY OF 

613
00:24:32,204 --> 00:24:33,272
THOSE AS WE COULD. 

614
00:24:33,272 --> 00:24:35,541
I THINK THAT WE NEED TO REALLY 

615
00:24:35,541 --> 00:24:38,744
LOOK FOR MANY MORE OF THOSE. 

616
00:24:38,744 --> 00:24:41,013
THE -- WHEN THOSE HAPPEN, YOU 

617
00:24:41,013 --> 00:24:42,548
GET A REAL WILLINGNESS ON THE 

618
00:24:42,548 --> 00:24:44,917
PART OF BOTH OF THE INDUSTRY 

619
00:24:44,917 --> 00:24:47,519
PARTNER AND THE NIH PARTNER TO 

620
00:24:47,519 --> 00:24:50,489
REALLY, YOU KNOW, GET AGREEMENTS

621
00:24:50,489 --> 00:24:52,257
SET AND READY TO GO. 

622
00:24:52,257 --> 00:24:55,361
I HAVE ALWAYS FOUND THAT WHEN 

623
00:24:55,361 --> 00:24:57,529
THERE IS VERY STRONG MUTUAL 

624
00:24:57,529 --> 00:24:59,164
SELF-INTEREST, THAT MAKES THINGS

625
00:24:59,164 --> 00:25:00,899
FLOW VERY QUICKLY. 

626
00:25:00,899 --> 00:25:02,735
THAT DOESN'T MEAN WE SHOULDN'T 

627
00:25:02,735 --> 00:25:05,037
DIVE INTO MORE DIFFICULT ISSUES.

628
00:25:05,037 --> 00:25:08,574
YOU KNOW, FOR EXAMPLE, THE -- I 

629
00:25:08,574 --> 00:25:10,009
HAVE HAD LOTS OF EXPERIENCE 

630
00:25:10,009 --> 00:25:12,111
WORKING WITH THE PHARMACEUTICAL 

631
00:25:12,111 --> 00:25:14,380
INDUSTRY LOOKING AT NEW USES OF 

632
00:25:14,380 --> 00:25:16,548
CURRENT MARKET -- CURRENTLY 

633
00:25:16,548 --> 00:25:17,583
MARKETED DRUGS. 

634
00:25:17,583 --> 00:25:21,253
YOU KNOW, THAT COULD BE A REALLY

635
00:25:21,253 --> 00:25:24,423
CHALLENGING COLLABORATION SPACE.

636
00:25:24,423 --> 00:25:28,694
ONE THING I WILL SAY IS WE ALL 

637
00:25:28,694 --> 00:25:30,496
KNOW THAT THOSE DRUGS AND 

638
00:25:30,496 --> 00:25:32,631
SERVICES BOTH ON THE PHARMAEND 

639
00:25:32,631 --> 00:25:36,368
AND ON NIH-END, WE HAVE A REAL 

640
00:25:36,368 --> 00:25:37,536
MANDATE TO MAKE SURE THAT 

641
00:25:37,536 --> 00:25:40,506
TESTING AND DATA THAT UNDERLIES 

642
00:25:40,506 --> 00:25:41,573
THEIR USE IS THE BROADEST 

643
00:25:41,573 --> 00:25:42,608
POSSIBLE AVAILABLE. 

644
00:25:42,608 --> 00:25:44,777
I CAN'T THINK OF A BETTER 

645
00:25:44,777 --> 00:25:47,713
PARTNER THAN NIH, WHICH IS VERY 

646
00:25:47,713 --> 00:25:50,048
BROAD AND CLINICAL TRIAL REACH 

647
00:25:50,048 --> 00:25:52,217
THAT GETS INTO DIVERSE 

648
00:25:52,217 --> 00:25:52,618
COMMUNITIES. 

649
00:25:52,618 --> 00:25:54,620
I CAN'T THINK OF A BETTER 

650
00:25:54,620 --> 00:25:56,355
PARTNER FOR INDUSTRY COMMUNITIES

651
00:25:56,355 --> 00:25:58,690
WHEN THERE IS A NEED TO MAKE 

652
00:25:58,690 --> 00:26:00,859
SURE THAT DATA UNDERLYING USE OF

653
00:26:00,859 --> 00:26:03,162
AGENTS IS, YOU KNOW, REPRESENTS 

654
00:26:03,162 --> 00:26:04,029
ALL PEOPLE. 

655
00:26:04,029 --> 00:26:05,364
THAT IS A GREAT CONTRIBUTION. 

656
00:26:05,364 --> 00:26:07,766
I THINK THAT IS ONE THAT SHOULD 

657
00:26:07,766 --> 00:26:09,334
BE CONSIDERED MORE. 

658
00:26:09,334 --> 00:26:10,769
FINALLY, WHEN WE SAY THAT WE 

659
00:26:10,769 --> 00:26:13,806
WANT PARTNERSHIPS, WE ARE ALSO 

660
00:26:13,806 --> 00:26:15,908
VERY WILLING TO LISTEN TO NEW 

661
00:26:15,908 --> 00:26:17,309
STRATEGIES THAT WILL WORK BEST 

662
00:26:17,309 --> 00:26:19,044
FOR INDUSTRY PARTNERS. 

663
00:26:19,044 --> 00:26:21,713
YOU KNOW, IT DOESN'T -- JUST 

664
00:26:21,713 --> 00:26:23,649
EVEN ENGAGING DOESN'T -- AND 

665
00:26:23,649 --> 00:26:25,551
PROCESS DOING THIS DOES NOT NEED

666
00:26:25,551 --> 00:26:28,120
TO BE A ONE-WAY STREET. 

667
00:26:28,120 --> 00:26:29,655
WE WOULD WELCOME ANY 

668
00:26:29,655 --> 00:26:33,358
INTERACTIONS LEADING TO BETTER 

669
00:26:33,358 --> 00:26:40,365
RESULTS FOR BOTH OF US. 

670
00:26:40,365 --> 00:26:40,699
OOPS. 

671
00:26:40,699 --> 00:26:43,001
YOU ARE ON MUTE, AMY. 

672
00:26:43,001 --> 00:26:45,804
>> I KNOW.  LIKE I SAID,
I'M 

673
00:26:45,804 --> 00:26:47,639
HAVING TECHNOLOGICAL 

674
00:26:47,639 --> 00:26:47,973
DIFFICULTIES. 

675
00:26:47,973 --> 00:26:49,575
THERE IS ANOTHER QUESTION IN THE

676
00:26:49,575 --> 00:26:49,775
CHAT. 

677
00:26:49,775 --> 00:26:54,046
DOES NIH HAVE A DATA BASE WITH 

678
00:26:54,046 --> 00:26:57,716
PATENTS TECHNOLOGIES AND 

679
00:26:57,716 --> 00:26:58,917
THERAPEUTIC AREAS?  

680
00:26:58,917 --> 00:26:59,785
COMPLICATED QUESTION. 

681
00:26:59,785 --> 00:27:01,119
>> CAN I JUMP IN?  

682
00:27:01,119 --> 00:27:03,455
>> YEAH.  YOU GOT IT. 

683
00:27:03,455 --> 00:27:06,191
>> IN THE SWAP CARD IS A
LINK 

684
00:27:06,191 --> 00:27:10,395
SAYING NIH TECHNOLOGIES LEADING 

685
00:27:10,395 --> 00:27:11,497
TO DATA BASE WITH COLLABORATION 

686
00:27:11,497 --> 00:27:12,364
AND OPPORTUNITIES. 

687
00:27:12,364 --> 00:27:14,099
YOU CAN CLICK ON THAT AND GET 

688
00:27:14,099 --> 00:27:15,901
ALL OF THE INFORMATION.  SORRY 

689
00:27:15,901 --> 00:27:17,102
TO INTERRUPT. 

690
00:27:17,102 --> 00:27:20,772
>> NOT AN INTERRUPTION. 
THANK 

691
00:27:20,772 --> 00:27:23,709
YOU VERY MUCH, MICHAEL. 

692
00:27:23,709 --> 00:27:25,677
THERE IS ONE OTHER QUESTION IN 

693
00:27:25,677 --> 00:27:29,882
THE CHAT THAT IS RELATED TO 

694
00:27:29,882 --> 00:27:34,286
SPECIFIC TOPICS IN THE NIH 

695
00:27:34,286 --> 00:27:36,421
STRATEGIC PLAN FOR THE NEXT FIVE

696
00:27:36,421 --> 00:27:37,689
YEARS THAT I'M NOT SURE THAT IS 

697
00:27:37,689 --> 00:27:41,126
IN THE -- REALLY IN THE SCOPE OF

698
00:27:41,126 --> 00:27:44,796
-- OF THIS MEETING. 

699
00:27:44,796 --> 00:27:44,963
SO. 

700
00:27:44,963 --> 00:27:47,065
>> I WOULD BE HAPPY TO
SPEAK TO 

701
00:27:47,065 --> 00:27:48,066
IT, IF YOU WANT. 

702
00:27:48,066 --> 00:27:51,203
I WILL TELL YOU WE HAVE TWO -- 

703
00:27:51,203 --> 00:27:53,739
TWO AREAS OF FOCUS THAT WE ARE 

704
00:27:53,739 --> 00:27:55,774
ACTIVELY WORKING ON FROM THE 

705
00:27:55,774 --> 00:27:58,243
DIRECTOR'S OFFICE AND ACTIVELY 

706
00:27:58,243 --> 00:27:59,478
WORKING ACROSS ALL INSTITUTES 

707
00:27:59,478 --> 00:28:01,680
AND CENTERS AND ONE OF THEM IS 

708
00:28:01,680 --> 00:28:06,618
AN APPROACH TO REALLY 

709
00:28:06,618 --> 00:28:08,387
ORGANIZING, COORDINATING AND 

710
00:28:08,387 --> 00:28:10,856
USING OUR REALLY INCREDIBLE DATA

711
00:28:10,856 --> 00:28:13,559
RESOURCES IN A MUCH BETTER WAY 

712
00:28:13,559 --> 00:28:14,993
TO PRODUCE MUCH BETTER RESULTS. 

713
00:28:14,993 --> 00:28:17,796
THIS IS A CENTRAL ACTIVITY 

714
00:28:17,796 --> 00:28:21,600
WHERE YOU KNOW YOU KNOW THERE IS

715
00:28:21,600 --> 00:28:24,703
AN NIH-DATA SHARING POLICY 

716
00:28:24,703 --> 00:28:27,339
ASKING EVERY ONE OF THE GRANTEES

717
00:28:27,339 --> 00:28:29,308
TO DESCRIBE HOW DATA THEY 

718
00:28:29,308 --> 00:28:31,610
GENERATED COULD BE REUSED BY 

719
00:28:31,610 --> 00:28:34,179
BROADER RESEARCH COMMUNITY AND 

720
00:28:34,179 --> 00:28:36,181
WE ARE FOCUSED ON FINDING WAYS 

721
00:28:36,181 --> 00:28:38,917
TO IMPLEMENT THAT IN WAYS THAT 

722
00:28:38,917 --> 00:28:40,953
DON'T JUST ALLOW DATA TO BE 

723
00:28:40,953 --> 00:28:42,254
SHARED BUT TO BE USED. 

724
00:28:42,254 --> 00:28:44,723
SO THE REASON THAT I ALSO BRING 

725
00:28:44,723 --> 00:28:47,859
THIS TO THIS PARTICULAR 

726
00:28:47,859 --> 00:28:52,264
COMMUNITY IS ACCESS TO DATA THAT

727
00:28:52,264 --> 00:28:54,633
COULD BE SHARED THROUGHOUT THE 

728
00:28:54,633 --> 00:28:57,803
ENTIRE BIOMEDICAL RESEARCH 

729
00:28:57,803 --> 00:28:59,638
ENVIRONMENT THAT IS ONE OF THE 

730
00:28:59,638 --> 00:29:00,405
KEY GOALS. 

731
00:29:00,405 --> 00:29:03,942
THAT MEANS THAT OUR PARTNERS -- 

732
00:29:03,942 --> 00:29:05,544
RELATIONSHIPS WITH INDUSTRY 

733
00:29:05,544 --> 00:29:07,212
PARTNERS WILL ALSO LOOK TO THAT 

734
00:29:07,212 --> 00:29:09,948
AS A -- AS A STANDARD FOR HOW WE

735
00:29:09,948 --> 00:29:10,816
WOULD APPROACH OUR WORK. 

736
00:29:10,816 --> 00:29:12,618
NO THE THAT WE WOULD WANT TO, 

737
00:29:12,618 --> 00:29:15,187
YOU KNOW, OF COURSE WE CAN PUT 

738
00:29:15,187 --> 00:29:17,723
ADEQUATE PROTECTIONS ON THINGS 

739
00:29:17,723 --> 00:29:20,092
LIKE INTELLECTUAL PROPERTY BUT 

740
00:29:20,092 --> 00:29:22,227
ALSO WANT AN ENVIRONMENT WHERE 

741
00:29:22,227 --> 00:29:23,528
DATA FROM CLINICAL CARE 

742
00:29:23,528 --> 00:29:25,631
ENVIRONMENT COULD BE ACTIVELY 

743
00:29:25,631 --> 00:29:26,298
SHARED. 

744
00:29:26,298 --> 00:29:28,667
THAT IS ONE INITIATIVE. 

745
00:29:28,667 --> 00:29:31,770
ANOTHER REALLY SEEKS AT A LEVEL 

746
00:29:31,770 --> 00:29:36,241
TO HAVE MORE IMPACT AT DELIVERY 

747
00:29:36,241 --> 00:29:37,109
OF CARE INDIVIDUAL PATIENT 

748
00:29:37,109 --> 00:29:37,609
TREATMENT LEVEL. 

749
00:29:37,609 --> 00:29:40,979
WE ARE LOOKING TO FOCUS 

750
00:29:40,979 --> 00:29:43,215
ACTIVITIES ON ACHIEVING THE LAST

751
00:29:43,215 --> 00:29:46,385
MILE OF BEING ABLE TO GET 

752
00:29:46,385 --> 00:29:48,720
PROMISING NEW TREATMENT TESTED 

753
00:29:48,720 --> 00:29:50,956
IN PATIENT POPULATIONS THROUGH 

754
00:29:50,956 --> 00:29:55,260
MORE AND MORE AGILE AND NIMBLE 

755
00:29:55,260 --> 00:29:57,162
AND EFFECTIVE CLINICAL TRIAL 

756
00:29:57,162 --> 00:29:58,964
APPROACHES AND GET MORE 

757
00:29:58,964 --> 00:30:00,632
PROMISING TREATMENT OPTIONS AND 

758
00:30:00,632 --> 00:30:03,201
TECHNOLOGIES ACTUALLY DELIVERED 

759
00:30:03,201 --> 00:30:06,405
TO PEOPLE THAT NEED THEM. 

760
00:30:06,405 --> 00:30:09,675
I THINK THESE BROAD INITIATIVES 

761
00:30:09,675 --> 00:30:11,543
WOULD HAVE GREAT IMPACT TO DO 

762
00:30:11,543 --> 00:30:14,980
THEM IN COLLABORATION WITH 

763
00:30:14,980 --> 00:30:16,515
INDUSTRY PARTNERS. 

764
00:30:16,515 --> 00:30:20,819
I THINK YOU ARE BACK ON MUTED 

765
00:30:20,819 --> 00:30:23,255
AGA

766
00:30:23,255 --> 00:30:23,488
AGAIN. 

767
00:30:23,488 --> 00:30:28,493
>> I'M TRYING TO AVOID
EXTRA 

768
00:30:28,493 --> 00:30:31,897
NOISE WHEN YOU ARE SPEAKING AND 

769
00:30:31,897 --> 00:30:33,432
ACCELERATED PROGRAM COORDINATED 

770
00:30:33,432 --> 00:30:37,569
WITH FDA AND THEY FILED PATENTS 

771
00:30:37,569 --> 00:30:40,005
FOR THERAPEUTICS AND HAVE 

772
00:30:40,005 --> 00:30:42,641
COLLABORATIVE SCIENTISTS ON 

773
00:30:42,641 --> 00:30:44,776
OUTSIDE AND FDA-GUIDED LAB. 

774
00:30:44,776 --> 00:30:46,745
>> I DON'T KNOW WHETHER
THE 

775
00:30:46,745 --> 00:30:50,415
QUESTION IS SPEAKING OF 

776
00:30:50,415 --> 00:30:52,417
ACCELERATED MEDICINES 

777
00:30:52,417 --> 00:30:54,720
PARTNERSHIP AND POINTING TO BEST

778
00:30:54,720 --> 00:30:56,188
INFORMATION THAT IS FOUND ON 

779
00:30:56,188 --> 00:30:59,091
FOUNDATION OF NIH WEBSITE AND 

780
00:30:59,091 --> 00:31:00,525
VARIOUS ACTIVITIES CONDUCTED 

781
00:31:00,525 --> 00:31:02,394
THERE OR WHETHER THAT SOUNDS 

782
00:31:02,394 --> 00:31:07,733
LIKE THIS IS WHAT THIS IS FOR. 

783
00:31:07,733 --> 00:31:09,434
THERE IS LABORATORY WORK 

784
00:31:09,434 --> 00:31:12,971
INVOLVED AND YOU KNOW THAT NIH 

785
00:31:12,971 --> 00:31:14,806
CONTRIBUTED SIGNIFICANTLY TO 

786
00:31:14,806 --> 00:31:16,842
ACCELERATED APPROVAL OF 

787
00:31:16,842 --> 00:31:17,843
THERAPEUTICS THAT ARE OUT THERE 

788
00:31:17,843 --> 00:31:21,780
AND ONE OF THE YOU KNOW SWEET 

789
00:31:21,780 --> 00:31:26,118
SPOTS FOR US HAS BEEN TO 

790
00:31:26,118 --> 00:31:27,052
REEMPHASIZE RARE DISEASES WHERE 

791
00:31:27,052 --> 00:31:31,022
IT IS REALLY HARD AND CAN BE 

792
00:31:31,022 --> 00:31:32,891
REALLY DIFFICULT TO GATHER PASH 

793
00:31:32,891 --> 00:31:35,227
YENLTS TOGETHER TO PRODUCE DATA 

794
00:31:35,227 --> 00:31:37,763
REQUIRED FOR ACCELERATED 

795
00:31:37,763 --> 00:31:40,999
APPROVAL FOR A DRUG AND CLINICAL

796
00:31:40,999 --> 00:31:43,969
CENTER REALLY SHINES AND NETWORK

797
00:31:43,969 --> 00:31:47,272
THAT IS RUN BY THE NCI. 

798
00:31:47,272 --> 00:31:50,776
ALSO FOR -- FOR, AGAIN, 

799
00:31:50,776 --> 00:31:53,411
POPULATIONS, SPECIAL INDICATIONS

800
00:31:53,411 --> 00:31:59,951
FOR POPULATIONS THAT HAVE NOT 

801
00:31:59,951 --> 00:32:02,053
TRADITIONALLY BEEN STUDIED ALONE

802
00:32:02,053 --> 00:32:05,924
BY INDUSTRY AND ELDERLY PATIENTS

803
00:32:05,924 --> 00:32:09,394
WITH COMORBID CONDITIONS OR 

804
00:32:09,394 --> 00:32:13,899
PATIENTS LOCATED IN VERY DIVERSE

805
00:32:13,899 --> 00:32:14,232
COMMUNITIES. 

806
00:32:14,232 --> 00:32:17,335
>> I THINK MAYBE OUR LAST 

807
00:32:17,335 --> 00:32:22,641
QUESTION OR NOT. 

808
00:32:22,641 --> 00:32:24,476
I WILL STATE THE LAST QUESTION 

809
00:32:24,476 --> 00:32:26,478
OR ONE I WOULD POSE FOR THE LAST

810
00:32:26,478 --> 00:32:27,979
QUESTION AND QUESTION CAME IN 

811
00:32:27,979 --> 00:32:30,982
WHERE DOES ONE GO IN NIH FOR 

812
00:32:30,982 --> 00:32:32,217
COLLABORATIONS AND PROJECTS 

813
00:32:32,217 --> 00:32:36,188
RELATED TO TELEHEALTH AND 

814
00:32:36,188 --> 00:32:37,289
BIOCOMPUTING?  

815
00:32:37,289 --> 00:32:40,325
>> BIOCOMPUTING IS ONE I
DON'T 

816
00:32:40,325 --> 00:32:40,625
UNDERSTAND. 

817
00:32:40,625 --> 00:32:42,894
I'LL TELL YOU A PLACE TO START, 

818
00:32:42,894 --> 00:32:48,099
PERHAPS, CERTAINLY CALLING THE 

819
00:32:48,099 --> 00:32:53,238
MAIN OFFICE AND I THINK MUCOLA 

820
00:32:53,238 --> 00:32:57,108
WILL HAVE A LINK FOR YOU TO ASK 

821
00:32:57,108 --> 00:32:57,809
QUESTIONS LIKE THIS. 

822
00:32:57,809 --> 00:32:59,110
>> RIGHT. 

823
00:32:59,110 --> 00:33:00,378
>> WHERE ARE QUESTIONS. 

824
00:33:00,378 --> 00:33:04,516
>> I WILL SAY SOUNDS LIKE 

825
00:33:04,516 --> 00:33:10,121
INSTITUTE YOU MIGHT WANT TO LOOK

826
00:33:10,121 --> 00:33:12,624
AT IS BOB INSTITUTE OF 

827
00:33:12,624 --> 00:33:14,459
BIOTECHNOLOGY THAT HAS AN 

828
00:33:14,459 --> 00:33:16,261
INCREDIBLE PROGRAM FOLK YUTSED 

829
00:33:16,261 --> 00:33:18,530
ON AND GREAT KNOWLEDGE AND 

830
00:33:18,530 --> 00:33:20,031
PARTNERSHIP IN INDUSTRY AND THIS

831
00:33:20,031 --> 00:33:22,367
MIGHT BE FOCUS FOR THE 

832
00:33:22,367 --> 00:33:23,902
QUESTIONER AND IF THAT IS THE 

833
00:33:23,902 --> 00:33:26,171
LAST QUESTION I WILL END BY 

834
00:33:26,171 --> 00:33:27,873
THANKING YOU FOR BEING HERE. 

835
00:33:27,873 --> 00:33:30,642
WE ARE EAGER TO WORK WITH YOU 

836
00:33:30,642 --> 00:33:35,614
AND THANK YOU TO DR. CLION FOR 

837
00:33:35,614 --> 00:33:37,048
INVITING ME TO THIS TALK AND 

838
00:33:37,048 --> 00:33:38,950
LOOK FORWARD TO A PRODUCTIVE 

839
00:33:38,950 --> 00:33:40,352
MEETING FOR YOU ALL. 

840
00:33:40,352 --> 00:33:41,019
THANKS SO MUCH. 

841
00:33:41,019 --> 00:33:42,821
>> THANK YOU.  LAST
MESSAGE IN 

842
00:33:42,821 --> 00:33:45,223
THE CHAT IS THANK YOU.  WE ARE 

843
00:33:45,223 --> 00:33:46,491
GRATEFUL FOR EVERYTHING THAT THE

844
00:33:46,491 --> 00:33:47,726
NIH DOES. 

845
00:33:47,726 --> 00:33:49,728
>> THANK YOU.  TAKE CARE. 
HAVE 

846
00:33:49,728 --> 00:33:50,662
A GREAT MEETING. 

847
00:33:50,662 --> 00:34:01,106
>> THANK YOU.  BYE, BYE. 

848
00:34:03,608 --> 00:34:12,684
>> HELLO. 

849
00:34:12,684 --> 00:34:16,154
>> HELLO.  I WILL START
SHARING 

850
00:34:16,154 --> 00:34:26,364
MY SCREEN. 

851
00:34:27,532 --> 00:34:31,136
WELCOME, EVERYBODY.  I'M JOHN 

852
00:34:31,136 --> 00:34:35,140
TIS DALE AT THE NATIONAL HEART, 

853
00:34:35,140 --> 00:34:36,474
LUNG, AND BLOOD INSTITUTE AND 

854
00:34:36,474 --> 00:34:38,710
JOINED BY MY COLLEAGUE WHO IS A 

855
00:34:38,710 --> 00:34:44,382
CHIEF SCIENTIFIC OFFICER WHO WAS

856
00:34:44,382 --> 00:34:46,451
PREVIOUSLY AT BLUEBERG.  WE 

857
00:34:46,451 --> 00:34:50,021
WORKED TOGETHER FOR A DECADE AND

858
00:34:50,021 --> 00:34:51,790
PASSING IT TO HER TO SET THE 

859
00:34:51,790 --> 00:34:53,325
STAGE.  WE WILL GO BACK AND 

860
00:34:53,325 --> 00:34:57,062
FORTH AS WE DID FOR THAT DECADE 

861
00:34:57,062 --> 00:35:02,367
TO SOLVE PROBLEMS AS THEY CAME 

862
00:35:02,367 --> 00:35:04,202
ALONG TO THIS JOURNEY DEVELOPING

863
00:35:04,202 --> 00:35:06,771
FIRST GENE THERAPY OF THE FIRST 

864
00:35:06,771 --> 00:35:07,405
MOLECULAR DISEASE. 

865
00:35:07,405 --> 00:35:12,344
>> THANK YOU.  WHAT A
JOURNEY IT

866
00:35:12,344 --> 00:35:12,644
W

867
00:35:12,644 --> 00:35:12,844
WAS. 

868
00:35:12,844 --> 00:35:14,045
>> WHAT WE WILL TRY TO 

869
00:35:14,045 --> 00:35:15,847
ACCOMPLISH FOR YOU IN THE NEXT 

870
00:35:15,847 --> 00:35:19,017
30 MINUTES IS SICKLE CELL 

871
00:35:19,017 --> 00:35:21,186
DISEASE AND SPECIFICALLY 

872
00:35:21,186 --> 00:35:23,888
DEVELOPMENT OF GENE THERAPY FOR 

873
00:35:23,888 --> 00:35:24,789
SICKLE CELL DISEASE THAT IS 

874
00:35:24,789 --> 00:35:29,060
TESTED IN PATIENTS IN STUDY 

875
00:35:29,060 --> 00:35:30,895
HTB206 THAT YOU WILL COME TO 

876
00:35:30,895 --> 00:35:33,031
FIND OUT DIVIDED INTO THREE 

877
00:35:33,031 --> 00:35:33,398
GROUPS. 

878
00:35:33,398 --> 00:35:35,300
WE WILL FOCUS ORIGINALLY AT 

879
00:35:35,300 --> 00:35:37,869
FIRST ON GROUP A THAT IS 

880
00:35:37,869 --> 00:35:38,870
ORIGINAL PATIENTS TREATED AS 

881
00:35:38,870 --> 00:35:40,338
PART OF THE STUDY. 

882
00:35:40,338 --> 00:35:43,875
WE WILL DIVE INTO SOME OF THE 

883
00:35:43,875 --> 00:35:47,278
NUANCES IN THE GROUP A PATIENTS 

884
00:35:47,278 --> 00:35:55,820
RELATED TO EFFICACY OUTCOMES AN 

885
00:35:55,820 --> 00:35:59,958
TALK BEING PROTOCOL REFINEMENTS 

886
00:35:59,958 --> 00:36:01,826
INSTITUTED TO IMPROVE EFFICACY 

887
00:36:01,826 --> 00:36:04,696
AND WHAT LED TO FDA APPROVAL FOR

888
00:36:04,696 --> 00:36:06,731
GENE THERAPY FOR SICKLE CELL 

889
00:36:06,731 --> 00:36:06,998
DISEASE. 

890
00:36:06,998 --> 00:36:09,901
TAKE IT AWAY WITH SICKLE CELL 

891
00:36:09,901 --> 00:36:10,869
DISEASE AND TREATMENTS. 

892
00:36:10,869 --> 00:36:13,271
>> THANK YOU, MELISSA. 

893
00:36:13,271 --> 00:36:15,473
I HOPE TO CONVINCE YOU IT IS 

894
00:36:15,473 --> 00:36:17,342
TIME TO ENVISIONED BEFORELY 

895
00:36:17,342 --> 00:36:19,277
AVAILABLE CURES AND UNDERLYING 

896
00:36:19,277 --> 00:36:21,079
OF THE S ON PURPOSE. 

897
00:36:21,079 --> 00:36:23,181
WE DIDN'T INVENT ONLY WAY TO DO 

898
00:36:23,181 --> 00:36:23,381
THIS. 

899
00:36:23,381 --> 00:36:26,851
WE ARE HAPPY THERE ARE NOW 

900
00:36:26,851 --> 00:36:28,153
MULTIPLE WAYS TO THINK ABOUT 

901
00:36:28,153 --> 00:36:29,154
CURING THIS DISEASE. 

902
00:36:29,154 --> 00:36:30,288
IT IS ABOUT TIME. 

903
00:36:30,288 --> 00:36:31,956
WE HAVE KNOWN ABOUT THE DISEASE 

904
00:36:31,956 --> 00:36:34,459
FOR MORE THAN A CENTURY THAT WAS

905
00:36:34,459 --> 00:36:36,694
ORIGINALLY DESCRIBED BY A 

906
00:36:36,694 --> 00:36:40,065
MEDICAL STUDENT IN WEST INDIES 

907
00:36:40,065 --> 00:36:42,567
AND PAIN AND PROLIVERAL BLOOD 

908
00:36:42,567 --> 00:36:46,504
FILM AND RED CELLS HAD A SICKLE 

909
00:36:46,504 --> 00:36:49,274
SHAPE AND FIRST MOLECULAR 

910
00:36:49,274 --> 00:36:51,109
DISEASE DESCRIBED BY LINUS 

911
00:36:51,109 --> 00:36:53,978
PAULING AND COLLEAGUES IN 1949 

912
00:36:53,978 --> 00:36:56,481
BASED ON DIFFERENCE BETWEEN 

913
00:36:56,481 --> 00:36:58,450
HEMOGLOBIN MOLECULE IN PATIENTS 

914
00:36:58,450 --> 00:37:00,351
AND NORMALS. 

915
00:37:00,351 --> 00:37:03,888
YOU KNOW, LINUS WENT ON TO GET A

916
00:37:03,888 --> 00:37:06,291
NOBLE PRICE IN PROTEIN 

917
00:37:06,291 --> 00:37:07,525
BIOCHEMISTRY WORK BASED IN PART 

918
00:37:07,525 --> 00:37:09,861
ON FINDINGS THAT RESULTS FROM 

919
00:37:09,861 --> 00:37:11,629
SINGLE SUBSTITUTION OF POSITION 

920
00:37:11,629 --> 00:37:14,466
6 OF BETA GLOBIN CHAIN PRODUCING

921
00:37:14,466 --> 00:37:19,537
ABNORMAL HEMOGLOBIN IN RED CELLS

922
00:37:19,537 --> 00:37:23,274
PRONE TO DEOXYGENATION 

923
00:37:23,274 --> 00:37:26,511
PROPENSITY TO HAVE A ROCK HARD 

924
00:37:26,511 --> 00:37:28,680
HEMOGLOBIN INSIDE THAT OBSTRUCTS

925
00:37:28,680 --> 00:37:31,249
CIRCULATION MAKING RED CELLS 

926
00:37:31,249 --> 00:37:34,786
FRAGILE CAUSING SEVERE ANEMIA 

927
00:37:34,786 --> 00:37:38,223
AND FREQUENT PAIN PARTS OF BODY 

928
00:37:38,223 --> 00:37:42,894
ARE DEPRIVED OF CIRCULATION AND 

929
00:37:42,894 --> 00:37:45,230
ORGAN AND STROKE IN KIDS AND 

930
00:37:45,230 --> 00:37:47,732
EARLY MORTALITY AND RARE IN 

931
00:37:47,732 --> 00:37:49,634
US100,000 INDIVIDUALS IN THE US 

932
00:37:49,634 --> 00:37:50,802
WITH THIS DISEASE THAT IS NOT 

933
00:37:50,802 --> 00:37:52,837
RARE IN THE WORLD AND 

934
00:37:52,837 --> 00:37:56,741
CONCENTRATED IN AREAS THERE IS 

935
00:37:56,741 --> 00:37:57,041
MALARIA. 

936
00:37:57,041 --> 00:38:00,545
THIS EVOLVED AS AN EVOLUTIONARY 

937
00:38:00,545 --> 00:38:02,213
PROTECTION AGAINST MALARIA WITH 

938
00:38:02,213 --> 00:38:03,848
SINGLE COMPUTATION OF THE GENE 

939
00:38:03,848 --> 00:38:08,386
AND MANY MILLIONS ACROSS SUBIS A

940
00:38:08,386 --> 00:38:11,589
HAIRANT AFRICA AND INDIA AND 

941
00:38:11,589 --> 00:38:13,358
LIMITED AND MOSTLY SUPPORTED AND

942
00:38:13,358 --> 00:38:16,861
WE NEED CLINICAL TRIALS TO TEST 

943
00:38:16,861 --> 00:38:17,328
CURATIVE APPROACHES. 

944
00:38:17,328 --> 00:38:19,264
I MADE THIS SLIDE A FEW YEARS 

945
00:38:19,264 --> 00:38:23,067
AGO WITH COLLEAGUES HERE AT NIH 

946
00:38:23,067 --> 00:38:24,903
DESCRIBING CURRENT THERAPIES 

947
00:38:24,903 --> 00:38:29,140
WITH DRUGS GETTING RED CELL 

948
00:38:29,140 --> 00:38:31,643
THROUGH CIRCULATION BEFORE IT 

949
00:38:31,643 --> 00:38:37,248
SICKLES AND HYDROXY RHEA. 

950
00:38:37,248 --> 00:38:41,019
IT PREVENTS SICKLING AND 

951
00:38:41,019 --> 00:38:43,154
ALLOGENEIC TRANSPLANTATION 

952
00:38:43,154 --> 00:38:45,657
TAKING BONE MARROW STEM CELLS 

953
00:38:45,657 --> 00:38:48,059
FROM SOMEONE ELSE THAT IS FROM A

954
00:38:48,059 --> 00:38:49,761
BROTHER OR SISTER INTO 

955
00:38:49,761 --> 00:38:53,865
TRANSPLANT AND GENE EDITING 

956
00:38:53,865 --> 00:38:55,934
THERAPY AND VIRAL VECTORS WE 

957
00:38:55,934 --> 00:38:57,135
WILL TALK ABOUT AND CRISPR WE 

958
00:38:57,135 --> 00:38:59,037
WON'T HAVE TIME TO TALK ABOUT 

959
00:38:59,037 --> 00:39:01,573
AND HAVING TO MOVE THIS DOTTED 

960
00:39:01,573 --> 00:39:03,908
LINE OVER NOW THEY NOW RECENTLY 

961
00:39:03,908 --> 00:39:05,910
IN DECEMBER HAVE BEEN FDA 

962
00:39:05,910 --> 00:39:07,278
APPROVED AND WE AND OTHERS ARE 

963
00:39:07,278 --> 00:39:10,815
WORKING ON WAYS TO DEVELOP IN 

964
00:39:10,815 --> 00:39:12,383
VIVO GENE THERAPY AND MELISSA 

965
00:39:12,383 --> 00:39:14,352
DIDN'T TELL US WHAT SHE IS UP TO

966
00:39:14,352 --> 00:39:19,290
PROBABLY PART OF THIS IN HER 

967
00:39:19,290 --> 00:39:29,133
PIPELINE -- YOU CAN CURE KIDS 

968
00:39:29,133 --> 00:39:32,303
WITH SICKLE CELL DISEASE WITH 

969
00:39:32,303 --> 00:39:39,210
STANDARD BONE MARROW TRANSPLANT 

970
00:39:39,210 --> 00:39:41,179
USING IMMUNOOBLATED -- AND IT 

971
00:39:41,179 --> 00:39:42,614
WORKS AND WORKS MOEFT OF THE 

972
00:39:42,614 --> 00:39:46,351
TIME AND WE HAVE BETTER OVER THE

973
00:39:46,351 --> 00:39:50,655
YEARS TO MODERN DAY KID WITH SIB

974
00:39:50,655 --> 00:39:53,891
BLING CAN EXPECT 95% CHANCE OF 

975
00:39:53,891 --> 00:39:56,127
BEING CURED AND DEAL MOSTLY WITH

976
00:39:56,127 --> 00:39:58,029
ADULT PATIENTS WE COULDN'T DO 

977
00:39:58,029 --> 00:40:02,400
WITH ADULT PATIENTS.  ORGAN 

978
00:40:02,400 --> 00:40:03,601
[INDISCERNIBLE] THAT IS 

979
00:40:03,601 --> 00:40:05,536
ACCUMULATED OVER THE YEARS -- WE

980
00:40:05,536 --> 00:40:07,639
ASKED A QUESTION WHETHER WE 

981
00:40:07,639 --> 00:40:09,741
COULD DO IT WITHOUT OBLATING AND

982
00:40:09,741 --> 00:40:14,779
NO CHEMOTHERAPY AND ANTIBODY FOR

983
00:40:14,779 --> 00:40:17,115
LYMPHOCYTES AND ORAL DRUG TO 

984
00:40:17,115 --> 00:40:18,516
PROMOTE TOLERANCE THAT WORKED IN

985
00:40:18,516 --> 00:40:21,219
9 OF FIRST 10 AND RESOLUTION OF 

986
00:40:21,219 --> 00:40:23,187
DISEASE AND NO ANEMIA OR 

987
00:40:23,187 --> 00:40:25,356
[INDISCERNIBLE] DISEASE THAT IS 

988
00:40:25,356 --> 00:40:29,060
A COMMON AND CAN BE DEADLY 

989
00:40:29,060 --> 00:40:30,128
COMPLICATION OF A TRANSPLANT 

990
00:40:30,128 --> 00:40:33,531
GOING ON EXTENDING IT TO 30 

991
00:40:33,531 --> 00:40:36,868
PATIENTS WITH RULES FOR WEENING 

992
00:40:36,868 --> 00:40:38,436
IMMUNOSUPPRESSION AND WEENED 

993
00:40:38,436 --> 00:40:41,973
MORE THAN 80% OF PATIENTS AND 

994
00:40:41,973 --> 00:40:43,274
IMMUNOSUPPRESSION IN FIRST YEAR 

995
00:40:43,274 --> 00:40:45,510
AND SET STAGE FOR US LAUNCHING 

996
00:40:45,510 --> 00:40:48,313
STUDIES INTO TRANCE PLANTS WITH 

997
00:40:48,313 --> 00:40:51,249
COURT ANY IN THE INTRAMURAL 

998
00:40:51,249 --> 00:41:01,626
PROGRAM RUNNING EFFORTS -- THIS 

999
00:41:01,626 --> 00:41:05,630
IS MORE OR LESS MYELOID SERIES 

1000
00:41:05,630 --> 00:41:08,800
COMING FROM DONOR AROUND 50% 

1001
00:41:08,800 --> 00:41:12,170
FROM LYMPHOID CELLS AND 80% FROM

1002
00:41:12,170 --> 00:41:15,239
MYELOID CELLS RESOLUTION OF 

1003
00:41:15,239 --> 00:41:25,783
ANEMIA AND HEMOLYTIC PARAMETERS.

1004
00:41:26,384 --> 00:41:31,189
WE NEED TO KNOW WHEN WE REACHED 

1005
00:41:31,189 --> 00:41:32,490
THAT THRESHOLD AND BY TIME 

1006
00:41:32,490 --> 00:41:33,791
TAUGHT ABOUT ANSWERING QUESTION 

1007
00:41:33,791 --> 00:41:36,694
WE HAD 100 PATIENTS TRANCE 

1008
00:41:36,694 --> 00:41:38,796
PLANTED IN INTRAMURAL PROGRAM 

1009
00:41:38,796 --> 00:41:42,200
AND 67 WITH LONG-TIME FOLLOW UP 

1010
00:41:42,200 --> 00:41:44,202
MONITORING RED CELLS COMING FROM

1011
00:41:44,202 --> 00:41:45,837
DONOR AND PERCENTAGE THEY WERE 

1012
00:41:45,837 --> 00:41:50,041
AND PERCENTAGE OF MYELOID CELLS 

1013
00:41:50,041 --> 00:41:53,544
AND NEUTROPHILS SHORT HALF LIFE 

1014
00:41:53,544 --> 00:41:54,912
AND REFLECT STEM CELL 

1015
00:41:54,912 --> 00:41:56,914
COMPARTMENT CAME FROM DONOR AND 

1016
00:41:56,914 --> 00:41:59,450
ALL DATA AND AT SAME TIME THREE 

1017
00:41:59,450 --> 00:42:00,418
PATIENTS DESPITE HAVING 

1018
00:42:00,418 --> 00:42:03,154
RESOLUTION OF DISEASE EARLY HAD 

1019
00:42:03,154 --> 00:42:04,655
DECLINING LEVELS OF DONOR 

1020
00:42:04,655 --> 00:42:07,258
MYELOID CHIMERISM AND 

1021
00:42:07,258 --> 00:42:08,593
NEUTROPHILS COMING FROM DONOR 

1022
00:42:08,593 --> 00:42:11,262
AND ALL PATIENTS HAD SICKLE 

1023
00:42:11,262 --> 00:42:15,333
TRAIT DONORS AND THEY WERE LIKE 

1024
00:42:15,333 --> 00:42:18,002
CARRIER STATE WHEN MYELOID 

1025
00:42:18,002 --> 00:42:21,105
TIMERS FELL BELOW 20% WE SAW 

1026
00:42:21,105 --> 00:42:24,942
UPTICK IN HEMOGLOBIN S SHOWING 

1027
00:42:24,942 --> 00:42:35,286
RETURN OF DISEASE. 

1028
00:42:41,859 --> 00:42:44,362
THIS TAUGHT US A VERY IMPORTANT 

1029
00:42:44,362 --> 00:42:45,129
LESSON. 

1030
00:42:45,129 --> 00:42:49,067
WE WONDERED WHY IT IS 1 IN 5 

1031
00:42:49,067 --> 00:42:50,568
HEMOPOETIC STEM CELLS MAKE ALL 

1032
00:42:50,568 --> 00:42:52,537
RED CELLS FROM DONOR IN 

1033
00:42:52,537 --> 00:42:55,907
CIRCULATION AND THOUGHT IT WAS 

1034
00:42:55,907 --> 00:42:57,408
FROM DIFFERENCES IN LIFESPAN OF 

1035
00:42:57,408 --> 00:42:59,610
THE RED CELL COMING FROM DONOR 

1036
00:42:59,610 --> 00:43:03,247
VERSUS RED CELLS FROM THE 

1037
00:43:03,247 --> 00:43:04,816
RECIPIENT KNOWING SICKLE CELLS 

1038
00:43:04,816 --> 00:43:08,352
RED CELLS HAVE A SHORT HALF LIFE

1039
00:43:08,352 --> 00:43:11,289
AND DEVELOPING MATHEMATICAL 

1040
00:43:11,289 --> 00:43:13,958
MODEL TO PREDICT ONLY BASED ON 

1041
00:43:13,958 --> 00:43:16,027
LIFESPAN WHAT WOULD HAPPEN WITH 

1042
00:43:16,027 --> 00:43:18,396
FALLING DONOR MYELOID CHIMERISM 

1043
00:43:18,396 --> 00:43:19,263
LEVELS?  

1044
00:43:19,263 --> 00:43:21,199
IN RED ON THE RIGHT HAND PANEL 

1045
00:43:21,199 --> 00:43:24,502
YOU SEE OBSERVED DATA PRACH 

1046
00:43:24,502 --> 00:43:26,671
FALLING DONOR MYELOID CHIMERISM 

1047
00:43:26,671 --> 00:43:31,109
COMING FROM 60% DOWN TO 10% OVER

1048
00:43:31,109 --> 00:43:32,643
THE YEARS POST TRANSPLANT THAT 

1049
00:43:32,643 --> 00:43:33,878
IS TIME AND YEARS. 

1050
00:43:33,878 --> 00:43:38,483
YOU CAN SEE WHEN IT REACHES 20% 

1051
00:43:38,483 --> 00:43:42,053
DONOR MYELOID CHIMERISM LEVEL IN

1052
00:43:42,053 --> 00:43:44,288
RED MEASURED HEMOGLOBIN S RISES 

1053
00:43:44,288 --> 00:43:49,393
IF OF THE% AND WE SAW RETURN OF 

1054
00:43:49,393 --> 00:43:52,163
SYMPTOMS TAKING INTO ACCOUNT 

1055
00:43:52,163 --> 00:43:54,732
LIFESPAN AND PREDICTED RESULTS 

1056
00:43:54,732 --> 00:43:56,767
IN BLUE HERE ARE SUPERIMPOSABLE 

1057
00:43:56,767 --> 00:43:59,036
ON OBSERVED CELLS AND THAT IS 

1058
00:43:59,036 --> 00:44:01,873
BECAUSE THEY HAD A LONGER 

1059
00:44:01,873 --> 00:44:04,141
LIFESPAN AND THEY TAKE OVER IN 

1060
00:44:04,141 --> 00:44:06,677
PERIPHERY AND WE SAID CAN WE DO 

1061
00:44:06,677 --> 00:44:08,613
GENE EDITION AND DO SAME THING 

1062
00:44:08,613 --> 00:44:12,450
GETTING 1 IN 5 HEMOPOETIC STEM 

1063
00:44:12,450 --> 00:44:14,719
CELLS MAKING DISEASE GO AWAY. 

1064
00:44:14,719 --> 00:44:19,490
WE USE VIRAL VECTORS PACKAGING 

1065
00:44:19,490 --> 00:44:23,528
BETA DMROBIN GENE AND REGULATORY

1066
00:44:23,528 --> 00:44:25,930
ELEMENTS ACTING LIKE TROEJEN 

1067
00:44:25,930 --> 00:44:27,665
HORSE MAKING GENETIC 

1068
00:44:27,665 --> 00:44:29,700
MODIFICATION EFFICIENT ENOUGH TO

1069
00:44:29,700 --> 00:44:31,969
PRODUCE NORMAL HEMOGLOBIN AND 

1070
00:44:31,969 --> 00:44:34,372
CARTOON MAKES IT SIMPLE. 

1071
00:44:34,372 --> 00:44:36,674
IT HAS BEEN A COMPLICATED 

1072
00:44:36,674 --> 00:44:38,509
PROCESS AND STRINGENT 

1073
00:44:38,509 --> 00:44:42,179
REQUIREMENTS FROM HEMOGLOBIN 

1074
00:44:42,179 --> 00:44:43,581
SICKLE CELL AND EXPRESSION OF 

1075
00:44:43,581 --> 00:44:46,951
THE THERAPEUTIC GENE AND LEAVING

1076
00:44:46,951 --> 00:44:49,187
HEMOGLOBIN S IN PLACE IN GENOME 

1077
00:44:49,187 --> 00:44:50,755
HAS TO BE ENOUGH TO OVERCOME 

1078
00:44:50,755 --> 00:44:51,923
THAT.  THAT WAS REALLY DIFFICULT

1079
00:44:51,923 --> 00:44:53,925
TO DO OVER THE YEARS AND SOME 

1080
00:44:53,925 --> 00:44:55,493
EARLIER VECTORS I TALKED ABOUT 

1081
00:44:55,493 --> 00:44:57,762
IN ONE OF THE SESSIONS THIS 

1082
00:44:57,762 --> 00:45:00,665
MORNING COULD NOT PACKAGE 

1083
00:45:00,665 --> 00:45:03,267
COMPLEX PAY LOADS AND BECAME 

1084
00:45:03,267 --> 00:45:06,003
FEASIBLE SWITCHING TO HIV-1 AS 

1085
00:45:06,003 --> 00:45:08,940
BACKBONE TO VECTORS SHOWN BY 

1086
00:45:08,940 --> 00:45:11,342
MICHELE'S GROUP AND LATER FEL 

1087
00:45:11,342 --> 00:45:14,679
EEP'S GROUP WHO TESTED THIS IN 

1088
00:45:14,679 --> 00:45:16,781
TWO TRANSGENIC MODELS OF SICKLE 

1089
00:45:16,781 --> 00:45:19,350
CELL DISEASE AND VECTOR SERVED 

1090
00:45:19,350 --> 00:45:23,721
AS BACKBONE FOR VECTOR USED IN 

1091
00:45:23,721 --> 00:45:33,998
CLINICAL TRIAL. 

1092
00:45:38,302 --> 00:45:48,613
THIS IS HTP26 STUDY. 

1093
00:45:53,517 --> 00:45:55,486
WE COULDN'T MOBILIZE WITH THEN 

1094
00:45:55,486 --> 00:45:59,457
ONLY REAGENT FOR MOBILIZATION 

1095
00:45:59,457 --> 00:46:00,791
GCSF BECAUSE OF COMPLICATIONS 

1096
00:46:00,791 --> 00:46:02,793
WITH PATIENTS WITH SICKLE CELL 

1097
00:46:02,793 --> 00:46:04,695
DISEASE AND USED ORIGINAL 

1098
00:46:04,695 --> 00:46:08,232
MANUFACTURING PROCESS PRODUCING 

1099
00:46:08,232 --> 00:46:09,500
TRANSDUCTION EFFICIENCIES WE 

1100
00:46:09,500 --> 00:46:11,268
THOUGHT WERE SUFFICIENT AND 

1101
00:46:11,268 --> 00:46:13,237
LEARNED LATER WERE NOT.  THESE 

1102
00:46:13,237 --> 00:46:15,406
CELLS GO TO CENTRALIZED 

1103
00:46:15,406 --> 00:46:16,874
MANUFACTURING FACILITY TRANCE 

1104
00:46:16,874 --> 00:46:20,578
DEUCED WITH VECTOR FROZEN IN ALL

1105
00:46:20,578 --> 00:46:23,381
LOT RELEASE CRITERIA ARE MET 

1106
00:46:23,381 --> 00:46:25,383
PATIENTS COME BACK AND 

1107
00:46:25,383 --> 00:46:28,786
CONDITIONING AND GET RID OF ALL 

1108
00:46:28,786 --> 00:46:38,963
MARROW -- 

1109
00:46:46,504 --> 00:46:49,340
THESE RESULTS HAVE BEEN 

1110
00:46:49,340 --> 00:46:50,741
PUBLISHED AND WILL TAKE YOU TRU 

1111
00:46:50,741 --> 00:46:53,577
SOME OF THE OBSERVATIONS THAT 

1112
00:46:53,577 --> 00:46:55,913
HAD US BACK AND FORTH ON MANY 

1113
00:46:55,913 --> 00:46:57,748
ZOOM MEETINGS OVER THE YEARS AND

1114
00:46:57,748 --> 00:47:08,292
VISITS BACK AND FORTH THAT IS. 

1115
00:47:12,897 --> 00:47:15,299
VECTOR COPY NUMBER WAS 1 AND 

1116
00:47:15,299 --> 00:47:17,902
WHEN WE MEASURED AFTER 

1117
00:47:17,902 --> 00:47:21,038
RECONSTITUTION IN PATIENT VECTOR

1118
00:47:21,038 --> 00:47:24,842
COPY NUMBER DROPPED 10 FOLD TO 

1119
00:47:42,593 --> 00:47:42,960
.1. 

1120
00:47:42,960 --> 00:47:45,429
10% IS NOT ENOUGH WE HAD LEVELS 

1121
00:47:45,429 --> 00:47:48,265
OF HEMOGLOBIN COMING FROM VECTOR

1122
00:47:48,265 --> 00:47:53,037
SHOWN IN PINK AND TOTAL 

1123
00:47:53,037 --> 00:47:55,206
HEMOGLOBIN DEPICTED IN CRUMBS 

1124
00:47:55,206 --> 00:47:59,343
BEING AS HIGH AS 20% IN ONE 

1125
00:47:59,343 --> 00:48:09,987
PATIENT AND MORE LIKE 5% AS 

1126
00:48:15,559 --> 00:48:17,895
OVERALL MEAN AND WE RECEIVED 

1127
00:48:17,895 --> 00:48:20,431
[INDISCERNIBLE] IN TWO PATIENTS 

1128
00:48:20,431 --> 00:48:21,932
IN GROUP A AND PASSING TO 

1129
00:48:21,932 --> 00:48:25,770
MELISSA TO TELL YOU HOW WE WENT 

1130
00:48:25,770 --> 00:48:36,247
ABOUT SORTING THIS OUT SKWL 

1131
00:48:38,048 --> 00:48:46,056
THANK YOU, JOHN.  

1132
00:48:46,056 --> 00:48:50,861
HOWEVER, IN 2018 WE HAD A 

1133
00:48:50,861 --> 00:48:51,662
PATIENT DIAGNOSED WITH 

1134
00:48:51,662 --> 00:48:52,963
[INDISCERNIBLE] SYNDROME THREE 

1135
00:48:52,963 --> 00:48:54,598
YEARS FOLLOWING TREATMENT WITH 

1136
00:48:54,598 --> 00:49:01,338
WHAT AT TIME WAS CALLED WENTY 

1137
00:49:01,338 --> 00:49:05,376
GLOBIN INVESTIGATIONAL PRODUCT 

1138
00:49:05,376 --> 00:49:07,278
THAT BECAME PART OF FOUNDATIONAL

1139
00:49:07,278 --> 00:49:09,280
DATA USED FOR APPROVAL. 

1140
00:49:09,280 --> 00:49:13,184
NOW THIS PATIENT JOHN IS SUPER 

1141
00:49:13,184 --> 00:49:15,085
FAMILIAR WITH AND ONE OF HIS 

1142
00:49:15,085 --> 00:49:18,489
PATIENTS ABLE TO RELATIVELY 

1143
00:49:18,489 --> 00:49:19,957
QUICKLY DETERMINE THAT BLAST 

1144
00:49:19,957 --> 00:49:24,328
CELLS IN MARROW AND BLOOD OF 

1145
00:49:24,328 --> 00:49:26,497
THIS PATIENT DIDN'T INCLUDE 

1146
00:49:26,497 --> 00:49:28,432
ANTIVIRAL INSERTION INSIGHTS 

1147
00:49:28,432 --> 00:49:31,402
MEANING THERE WAS NO MECHANISTIC

1148
00:49:31,402 --> 00:49:33,337
RATIONALE TO SUPPORT PRESENCE OF

1149
00:49:33,337 --> 00:49:36,974
VECTOR COULD HAVE CAUSED THE 

1150
00:49:36,974 --> 00:49:39,043
CAN

1151
00:49:39,043 --> 00:49:39,276
CANCER. 

1152
00:49:39,276 --> 00:49:41,645
WE WERE, YOU KNOW, HAPPY WITH 

1153
00:49:41,645 --> 00:49:42,880
THE OUTCOME THAT IT DIDN'T 

1154
00:49:42,880 --> 00:49:46,550
APPEAR TO BE VECTOR RELATED. 

1155
00:49:46,550 --> 00:49:48,853
AND WE WERE HOPEFUL THIS WOULD 

1156
00:49:48,853 --> 00:49:51,789
BE A ONE-OFF EVENT.  I MENTIONED

1157
00:49:51,789 --> 00:49:53,757
EARLIER JOHN AND I HAVE SEEN 

1158
00:49:53,757 --> 00:49:55,926
ABOUT EVERY POTENTIALLY 

1159
00:49:55,926 --> 00:49:57,928
THEORETICAL THING THAT COULD GO 

1160
00:49:57,928 --> 00:50:03,968
WRONG IN A CELL AND GENE THERAPY

1161
00:50:03,968 --> 00:50:04,235
SETTING. 

1162
00:50:04,235 --> 00:50:09,673
SECOND CASE OCCURRING IN 2021 

1163
00:50:09,673 --> 00:50:12,176
WITH A COMPLICATED CASE. 

1164
00:50:12,176 --> 00:50:14,778
2021 PATIENT DIAGNOSED WITH 

1165
00:50:14,778 --> 00:50:19,984
ACUTE MYELOID LEUKEMIA 5.5 YEARS

1166
00:50:19,984 --> 00:50:26,991
AND WERE ABLE TO ENRICH CELLS IN

1167
00:50:26,991 --> 00:50:27,258
PATIENT. 

1168
00:50:27,258 --> 00:50:28,726
IN THIS PARTICULAR CASE, THERE 

1169
00:50:28,726 --> 00:50:33,163
WAS AN INSERTION IN THE BLAST 

1170
00:50:33,163 --> 00:50:35,266
CELLS OF THE PATIENT THAT LED TO

1171
00:50:35,266 --> 00:50:39,203
THE QUESTION WAS THE INSERTION 

1172
00:50:39,203 --> 00:50:41,472
OF THE LENTIVIRAL VECTOR CAUSING

1173
00:50:41,472 --> 00:50:44,341
DEVELOPMENT OF AML OF THIS 

1174
00:50:44,341 --> 00:50:47,311
PATIENT OR IT IS HAPPENSTANCE 

1175
00:50:47,311 --> 00:50:52,249
AND THIS PATIENT DEVELOPED AML 

1176
00:50:52,249 --> 00:50:53,751
FOR OTHER REASONS THAT HAPPENS 

1177
00:50:53,751 --> 00:50:56,720
THIS IS CELL THAT IS INITIATING 

1178
00:50:56,720 --> 00:51:00,824
CELL THAT CONTAINED VECTOR 

1179
00:51:00,824 --> 00:51:02,259
INSERTION AND THERE FOR COULD BE

1180
00:51:02,259 --> 00:51:03,260
CONSIDERED PASSENGER MUTATION 

1181
00:51:03,260 --> 00:51:05,562
AND TONS OF WORK WENT INTO THIS 

1182
00:51:05,562 --> 00:51:07,564
WALKING THROUGH IT BRAEFLY AND 

1183
00:51:07,564 --> 00:51:09,600
GOING TO NEXT SLIDE YOU CAN LOOK

1184
00:51:09,600 --> 00:51:14,071
AT DETAILS HOW WE APPROACH THIS 

1185
00:51:14,071 --> 00:51:14,505
CASE. 

1186
00:51:14,505 --> 00:51:20,444
SO WHAT WE DETERMINED CRITICAL 

1187
00:51:20,444 --> 00:51:22,746
COMING UP WITH LIST OF RATIONALE

1188
00:51:22,746 --> 00:51:24,381
WHAT WE WOULD NEED TO SAY 

1189
00:51:24,381 --> 00:51:26,917
WHETHER OR NOT WITH A HIGH 

1190
00:51:26,917 --> 00:51:28,786
PROBABILITY WHETHER OR NOT THE 

1191
00:51:28,786 --> 00:51:32,256
VECTOR COULD BE POTENTIALLY A 

1192
00:51:32,256 --> 00:51:35,025
DRIVER OR PASSENGER MUTATION WAS

1193
00:51:35,025 --> 00:51:39,430
A CHECKLIST ESSENTIALLY OF 

1194
00:51:39,430 --> 00:51:40,664
ATTRIBUTES. 

1195
00:51:40,664 --> 00:51:44,501
WE KNEW THERE WAS A VECTOR 

1196
00:51:44,501 --> 00:51:46,937
PRESENT IN TUMOR CELLS AND THERE

1197
00:51:46,937 --> 00:51:49,740
WERE DRIVER MUTATIONS THAT 

1198
00:51:49,740 --> 00:51:51,475
EXISTED IN TUMOR CELLS. 

1199
00:51:51,475 --> 00:51:53,177
WASN'T ONLY THING THAT WAS 

1200
00:51:53,177 --> 00:51:54,645
UNUSUAL ABOUT CELLS WAS PRESENCE

1201
00:51:54,645 --> 00:51:58,615
OF VECTOR THAT CONTAINED 

1202
00:51:58,615 --> 00:52:00,884
CLASSICAL DRIVER MUTATIONS OF 

1203
00:52:00,884 --> 00:52:02,019
AML AS WELL. 

1204
00:52:02,019 --> 00:52:04,054
THE OTHER QUESTION WE HAD WAS IF

1205
00:52:04,054 --> 00:52:10,794
THE VECTOR IS CAUSATIVE OF 

1206
00:52:10,794 --> 00:52:14,531
LEUKEMIA WE SHOULD BE ABLE TO 

1207
00:52:14,531 --> 00:52:16,734
DETECT MOLECULAR OR BIOLOGICAL 

1208
00:52:16,734 --> 00:52:18,402
CHANGE DRIVING EMERGENCE OF 

1209
00:52:18,402 --> 00:52:20,704
DISEASE AND QUESTIONS WE ASKED 

1210
00:52:20,704 --> 00:52:22,473
INCLUDE AND I WON'T READ THROUGH

1211
00:52:22,473 --> 00:52:26,110
THIS LIST FOR SAKE OF TIME. 

1212
00:52:26,110 --> 00:52:27,311
INCLUDING IS VECTOR 

1213
00:52:27,311 --> 00:52:29,546
TRANSCRIPTION ALLEY ACTIVE IN 

1214
00:52:29,546 --> 00:52:31,982
CELLS AND TURNING ON OR OFF THE 

1215
00:52:31,982 --> 00:52:35,085
GENE THAT IS KNOWN PROTOONCO 

1216
00:52:35,085 --> 00:52:38,622
GENE SUPPRESSOR RESPECTIVELY TO 

1217
00:52:38,622 --> 00:52:40,491
BIOLOGICALLY LINK PRESENCE OF 

1218
00:52:40,491 --> 00:52:43,227
VECTOR TO POTENTIAL EMERGENCE OF

1219
00:52:43,227 --> 00:52:43,761
DISEASE?  

1220
00:52:43,761 --> 00:52:45,262
LONG STORY SHORT AND GOING 

1221
00:52:45,262 --> 00:52:47,131
THROUGH DETAILS HERE BUT ANSWER 

1222
00:52:47,131 --> 00:52:50,701
IS NO IT DIDN'T APPEAR THAT 

1223
00:52:50,701 --> 00:52:52,936
VECTOR WAS ACTUALLY INFLUENCING 

1224
00:52:52,936 --> 00:52:55,272
ANY IN THESE CELLS THAT APPEARS 

1225
00:52:55,272 --> 00:52:57,841
TO BE A PASSENGER MUTATION. 

1226
00:52:57,841 --> 00:52:59,777
SO FIRST AND FOREMOST 

1227
00:52:59,777 --> 00:53:01,311
INTEGRATION WAS MAPPED AND WE 

1228
00:53:01,311 --> 00:53:02,980
WERE ABLE TO DETERMINE THAT 

1229
00:53:02,980 --> 00:53:04,882
THERE WAS A SINGLE INSERTION IN 

1230
00:53:04,882 --> 00:53:09,219
THE BLAST CELLS IN A GENE CALLED

1231
00:53:09,219 --> 00:53:10,254
VAM P 4. 

1232
00:53:10,254 --> 00:53:11,688
AND BEFORE THIS CASE I DON'T 

1233
00:53:11,688 --> 00:53:14,591
THINK I HEARD OF THE GENE VAM P 

1234
00:53:14,591 --> 00:53:14,925
4. 

1235
00:53:14,925 --> 00:53:18,095
IT DOESN'T SEEM TO BE A VERY 

1236
00:53:18,095 --> 00:53:19,596
INTERESTING GENE THAT IS 

1237
00:53:19,596 --> 00:53:23,033
CERTAINLY NOT A PROTOON CO GENE 

1238
00:53:23,033 --> 00:53:27,137
NOR A TUMOR SUPPRESSOR AND IN 

1239
00:53:27,137 --> 00:53:29,173
ADDITION ASSERTION IS IN REGION 

1240
00:53:29,173 --> 00:53:32,242
4 THAT IS NOT UNUSUAL.  

1241
00:53:32,242 --> 00:53:33,944
LENTIVIRAL VECTORS HAVE 

1242
00:53:33,944 --> 00:53:36,113
INTEGRATION WITH EVENTS AND 

1243
00:53:36,113 --> 00:53:40,517
REGIONS WITH DNA THAT IS ALIGNED

1244
00:53:40,517 --> 00:53:43,854
WITH PATTERN OF THIS ASSERTION 

1245
00:53:43,854 --> 00:53:46,056
AND PRESUMED UNLIKELY TO HAVE 

1246
00:53:46,056 --> 00:53:49,393
ANY SORT OF POTENTIAL IMPACT ON 

1247
00:53:49,393 --> 00:53:51,295
TRANSCRIPTION ON GENE ITSELF AND

1248
00:53:51,295 --> 00:53:55,332
WE DID THAT WORK TO SHOW THAT. 

1249
00:53:55,332 --> 00:53:58,235
IF WE GO TO NEXT SLIDE, PLEASE. 

1250
00:53:58,235 --> 00:54:00,804
WE DID RNA-SEQUENCING TO 

1251
00:54:00,804 --> 00:54:01,672
DETERMINE IF THERE WAS 

1252
00:54:01,672 --> 00:54:03,373
EXPRESSION CHANGES SPECIFICALLY 

1253
00:54:03,373 --> 00:54:07,277
WITHIN THE VAM P 4 GENE AND 

1254
00:54:07,277 --> 00:54:11,615
LOCUST AND BROADLY FROM A 

1255
00:54:11,615 --> 00:54:12,983
CHROMOSOME PERSPECTIVE AND 

1256
00:54:12,983 --> 00:54:15,018
SEEING ANYTHING ATTRIBUTED TO 

1257
00:54:15,018 --> 00:54:16,720
PRESENCE OF VECTOR ASSERTION. 

1258
00:54:16,720 --> 00:54:19,189
AND YOU ARE SEEING HERE YOU KNOW

1259
00:54:19,189 --> 00:54:21,825
ESSENTIALLY WE ARE LOOKING AT 

1260
00:54:21,825 --> 00:54:23,994
DISTRIBUTION OF TRANSCRIPTION OF

1261
00:54:23,994 --> 00:54:26,063
GENES KIND OF BROADLY GOING LEFT

1262
00:54:26,063 --> 00:54:28,999
TO RIGHT AND ACROSS ALL OF 

1263
00:54:28,999 --> 00:54:30,701
CHROMOSOME 1 IN THE CENTER PANEL

1264
00:54:30,701 --> 00:54:34,238
AND LOOKING AT GENES CENTERED IN

1265
00:54:34,238 --> 00:54:36,907
10 MEGA BASINS OF THE SITE AND 

1266
00:54:36,907 --> 00:54:40,644
AS FRANKLY AS A POSITIVE CONTROL

1267
00:54:40,644 --> 00:54:42,946
EXAMPLE ON RIGHT-HAND SIDE HERE 

1268
00:54:42,946 --> 00:54:45,516
WE HAVE CHROMOSOME 7 AND KNOW 

1269
00:54:45,516 --> 00:54:49,186
BLAST CELLS HERE HAVE MONOSOMY 7

1270
00:54:49,186 --> 00:54:52,389
THERE IS LEFTWARD SHIFT OF 

1271
00:54:52,389 --> 00:54:54,124
EXPRESSION THAT IS CONSISTENT 

1272
00:54:54,124 --> 00:54:56,827
WITH LOSS OF ENTIRE CHROMOSOME 7

1273
00:54:56,827 --> 00:54:58,996
AND SEE FOR THE OTHERS THAT 

1274
00:54:58,996 --> 00:55:01,231
EVERYTHING IS CENTERED AROUND 

1275
00:55:01,231 --> 00:55:05,736
ONE AND THIS IS NORMALIZED TO 

1276
00:55:05,736 --> 00:55:07,171
BLAST DEPLETED CELL POPULATIONS 

1277
00:55:07,171 --> 00:55:08,906
IN THIS PATIENT THAT YOU CAN SEE

1278
00:55:08,906 --> 00:55:12,109
THERE IS NO CHANGES HERE IN 

1279
00:55:12,109 --> 00:55:13,110
TRANSCRIPTIONAL PROFILE 

1280
00:55:13,110 --> 00:55:15,145
ATTRIBUTED TO PRESENCE OF VECTOR

1281
00:55:15,145 --> 00:55:17,047
AND IN FACT THIS PARTICULAR GENE

1282
00:55:17,047 --> 00:55:18,749
IS ACTUALLY PRETTY WELL INSERTED

1283
00:55:18,749 --> 00:55:22,219
WE HAVE TONS OF PATIENTS WHO 

1284
00:55:22,219 --> 00:55:27,257
HAVE INSERTION SITES IN VAM P 4 

1285
00:55:27,257 --> 00:55:30,894
ACROSS OUR [INDISCERNIBLE] 

1286
00:55:30,894 --> 00:55:32,663
PROGRAM AND THAT'LLCEMIA 

1287
00:55:32,663 --> 00:55:35,632
PROGRAM.  YOU ARE LOOKING AT IN 

1288
00:55:35,632 --> 00:55:38,602
GRAPH TRIANGLE INSERTION SITE 

1289
00:55:38,602 --> 00:55:41,038
FOUND IN PATIENT AND THERE IS --

1290
00:55:41,038 --> 00:55:43,407
AGAIN, VERY CONSISTENT WITH 

1291
00:55:43,407 --> 00:55:46,944
INTEGRATION PATTERN OF ANTIVIRAL

1292
00:55:46,944 --> 00:55:50,714
VECTOR.  YOU SEE OTHER PATIENTS 

1293
00:55:50,714 --> 00:55:55,018
WITH INSERTION CITES IN SIMILAR 

1294
00:55:55,018 --> 00:55:57,254
REGION OF INSERTION CITES AND 

1295
00:55:57,254 --> 00:56:00,724
PATIENTS DON'T HAVE EVIDENCE OF 

1296
00:56:00,724 --> 00:56:02,459
HEMATOLOGIOGICAL MALIGNANCY B 

1297
00:56:02,459 --> 00:56:04,928
NOR DO THEY HAVE EVIDENCE OF 

1298
00:56:04,928 --> 00:56:07,164
EXPANDED CLONE THAT IS 

1299
00:56:07,164 --> 00:56:10,133
NONMALIGNANT BUT COULD SUGGEST 

1300
00:56:10,133 --> 00:56:13,337
THERE IS SOME SORT OF ADVANTAGE 

1301
00:56:13,337 --> 00:56:15,872
TO HAVING THE INSERTION IN THIS 

1302
00:56:15,872 --> 00:56:19,176
VAM P 4 GENE THAT IS LEADING TO 

1303
00:56:19,176 --> 00:56:20,911
EXPANSION OF A CELL CONTAINING 

1304
00:56:20,911 --> 00:56:21,879
THAT INSERTION. 

1305
00:56:21,879 --> 00:56:23,247
WE SAW NONE OF THAT. 

1306
00:56:23,247 --> 00:56:26,650
THAT IS GREAT AND CONSIST YENLT,

1307
00:56:26,650 --> 00:56:28,485
AGAIN, WITH A PASSENGER MUTATION

1308
00:56:28,485 --> 00:56:30,587
AND SO JUST TO KIND OF 

1309
00:56:30,587 --> 00:56:32,856
SUMMARIZE, AGAIN, FOR THE SAKE 

1310
00:56:32,856 --> 00:56:34,725
OF TIME, WE WILL REALLY 

1311
00:56:34,725 --> 00:56:36,760
HIGH-LEVEL THIS AND SHOW THAT 

1312
00:56:36,760 --> 00:56:37,794
ABUNDANCE OF EVIDENCE SUPPORTED 

1313
00:56:37,794 --> 00:56:40,631
THIS IS UNLIKELY TO BE A DRIVER 

1314
00:56:40,631 --> 00:56:41,798
INSERTION EVENT. 

1315
00:56:41,798 --> 00:56:42,799
YOU KNOW?  

1316
00:56:42,799 --> 00:56:45,235
IT IS ACTUALLY SUBSTANTIALLY 

1317
00:56:45,235 --> 00:56:47,004
MORE LIKELY THIS HAPPENS TO BE 

1318
00:56:47,004 --> 00:56:48,839
THE CASE THAT THIS PATIENT 

1319
00:56:48,839 --> 00:56:50,340
DEVELOPS LEUKEMIA AND HAPPENED 

1320
00:56:50,340 --> 00:56:52,409
THAT THE CELL THAT WAS 

1321
00:56:52,409 --> 00:56:54,311
INITIATING CELL CONTAINED A 

1322
00:56:54,311 --> 00:56:55,879
VECTOR INSERTION AND QUESTION 

1323
00:56:55,879 --> 00:56:58,749
WAS, WELL, HOW DOES THAT HAPPEN?

1324
00:56:58,749 --> 00:57:02,019
WHAT -- IF -- IF THE PRESENCE OF

1325
00:57:02,019 --> 00:57:05,055
THE VECTOR IS NOT CAUSATIVE OF 

1326
00:57:05,055 --> 00:57:07,224
LEUKEMIA, WHAT IS DRIVING IT?  

1327
00:57:07,224 --> 00:57:10,127
WE HAVE TWO PATIENTS NOW BOTH 

1328
00:57:10,127 --> 00:57:12,095
TREATED IN GROUP A WITH ORIGINAL

1329
00:57:12,095 --> 00:57:15,265
MANUFACTURING PROCESS WHERE WE 

1330
00:57:15,265 --> 00:57:18,335
HAD RELATIVELY LOW TRANSDUCTION 

1331
00:57:18,335 --> 00:57:19,636
EFFICIENCIES OF DRUG PRODUCTS 

1332
00:57:19,636 --> 00:57:22,973
WHO HAVE NOW DEVELOPED 

1333
00:57:22,973 --> 00:57:26,810
HEMOTOLOGIC MALIGNANCY AND BOTH 

1334
00:57:26,810 --> 00:57:29,579
HAD SIMILAR DRIVER MUTATIONS AND

1335
00:57:29,579 --> 00:57:31,815
MUTE ARGSS IN [INDISCERNIBLE] 

1336
00:57:31,815 --> 00:57:36,953
AND MONOSOMY 7 VERY CLEAR 

1337
00:57:36,953 --> 00:57:37,287
MUTATIONS. 

1338
00:57:37,287 --> 00:57:38,989
AND WE WERE CURIOUS TO 

1339
00:57:38,989 --> 00:57:41,191
UNDERSTAND WHAT COULD 

1340
00:57:41,191 --> 00:57:42,826
BEINISHATING EVENT HERE?  

1341
00:57:42,826 --> 00:57:48,098
YOU KNOW, EVERYBODY ON OUR 

1342
00:57:48,098 --> 00:57:51,268
TRIALS ARE GETTING OT OL GAUS 

1343
00:57:51,268 --> 00:57:55,005
GENE THERAPY AND THERE ARE LOTS 

1344
00:57:55,005 --> 00:57:58,241
OF PIECES HERE THAT SEEM TO 

1345
00:57:58,241 --> 00:58:02,879
SUGGEST IN EVENT WHERE YOU HAVE 

1346
00:58:02,879 --> 00:58:05,349
OT OL GAUS TRANSPLANT RECEIVING 

1347
00:58:05,349 --> 00:58:09,186
A DRUG PRODUCT WITH LOW 

1348
00:58:09,186 --> 00:58:10,020
TRANSDUCTION EFFICIENCY LEADING 

1349
00:58:10,020 --> 00:58:12,189
TO LACK OF CLINICAL BENEFIT 

1350
00:58:12,189 --> 00:58:14,191
WHICH IS WHAT PATIENTS IN GROUP 

1351
00:58:14,191 --> 00:58:19,529
A SAW THAT YOU ARE LIKELY 

1352
00:58:19,529 --> 00:58:23,100
EXACERBATING SOME HEMOTOLOGIC 

1353
00:58:23,100 --> 00:58:25,569
IMPACTS OF THE DISEASE. 

1354
00:58:25,569 --> 00:58:27,738
YOU HAVE STRESSORS THAT ARE 

1355
00:58:27,738 --> 00:58:29,106
OCCURRING BECAUSE OF CHRONIC 

1356
00:58:29,106 --> 00:58:31,875
ANEMIA ASSOCIATED WITH SICKLE 

1357
00:58:31,875 --> 00:58:34,311
CELL DISEASE THAT IS LIKELY 

1358
00:58:34,311 --> 00:58:36,113
EXACERBATED IN CONTEXT OF 

1359
00:58:36,113 --> 00:58:39,349
RECEIVING A DRUG PRODUCT WITH A 

1360
00:58:39,349 --> 00:58:42,753
RELATIVELY LOW CELL DOSE IN 

1361
00:58:42,753 --> 00:58:46,289
TRANSACTION EFFICIENCY AND DOG 

1362
00:58:46,289 --> 00:58:50,227
THIS IN REVERSE ORDER AND 

1363
00:58:50,227 --> 00:58:52,162
REFINEMENTS IN ORDER TO 

1364
00:58:52,162 --> 00:58:53,630
MALIGNANCIES THAT I DESCRIBED 

1365
00:58:53,630 --> 00:58:55,098
THAT WE BELIEVE STRONG WILL I 

1366
00:58:55,098 --> 00:58:57,934
THAT PROTOCOL REFINEMENTS ARE 

1367
00:58:57,934 --> 00:59:00,404
LIKELY GOING TO MITIGATE DISEASE

1368
00:59:00,404 --> 00:59:03,273
IN OUR KIND OF FURTHER COHORTS 

1369
00:59:03,273 --> 00:59:04,341
OF PATIENTS. 

1370
00:59:04,341 --> 00:59:06,910
GOING TO THE NEXT ONE. 

1371
00:59:06,910 --> 00:59:08,845
I CAN'T REMEMBER IF WE DECIDED I

1372
00:59:08,845 --> 00:59:10,881
WAS OR YOU WERE GOING TO DO 

1373
00:59:10,881 --> 00:59:11,248
THIS. 

1374
00:59:11,248 --> 00:59:12,949
>> YOU GO AHEAD, YUP. 

1375
00:59:12,949 --> 00:59:15,685
>> OKAY.  SORRY. 

1376
00:59:15,685 --> 00:59:16,219
[LAUGHING]. 

1377
00:59:16,219 --> 00:59:18,422
SO, ONE INTERESTING THING WE 

1378
00:59:18,422 --> 00:59:20,557
NOTICED ABOUT THESE CELLS COMING

1379
00:59:20,557 --> 00:59:22,759
FROM BONE MARROW OF SICKLE CELL 

1380
00:59:22,759 --> 00:59:26,863
DISEASE PATIENTS THEY DON'T LOOK

1381
00:59:26,863 --> 00:59:28,799
LIKE IT COMING FROM BONE MARROW 

1382
00:59:28,799 --> 00:59:30,434
OF HEALTHY INDIVIDUALS THAT YOU 

1383
00:59:30,434 --> 00:59:33,136
SEE DEPICTED IN GRAPH AND 

1384
00:59:33,136 --> 00:59:35,405
HISTOGRAM THERE IS POPULATIONS 

1385
00:59:35,405 --> 00:59:39,042
OF CD4 POSITIVE CELLS WITHIN 

1386
00:59:39,042 --> 00:59:40,744
BONE MARROW SICKLE CELL DISEASE 

1387
00:59:40,744 --> 00:59:43,547
IN THAT LOWER HISTOGRAM AND 

1388
00:59:43,547 --> 00:59:44,948
POPULATION TOWARDS LEFT AND 

1389
00:59:44,948 --> 00:59:46,116
[INDISCERNIBLE] POPULATION 

1390
00:59:46,116 --> 00:59:48,685
TOWARDS RIGHT AND WE CALL CD4 

1391
00:59:48,685 --> 00:59:51,254
HIGH AND IN HEALTHY INDIVIDUALS 

1392
00:59:51,254 --> 00:59:53,156
DOMINANT POPULATION IS AT CD4 

1393
00:59:53,156 --> 00:59:55,258
HIGH POPULATION AND IN SICKLE 

1394
00:59:55,258 --> 00:59:57,260
CELL INDIVIDUALS, THIS COULD BE 

1395
00:59:57,260 --> 01:00:01,965
UP TO 60% OF BONE MARROW IS 

1396
01:00:01,965 --> 01:00:04,968
ACTUALLY CD34 DIM AND IN 

1397
01:00:04,968 --> 01:00:06,903
COLLABORATION WITH JOHN AND 

1398
01:00:06,903 --> 01:00:09,072
ALEXIS WHO IS DEPICTED AT BOTTOM

1399
01:00:09,072 --> 01:00:11,408
OF THE SLIDE WE DID WORK LOOKING

1400
01:00:11,408 --> 01:00:15,278
INTO CD34 DIM CELLS TO TRY TO 

1401
01:00:15,278 --> 01:00:16,780
FIGURE OUT WHAT THEY ARE ARE 

1402
01:00:16,780 --> 01:00:19,749
THEY STEM CELLS CONTRIBUTING TO 

1403
01:00:19,749 --> 01:00:28,291
LONG-TERM HEMOPOETICESIS AND 

1404
01:00:28,291 --> 01:00:30,327
CONTAMINATING IN STARTING 

1405
01:00:30,327 --> 01:00:32,996
MATERIAL FOR MANUFACTURER OF 

1406
01:00:32,996 --> 01:00:36,466
HEMOPOETIC STEM CELLS IN GENE 

1407
01:00:36,466 --> 01:00:38,635
THERAPY PRODUCT AND IN ORDER TO 

1408
01:00:38,635 --> 01:00:40,570
OVERCOME THIS AND GET, YOU KNOW,

1409
01:00:40,570 --> 01:00:43,607
A BETTER QUALITY OF CD34 

1410
01:00:43,607 --> 01:00:47,110
POSITIVE PRODUCT AND B MORE STEM

1411
01:00:47,110 --> 01:00:49,880
CELLS GENERALLY AND CAVEAT ABOUT

1412
01:00:49,880 --> 01:00:52,449
BONE MARROW HARVEST FOR SICKLE 

1413
01:00:52,449 --> 01:00:55,819
CELL DISEASE PATIENTS IT IS 

1414
01:00:55,819 --> 01:01:00,223
CHALLENGING TO GET CD34 -- MOST 

1415
01:01:00,223 --> 01:01:02,025
PATIENTS UNDERGO MULTIPLE ROUNDS

1416
01:01:02,025 --> 01:01:07,264
OF BONE MARROW HARVEST THAT IS 

1417
01:01:07,264 --> 01:01:11,034
AN INCREDIBLY INTENSE AND, YOU 

1418
01:01:11,034 --> 01:01:13,637
KNOW, PAINFUL PROCEDURE TO HAVE 

1419
01:01:13,637 --> 01:01:15,639
OCCURRING MULTIPLE TIMES. 

1420
01:01:15,639 --> 01:01:17,507
SO, ONE THING THAT JOHN 

1421
01:01:17,507 --> 01:01:19,809
MENTIONED PREVIOUSLY IS THAT, 

1422
01:01:19,809 --> 01:01:23,079
YOU KNOW, THIS WAS A NECESSITY. 

1423
01:01:23,079 --> 01:01:27,183
YOU CANNOT USE GCSF TO MOBILIZE 

1424
01:01:27,183 --> 01:01:29,986
SICKLE CELL DISEASE PATIENT THAT

1425
01:01:29,986 --> 01:01:31,588
IS CONTRAINDICATED AND AROUND 

1426
01:01:31,588 --> 01:01:33,323
THIS TIME PEOPLE STARTED TO 

1427
01:01:33,323 --> 01:01:35,392
THINK ABOUT ARE THERE OTHER 

1428
01:01:35,392 --> 01:01:38,328
DRUGS YOU COULD USE TO 

1429
01:01:38,328 --> 01:01:40,330
POTENTIALLY BE APPLIED TO SICKLE

1430
01:01:40,330 --> 01:01:42,265
CELL DISEASE PATIENTS?  

1431
01:01:42,265 --> 01:01:43,934
ONE DRUG IS [INDISCERNIBLE] AND 

1432
01:01:43,934 --> 01:01:47,470
WORKING TOGETHER WE WERE ABLE TO

1433
01:01:47,470 --> 01:01:50,574
DETERMINE A REGIMENT THAT WORKED

1434
01:01:50,574 --> 01:01:54,277
WELL AND ALLOWING FOR COLLECTION

1435
01:01:54,277 --> 01:01:59,115
OF EMOBILIZED [INDISCERNIBLE] 

1436
01:01:59,115 --> 01:02:00,317
ADMINISTRATION OF 

1437
01:02:00,317 --> 01:02:02,552
[INDISCERNIBLE] WITHOUT GCSF AND

1438
01:02:02,552 --> 01:02:07,290
THIS WORK ALSO WAS PUBLISHED AND

1439
01:02:07,290 --> 01:02:10,193
HERE WE ARE DEMONSTRATING THAT 

1440
01:02:10,193 --> 01:02:13,797
WE CAN GET A LOT MORE CELLS. 

1441
01:02:13,797 --> 01:02:16,566
THEY LOOK MORE LIKE HEALTHY 

1442
01:02:16,566 --> 01:02:18,969
INDIVIDUAL CD34 CELLS THAN THEY 

1443
01:02:18,969 --> 01:02:22,872
LOOK LIKE BONE MARROW CD34 CELLS

1444
01:02:22,872 --> 01:02:24,307
COMING FROM SICKLE CELL DISEASE 

1445
01:02:24,307 --> 01:02:25,075
PATIENTS. 

1446
01:02:25,075 --> 01:02:26,743
HEALTHIER CELLS AND MORE CELLS 

1447
01:02:26,743 --> 01:02:28,144
AND IMPLEMENTED MANY 

1448
01:02:28,144 --> 01:02:30,313
MANUFACTURING CHANGES TO 

1449
01:02:30,313 --> 01:02:32,315
INCREASE TRANSDUCTION EFFICIENCY

1450
01:02:32,315 --> 01:02:35,251
OF DRUG PRODUCTS ABLE TO GET 

1451
01:02:35,251 --> 01:02:37,787
HIGHER EFFICIENCY TRANSDUCTION 

1452
01:02:37,787 --> 01:02:40,090
OF PRODUCTS AND WERE ULTIMATELY 

1453
01:02:40,090 --> 01:02:41,691
ABLE TO MAKE WHAT WE ASSUMED 

1454
01:02:41,691 --> 01:02:49,032
WOULD BE SUB S STAN SHALLY MORE 

1455
01:02:49,032 --> 01:02:51,701
EFFICACIOUS FOR MANUFACTURING 

1456
01:02:51,701 --> 01:02:52,669
CONDITIONS. 

1457
01:02:52,669 --> 01:02:54,004
THIS WAS TESTED. 

1458
01:02:54,004 --> 01:02:57,807
AS JOHN REFERENCED BEFORE HB206 

1459
01:02:57,807 --> 01:02:59,709
HAS MULTIPLE GROUPS SKIPPING 

1460
01:02:59,709 --> 01:03:03,780
GROUP B AND GOING TO GROUP C. 

1461
01:03:03,780 --> 01:03:06,082
GROUP C WE REQUIRED REGIMENTS 

1462
01:03:06,082 --> 01:03:07,651
THAT WERE THOUGHT TO ESSENTIALLY

1463
01:03:07,651 --> 01:03:09,886
TAKE SOME OF THE PRESSURE OFF 

1464
01:03:09,886 --> 01:03:13,657
THE BONE MARROW AND ARIDGE ROW 

1465
01:03:13,657 --> 01:03:16,626
POETIC STRESS OFF MARROW OF 

1466
01:03:16,626 --> 01:03:18,328
SICKLE CELL PATIENTS AND 

1467
01:03:18,328 --> 01:03:21,031
CHANGING SOURCE OF STEM CELLS 

1468
01:03:21,031 --> 01:03:23,800
AND REFINED MANUFACTURING 

1469
01:03:23,800 --> 01:03:26,069
PROTOCOL TO INCREASE 

1470
01:03:26,069 --> 01:03:28,638
TRANSDUCTION EFFICIENCY 

1471
01:03:28,638 --> 01:03:31,274
INCREASING CELL DOSE WE WERE 

1472
01:03:31,274 --> 01:03:32,308
ADMINISTERING THAT LED TO 

1473
01:03:32,308 --> 01:03:34,711
DIFFERENT AND BETTER RESULTS FOR

1474
01:03:34,711 --> 01:03:37,414
PATIENTS TREATED AND WILL LET 

1475
01:03:37,414 --> 01:03:39,182
JOHN WALK THROUGH CLINICAL DATA 

1476
01:03:39,182 --> 01:03:39,382
HERE. 

1477
01:03:39,382 --> 01:03:41,584
>> I CAN UPDATE YOU NOW. 

1478
01:03:41,584 --> 01:03:44,387
THANKS, MELISSA, ON GROUP C 

1479
01:03:44,387 --> 01:03:44,754
RESULTS. 

1480
01:03:44,754 --> 01:03:47,590
WE HAD NOW 47 PATIENTS FOR 

1481
01:03:47,590 --> 01:03:50,760
EFFICACY AND SAFETY ANALYSIS. 

1482
01:03:50,760 --> 01:03:54,664
WITH 35.5 MONTHS OF FOLLOW UP 

1483
01:03:54,664 --> 01:03:57,200
AND OVERALL EXPOSURE 106.2 

1484
01:03:57,200 --> 01:03:59,302
PATIENT YEARS AND LONGEST FOLLOW

1485
01:03:59,302 --> 01:04:01,304
UP OF 61 MONTHS AND HAD A GOOD 

1486
01:04:01,304 --> 01:04:05,108
SET OF PATIENTS ON DATA SETS TO 

1487
01:04:05,108 --> 01:04:05,475
LOOK AT. 

1488
01:04:05,475 --> 01:04:06,843
THIS IS A. 

1489
01:04:06,843 --> 01:04:10,413
THIS IS TYPICAL OF SICKLE CELL 

1490
01:04:10,413 --> 01:04:14,350
TRANSPLANT PROTOCOL AND AGE OF 

1491
01:04:14,350 --> 01:04:17,220
ENROLLMENT MEETING OF 23 MALE 

1492
01:04:17,220 --> 01:04:20,156
GREATER THAN FEMALE AND SEE IN 

1493
01:04:20,156 --> 01:04:24,327
ALOE TRANSPLANTS TOO AND MOSTLY 

1494
01:04:24,327 --> 01:04:28,998
BETA S BETA S PAIN CRISIS YOU 

1495
01:04:28,998 --> 01:04:33,136
SEE HERE THAT HAVE VASOOCCLUSIVE

1496
01:04:33,136 --> 01:04:36,773
PATIENTS AND FEW PATIENTS WITH 

1497
01:04:36,773 --> 01:04:39,008
HISTORY OF STROKE. 

1498
01:04:39,008 --> 01:04:43,279
PATIENTS GETTING TRANSFUSED OR 

1499
01:04:43,279 --> 01:04:47,250
HYDROXY URIA AND BASELINE 

1500
01:04:47,250 --> 01:04:51,588
HEMOGLOBIN OF 8.7 TWO 

1501
01:04:51,588 --> 01:04:56,126
MOBILIZATION CYCLES PER PATIENT 

1502
01:04:56,126 --> 01:05:00,163
AND DOSE 6.5 AND GOT GOOD DOSE 

1503
01:05:00,163 --> 01:05:01,331
OF [INDISCERNIBLE] AND END OF 

1504
01:05:01,331 --> 01:05:03,733
THE PATIENTS RECOVERY AS 

1505
01:05:03,733 --> 01:05:05,735
EXPECTED PATIENTS STAYED IN 

1506
01:05:05,735 --> 01:05:07,637
HOSPITAL FOR A MONTH AND VECTOR 

1507
01:05:07,637 --> 01:05:10,039
COPY IN PRODUCT WAS 4 AND MOST 

1508
01:05:10,039 --> 01:05:13,877
CELLS HAD VEKOR AND PERIPHERAL 

1509
01:05:13,877 --> 01:05:16,546
BLOOD VECTOR AT THIS TIME 

1510
01:05:16,546 --> 01:05:18,615
REMAINED MEDIAN OF 1 AND 

1511
01:05:18,615 --> 01:05:21,284
COMPARISON OF GROUP A AND GROUP 

1512
01:05:21,284 --> 01:05:24,654
A AND .1 NOW 60 MONTHS OF FOLLOW

1513
01:05:24,654 --> 01:05:27,290
UP IT IS STABLE BUT LOW TO 

1514
01:05:27,290 --> 01:05:29,192
EXPECT CLINICAL BENEFIT AND IT 

1515
01:05:29,192 --> 01:05:33,096
IS MEDIAN OF 1.45 THAT WAS 

1516
01:05:33,096 --> 01:05:34,531
ASSOCIATED WITH COMPLETE 

1517
01:05:34,531 --> 01:05:38,635
RESOLUTION OF ALL DOES AND 88% 

1518
01:05:38,635 --> 01:05:41,304
OF PATIENTS THESE ARE ACUTE PAIN

1519
01:05:41,304 --> 01:05:43,439
EVENTS DEFINED AS SHOWN HERE ON 

1520
01:05:43,439 --> 01:05:44,440
THE RIGHT. 

1521
01:05:44,440 --> 01:05:48,011
IMPORTANTLY 100% OF ADOLESCENT 

1522
01:05:48,011 --> 01:05:49,846
PATIENTS THAT WE THINK THIS IS 

1523
01:05:49,846 --> 01:05:51,514
BECAUSE PAIN HASN'T HAD 

1524
01:05:51,514 --> 01:05:53,416
OPPORTUNITY TO BECOME CHRONIC 

1525
01:05:53,416 --> 01:05:55,218
YET. 

1526
01:05:55,218 --> 01:05:59,088
WE HAD 94% OF PATIENTS 

1527
01:05:59,088 --> 01:06:00,190
EXPERIENCING COMPLETE RESOLUTION

1528
01:06:00,190 --> 01:06:07,564
OF ALL SEVERE VOES THAT ARE 

1529
01:06:07,564 --> 01:06:12,402
ENDPOINTS FOR FDA TO CONSIDER 

1530
01:06:12,402 --> 01:06:12,602
THIS. 

1531
01:06:12,602 --> 01:06:17,473
AMONG THOSE PATIENTS WITH PAIN 

1532
01:06:17,473 --> 01:06:20,743
EVENT POST INFUSION THEY WERE 

1533
01:06:20,743 --> 01:06:22,912
MOSTLY BRIEF NOT LIKE ONES 

1534
01:06:22,912 --> 01:06:25,448
BEFORE THAT COULD LASS FOR WEEKS

1535
01:06:25,448 --> 01:06:28,918
AND IMPROVEMENTS IN PAIN 

1536
01:06:28,918 --> 01:06:30,954
INTENSITY AND PAIN INTERFERENCE 

1537
01:06:30,954 --> 01:06:33,423
AND FATIGUE AND ALL THESE ARE 

1538
01:06:33,423 --> 01:06:34,691
GOING IN THE RIGHT DIRECTION 

1539
01:06:34,691 --> 01:06:36,426
THAT ARE CLINICAL WILL I 

1540
01:06:36,426 --> 01:06:38,828
MEANINGFUL IMPROVEMENTS IN 

1541
01:06:38,828 --> 01:06:40,964
MEASURES AS REPORTED NOT BY US 

1542
01:06:40,964 --> 01:06:45,368
BUT BY PATIENTS THAT YOU CAN SEE

1543
01:06:45,368 --> 01:06:50,139
HEMOFWLOBIN ATA32 HEMOGLOBIN 

1544
01:06:50,139 --> 01:06:52,775
ENCODED IN VECTOR IN BLUE 

1545
01:06:52,775 --> 01:06:55,044
PERCENTAGE OF TOTAL HEMOGLOBIN 

1546
01:06:55,044 --> 01:06:56,679
AND IMPORTANT TO NOTE THAT IT 

1547
01:06:56,679 --> 01:06:58,514
GOES TO THE NORMAL RANGE AND 

1548
01:06:58,514 --> 01:07:02,619
NEARLY HALF OF IT IS COMING FROM

1549
01:07:02,619 --> 01:07:03,987
VECTOR. 

1550
01:07:03,987 --> 01:07:06,623
86.8% PATIENTS ACHIEVED ARE 

1551
01:07:06,623 --> 01:07:08,992
GLOBIN RESPONSE TOO THAT WAS 

1552
01:07:08,992 --> 01:07:12,195
INCREASING GREATER THAN 3 GRAMS 

1553
01:07:12,195 --> 01:07:16,833
OR WEIGHTED AVERAGE OF 30% OF 

1554
01:07:16,833 --> 01:07:19,702
HEMOGLOBIN T87Q COMING FROM 

1555
01:07:19,702 --> 01:07:22,939
VECTOR OR ARISE GREATER THAN 10.

1556
01:07:22,939 --> 01:07:24,908
100% OF THOSE REACHING THIS GOAL

1557
01:07:24,908 --> 01:07:28,211
HAD IT BE DURABLE. 

1558
01:07:28,211 --> 01:07:29,913
THESE ARE HOM OL SOUS MARKERS 

1559
01:07:29,913 --> 01:07:35,251
LIKE I SHOWED YOU FOR ALLOGENEIC

1560
01:07:35,251 --> 01:07:37,587
TRANSPLANT PROTOCOL THEY 

1561
01:07:37,587 --> 01:07:40,623
APPROACH LEVELS AND 

1562
01:07:40,623 --> 01:07:42,058
[INDISCERNIBLE] RECEPTIC YOU'LLO

1563
01:07:42,058 --> 01:07:45,128
SITES BEING ELEVATED IN 

1564
01:07:45,128 --> 01:07:47,463
ALOSETTING AND CONTRAST TO GROUP

1565
01:07:47,463 --> 01:07:51,401
A WE SAW ONLY THOSE B SUL FAN 

1566
01:07:51,401 --> 01:07:53,403
RELATED TREATMENT OR ADVERSE 

1567
01:07:53,403 --> 01:07:56,739
EVENTS AND NO CASES OF VEENO OK 

1568
01:07:56,739 --> 01:08:00,743
COLLUSIVE DISEASE AND NO VECTOR 

1569
01:08:00,743 --> 01:08:03,079
COMPLICATIONS INCLUDING 

1570
01:08:03,079 --> 01:08:04,847
REPLICATION-COMPETENT LENTI 

1571
01:08:04,847 --> 01:08:06,783
VIRUS AND ONE DEATH 

1572
01:08:06,783 --> 01:08:08,418
UNFORTUNATELY IN INDIVIDUAL WITH

1573
01:08:08,418 --> 01:08:11,788
SIGNIFICANT CARDIO PULMONARY 

1574
01:08:11,788 --> 01:08:13,690
DISEASE WITH A SUDDENEN DEATH 

1575
01:08:13,690 --> 01:08:17,193
RELATED TO PRE-EXISTING CARDIO 

1576
01:08:17,193 --> 01:08:19,028
PULMONARY DISEASE AND RESULTS 

1577
01:08:19,028 --> 01:08:21,264
COMPARE FAVE RABBLY TO 

1578
01:08:21,264 --> 01:08:22,932
ALOTRANSPLANT SETTING ASKED TO 

1579
01:08:22,932 --> 01:08:24,734
COMPARE THEM TO WHAT IS SEEN 

1580
01:08:24,734 --> 01:08:28,104
FROM ALORECIPIENTS THAT NEVER 

1581
01:08:28,104 --> 01:08:29,439
HAD THESE THINGS DESCRIBED AND 

1582
01:08:29,439 --> 01:08:31,240
ASSUME THEY GO AWAY AND LOOKED 

1583
01:08:31,240 --> 01:08:35,445
AT PATIENTS ALEXIS AGAIN AND 

1584
01:08:35,445 --> 01:08:37,080
FOUND THAT AFTER ALOTRANSPLANT 

1585
01:08:37,080 --> 01:08:40,116
WE HAVE LOTS OF PAIN EVENTS IN 

1586
01:08:40,116 --> 01:08:42,785
SECOND YEAR ALMOST NONE SHOWN IN

1587
01:08:42,785 --> 01:08:45,188
RED WITH EXCEPTION OF PATIENTS 

1588
01:08:45,188 --> 01:08:47,056
AT TOP EXPERIENCING GRAPH 

1589
01:08:47,056 --> 01:08:48,658
REJECTION AND WILL PASS IT BACK 

1590
01:08:48,658 --> 01:08:51,260
TO MELISSA FOR HER TO SAY A 

1591
01:08:51,260 --> 01:08:53,529
COUPLE WORDS ABOUT APPROVAL. 

1592
01:08:53,529 --> 01:08:54,897
WE WILL TAKE QUESTIONS. 

1593
01:08:54,897 --> 01:08:56,933
>> YES.  YOU KNOW, FOR THE
SAKE 

1594
01:08:56,933 --> 01:08:59,535
OF TIME I WANT TO QUICKLY SAY 

1595
01:08:59,535 --> 01:09:00,803
[INDISCERNIBLE] FOR THIS. 

1596
01:09:00,803 --> 01:09:02,638
YOU KNOW, LIKE I SAID 

1597
01:09:02,638 --> 01:09:04,240
PREVIOUSLY, WE ENCOUNTERED A LOT

1598
01:09:04,240 --> 01:09:06,109
OF CHALLENGES WITH THE 

1599
01:09:06,109 --> 01:09:07,510
DEVELOPMENT OF THIS PROGRAM AND 

1600
01:09:07,510 --> 01:09:10,446
YOU KNOW PARTLY I THINK BECAUSE 

1601
01:09:10,446 --> 01:09:12,882
OF UNDERLYING DISEASE NUANCES 

1602
01:09:12,882 --> 01:09:15,218
THAT REALLY ONLY BECAME CLEARER 

1603
01:09:15,218 --> 01:09:16,686
OVER TIME AND PARTLY BECAUSE 

1604
01:09:16,686 --> 01:09:19,022
THIS IS HARD AND GENE AND CELL 

1605
01:09:19,022 --> 01:09:21,858
THERAPY IS REALLY HARD. 

1606
01:09:21,858 --> 01:09:27,230
YOU KNOW, WE WERE -- IT WAS 

1607
01:09:27,230 --> 01:09:29,465
INCREDIBLY FORTUNATE TO WORK 

1608
01:09:29,465 --> 01:09:31,034
WITH JOHN AND HIS TEAM AND THAT 

1609
01:09:31,034 --> 01:09:37,674
WE HAD A GREAT RELATIONSHIP WITH

1610
01:09:37,674 --> 01:09:38,207
NHLBI. 

1611
01:09:38,207 --> 01:09:40,209
I DON'T.  I CAN'T IMAGINE WE 

1612
01:09:40,209 --> 01:09:43,112
WOULD BE ABLE TO OVERCOME 

1613
01:09:43,112 --> 01:09:46,516
OBSTACLES IN A SHORT TIME PERIOD

1614
01:09:46,516 --> 01:09:48,751
OTHERWISE AND WE HAD AGAIN I 

1615
01:09:48,751 --> 01:09:50,787
MENTIONED EARLIER INCREDIBLY 

1616
01:09:50,787 --> 01:09:51,487
ALIGNED MOTIVATIONS AND 

1617
01:09:51,487 --> 01:09:54,390
INTERESTS AND WANTED TO REALLY 

1618
01:09:54,390 --> 01:09:57,827
DO WHAT WAS RIGHT FOR PATIENTS 

1619
01:09:57,827 --> 01:10:07,837
WITH SICKLE CELL DISEASE. 

1620
01:10:07,837 --> 01:10:10,873
WE ARE FORTUNATE WITH RECENT 

1621
01:10:10,873 --> 01:10:13,476
APPROVALS AND PRODUCT THAT WAS 

1622
01:10:13,476 --> 01:10:16,512
HERE TODAY COMING FROM BLUEBERG 

1623
01:10:16,512 --> 01:10:21,451
BIOWAS APPROVED AND NOW MARKETED

1624
01:10:21,451 --> 01:10:24,720
I'M NO LONGER WITH THEM AND 

1625
01:10:24,720 --> 01:10:27,557
CAN'T SPEAK TO THEM CURRENTLY 

1626
01:10:27,557 --> 01:10:30,426
THIS IS NOT BLUEBERG MARKETING 

1627
01:10:30,426 --> 01:10:30,760
NOW. 

1628
01:10:30,760 --> 01:10:33,362
FOR SICKLE CELL PATIENTS ANOTHER

1629
01:10:33,362 --> 01:10:35,765
PRODUCT APPROVED IN DECEMBER AS 

1630
01:10:35,765 --> 01:10:36,199
WELL. 

1631
01:10:36,199 --> 01:10:39,736
THAT IS A GENE-EDITED PRODUCT 

1632
01:10:39,736 --> 01:10:44,474
THAT IS A HEMOPOETIC STEM-CELL 

1633
01:10:44,474 --> 01:10:47,343
BASED PRODUCT TONS OF WORK AND 

1634
01:10:47,343 --> 01:10:48,778
DEDICATION AND TIME AND 

1635
01:10:48,778 --> 01:10:50,313
FORTUNATE TO HAVE COLLABORATION 

1636
01:10:50,313 --> 01:10:54,183
WE HAD AND RELATIONSHIPS WE WERE

1637
01:10:54,183 --> 01:10:55,218
ABLE TO BUILD. 

1638
01:10:55,218 --> 01:10:57,854
>> I WANTED TO SAY ONE
WORD 

1639
01:10:57,854 --> 01:11:00,189
ABOUT THE PERSON WHOSE PICTURE I

1640
01:11:00,189 --> 01:11:01,390
HAD UP. 

1641
01:11:01,390 --> 01:11:04,360
ACTUALLY FIRST PATIENT ON 

1642
01:11:04,360 --> 01:11:05,795
PROTOCOL AND WHO WAS DESCRIBED 

1643
01:11:05,795 --> 01:11:10,500
WITH MDS A FEW YEARS OUT DIDN'T 

1644
01:11:10,500 --> 01:11:12,068
SURVIVE UNFORTUNATELY. 

1645
01:11:12,068 --> 01:11:15,037
HE WAS A REAL PIONEER AND TOLD 

1646
01:11:15,037 --> 01:11:17,373
US WHEN CONSENTED THAT HE WANTED

1647
01:11:17,373 --> 01:11:19,675
TO DO THIS FOR OTHER PATIENTS 

1648
01:11:19,675 --> 01:11:21,277
WITH THE DISEASE REALIZING IT 

1649
01:11:21,277 --> 01:11:22,945
MIGHT TAKE TIME FOR US TO GET 

1650
01:11:22,945 --> 01:11:25,114
THERE AND REMINDING THANKING 

1651
01:11:25,114 --> 01:11:27,650
PARTICIPANTS IN CLINICAL TRIALS.

1652
01:11:27,650 --> 01:11:30,553
WITHOUT THEM, WE COULDN'T DO ANY

1653
01:11:30,553 --> 01:11:31,787
OF THIS. 

1654
01:11:31,787 --> 01:11:34,357
THEY ARE REALLY PARTNERS 

1655
01:11:34,357 --> 01:11:35,958
BRINGING TRANSFORMATIVE 

1656
01:11:35,958 --> 01:11:37,426
THERAPIES TO BEAR. 

1657
01:11:37,426 --> 01:11:38,928
THANK YOU. 

1658
01:11:38,928 --> 01:11:40,997
>> THANK YOU FOR THAT
FANTASTIC 

1659
01:11:40,997 --> 01:11:42,765
AND INSPIRING COLLABORATION 

1660
01:11:42,765 --> 01:11:43,065
STORY. 

1661
01:11:43,065 --> 01:11:45,101
WE ARE RUNNING A LITTLE SHORT OF

1662
01:11:45,101 --> 01:11:45,568
TIME. 

1663
01:11:45,568 --> 01:11:47,837
SO, MAYBE WE HAVE TIME FOR ONE 

1664
01:11:47,837 --> 01:11:50,907
QUESTION AND CAN GO ON TO THE 

1665
01:11:50,907 --> 01:11:53,509
NEXT SESSION. 

1666
01:11:53,509 --> 01:11:59,282
>> SO, MELISSA COULD YOU
TALK 

1667
01:11:59,282 --> 01:12:02,084
ABOUT YOUR EXPERIENCE ACTUAL 

1668
01:12:02,084 --> 01:12:04,854
GOING THROUGH THE PAPERWORK AND 

1669
01:12:04,854 --> 01:12:07,523
DEBT TRANSFER AND ACTUALLY 

1670
01:12:07,523 --> 01:12:10,526
MAKING ALL THIS HAPPEN?  

1671
01:12:10,526 --> 01:12:13,596
>> YEAH.  

1672
01:12:13,596 --> 01:12:15,798
I THINK THAT THERE IS LOTS OF 

1673
01:12:15,798 --> 01:12:17,333
ADVANTAGES TO THAT. 

1674
01:12:17,333 --> 01:12:19,602
THERE IS LOTS OF FLEXIBILITY IN 

1675
01:12:19,602 --> 01:12:22,471
TERMS OF UNDERLYING WORK AND 

1676
01:12:22,471 --> 01:12:24,640
MOTIVATIONS WERE CLEARLY ALIGNED

1677
01:12:24,640 --> 01:12:25,875
AS WELL. 

1678
01:12:25,875 --> 01:12:28,811
WE ENCOUNTERED ISSUES AND 

1679
01:12:28,811 --> 01:12:30,379
TACKLED THEM TOGETHER AND AT 

1680
01:12:30,379 --> 01:12:33,883
TIMES GOOD BENEFIT IS A PRETTY 

1681
01:12:33,883 --> 01:12:36,252
BROAD DEFINITION WHAT YOU ARE 

1682
01:12:36,252 --> 01:12:39,288
WORKING ON AND IT SEEMED THAT WE

1683
01:12:39,288 --> 01:12:41,057
COULD KEEP EXPANDING GOING OFF 

1684
01:12:41,057 --> 01:12:44,293
IN TANGENTS AND DETAILS TO WORK 

1685
01:12:44,293 --> 01:12:46,195
PROBLEMS AS THEY CAME UP YOU 

1686
01:12:46,195 --> 01:12:47,296
KNOW INSTEAD OF SOMETIMES WHEN 

1687
01:12:47,296 --> 01:12:50,199
YOU HAVE ACADEMIC RELATIONSHIP 

1688
01:12:50,199 --> 01:12:52,568
IT IS VERY MUCH DEFINED IN SCOPE

1689
01:12:52,568 --> 01:12:54,737
OF ORIGINAL AGREEMENT AND NOT 

1690
01:12:54,737 --> 01:12:57,073
LOTS OF FLEXIBILITY AND WIGGLE 

1691
01:12:57,073 --> 01:12:58,641
ROOM TO GO BEYOND THAT. 

1692
01:12:58,641 --> 01:13:01,744
IT IS NOT CASE HERE. 

1693
01:13:01,744 --> 01:13:04,347
I SAID EARLIER I HOLD RECORD FOR

1694
01:13:04,347 --> 01:13:06,649
LONGEST IT HAS TAKEN TO GET FOR 

1695
01:13:06,649 --> 01:13:10,586
A SPECIFIC ASPECT OF ONE THING 

1696
01:13:10,586 --> 01:13:12,521
WE DID. 

1697
01:13:12,521 --> 01:13:14,323
>> WHOLEHEARTEDLY I WILL 

1698
01:13:14,323 --> 01:13:16,525
CONTINUE TO SAY IT WAS WORTH IT.

1699
01:13:16,525 --> 01:13:17,093
RIGHT?  

1700
01:13:17,093 --> 01:13:19,095
IN THAT CASE JUICE WAS WORTH THE

1701
01:13:19,095 --> 01:13:19,362
SQUEEZE. 

1702
01:13:19,362 --> 01:13:22,198
WE WANTED TO WORK WITH JOHN. 

1703
01:13:22,198 --> 01:13:25,067
YOU HAVE A PLETHORA OF EXPERTS 

1704
01:13:25,067 --> 01:13:27,737
WHO ARE NOT ONLY INCREDIBLY 

1705
01:13:27,737 --> 01:13:29,839
SMART PEOPLE BUT DEDICATED AND 

1706
01:13:29,839 --> 01:13:34,677
PATIENT FOCUSED AND DRIVEN. 

1707
01:13:34,677 --> 01:13:36,345
THERE IS HUGE ADVANTAGES TO 

1708
01:13:36,345 --> 01:13:38,447
WORKING WITH INDIVIDUALS THAT 

1709
01:13:38,447 --> 01:13:42,885
EMBODY SAME VALUES THAT ARE 

1710
01:13:42,885 --> 01:13:43,152
EMBODIED. 

1711
01:13:43,152 --> 01:13:46,889
I HOPE A LOT ON THE CALL DO OR 

1712
01:13:46,889 --> 01:13:49,592
STRIVE TO DO. 

1713
01:13:49,592 --> 01:13:51,027
>> THANK YOU SO MUCH. 

1714
01:13:51,027 --> 01:13:53,262
I WILL NOW TURN THIS OVER TO 

1715
01:13:53,262 --> 01:13:56,832
MICHAEL WHO WILL INTRODUCE THE 

1716
01:13:56,832 --> 01:13:59,735
NEXT SPEAK ER. 

1717
01:13:59,735 --> 01:14:00,503
>> THANK YOU. 

1718
01:14:00,503 --> 01:14:02,738
>> THANK YOU VERY MUCH. 

1719
01:14:02,738 --> 01:14:03,906
WELCOME, EVERYBODY. 

1720
01:14:03,906 --> 01:14:09,278
NIH IS LARGELY KNOWN AS BEING 

1721
01:14:09,278 --> 01:14:13,182
THE LARGEST BASIC BIOMEDICAL 

1722
01:14:13,182 --> 01:14:15,484
RESEARCH CENTER THAT IS THOUGHT 

1723
01:14:15,484 --> 01:14:18,988
OF AS A LARGE FUNDER OF ACADEMIC

1724
01:14:18,988 --> 01:14:20,523
RESEARCH PUBLISHING ACADEMIC 

1725
01:14:20,523 --> 01:14:20,823
PAPERS. 

1726
01:14:20,823 --> 01:14:22,692
WHAT IS LESS KNOWN AND THIS 

1727
01:14:22,692 --> 01:14:24,727
EVENT IS CERTAINLY HELPING TO 

1728
01:14:24,727 --> 01:14:27,496
ADDRESS IS ALL OF THE WORK WE DO

1729
01:14:27,496 --> 01:14:31,167
WITH INDUSTRY PARTNERS TO GET 

1730
01:14:31,167 --> 01:14:33,602
IMPORTANT UNMET MEDICAL NEEDS TO

1731
01:14:33,602 --> 01:14:37,907
PATIENTS THAT NEED THEM AND NIH 

1732
01:14:37,907 --> 01:14:40,743
TRANSFER OFFICERS AND GREAT 

1733
01:14:40,743 --> 01:14:43,245
REPRESENTATIVE OF GO-TO PLACE 

1734
01:14:43,245 --> 01:14:46,115
FOR HEALTHCARE INDUSTRY THOUGHT 

1735
01:14:46,115 --> 01:14:49,385
LEADER OVERCOMING TECHNOLOGY AND

1736
01:14:49,385 --> 01:14:50,920
KNOWLEDGE GAP CONDUCTING FIRST 

1737
01:14:50,920 --> 01:14:53,222
TRIAL AND GETTING PRODUCT TO 

1738
01:14:53,222 --> 01:14:53,556
MARKET. 

1739
01:14:53,556 --> 01:14:56,525
I HAD TECHNOLOGY ANALYSIS AND 

1740
01:14:56,525 --> 01:14:59,528
MARKETING UNIT WITHIN NCI'S TECH

1741
01:14:59,528 --> 01:15:00,930
TRANSFER CENTER AND BUSINESS 

1742
01:15:00,930 --> 01:15:02,031
DEVELOPMENT GROUP AND IN 

1743
01:15:02,031 --> 01:15:04,467
ADDITION TO PEOPLE SEEING ON 

1744
01:15:04,467 --> 01:15:05,968
SCREEN HELPING PUT TOGETHER THIS

1745
01:15:05,968 --> 01:15:09,004
EVENT MY MISSION IS TO ACT AS 

1746
01:15:09,004 --> 01:15:10,406
CONNECTORS TO OUTSIDE COMMUNITY 

1747
01:15:10,406 --> 01:15:12,408
AND WOULD BE GLAD TO HEAR FROM 

1748
01:15:12,408 --> 01:15:19,248
ATTENDEES IF WE CAN BE OF 

1749
01:15:19,248 --> 01:15:26,055
SERV

1750
01:15:26,055 --> 01:15:26,322
SERVICE. 

1751
01:15:26,322 --> 01:15:29,025
I'LL TURN IT TO ANDY BURKE TO 

1752
01:15:29,025 --> 01:15:32,294
TALK ABOUT TECH TRANSFER AT 

1753
01:15:32,294 --> 01:15:32,928
NATIONAL INSTITUTES OF HEALTH. 

1754
01:15:32,928 --> 01:15:33,863
>> THANK YOU, MICHAEL.  I 

1755
01:15:33,863 --> 01:15:37,433
APPRECIATE THE INTRODUCTION.  I 

1756
01:15:37,433 --> 01:15:45,241
WILL SHARE MY SCREEN. 

1757
01:15:45,241 --> 01:15:55,785
I HOPE THAT IS UP FOR EVERYBODY.

1758
01:15:58,521 --> 01:16:00,423
ALL RIGHT.  THERE WE GO.  THANK 

1759
01:16:00,423 --> 01:16:03,793
YOU FOR THE KIND INTRODUCTION 

1760
01:16:03,793 --> 01:16:13,702
AND OPPORTUNITY TO SPEAK TODAY. 

1761
01:16:13,702 --> 01:16:18,240
WE HELP TO ENABLE SUCCESSFUL 

1762
01:16:18,240 --> 01:16:19,842
SCIENTIFIC PARTNERSHIPS. 

1763
01:16:19,842 --> 01:16:21,877
BEFORE I DO THAT I WANT TO TAKE 

1764
01:16:21,877 --> 01:16:24,380
AN OPPORTUNITY TO TALK ABOUT 

1765
01:16:24,380 --> 01:16:27,716
MYSELF.  THIS IS PURPOSEFUL. 

1766
01:16:27,716 --> 01:16:29,452
I WANT YOU TO APPRECIATE 

1767
01:16:29,452 --> 01:16:30,786
PERSPECTIVE YOU ARE RECEIVING 

1768
01:16:30,786 --> 01:16:32,021
TODAY TO UNDERSTAND THE SOURCE 

1769
01:16:32,021 --> 01:16:33,722
OF THE INFORMATION AND MAYBE I 

1770
01:16:33,722 --> 01:16:36,125
WILL INFORM SOME DECISIONS YOU 

1771
01:16:36,125 --> 01:16:37,293
MIGHT DRAW FROM IT. 

1772
01:16:37,293 --> 01:16:40,696
I SHOW THIS SORT OF ABBREVIATED 

1773
01:16:40,696 --> 01:16:41,864
CHART AT THE TOP. 

1774
01:16:41,864 --> 01:16:45,334
IF YOU LOOK YOUR WAY DOWN, YOU 

1775
01:16:45,334 --> 01:16:46,836
NOTICE I WILL COME TO YOU TODAY 

1776
01:16:46,836 --> 01:16:49,772
FROM DEEP IN THE ROSTER. 

1777
01:16:49,772 --> 01:16:51,974
I VERY MUCH ENGAGE IN THE 

1778
01:16:51,974 --> 01:16:54,110
DAY-TO-DAY TRANSACTIONAL WORK OF

1779
01:16:54,110 --> 01:16:56,979
TECH TRANSFER AND BIOMEDICAL 

1780
01:16:56,979 --> 01:16:58,247
RESEARCH SCIENTIST IN TRAINING 

1781
01:16:58,247 --> 01:17:00,082
AND I HAVE HAD OPPORTUNITY TO DO

1782
01:17:00,082 --> 01:17:02,117
HUNDREDS OF LICENSES AND 

1783
01:17:02,117 --> 01:17:02,451
AGREEMENTS. 

1784
01:17:02,451 --> 01:17:03,853
I WILL CELEBRATE THE FACT THAT 

1785
01:17:03,853 --> 01:17:07,356
WE HAVE BEEN ABLE TO GET TWO FDA

1786
01:17:07,356 --> 01:17:09,325
TREATMENTS APPROVED OVER THE 

1787
01:17:09,325 --> 01:17:12,228
FINISH LINE AND FINGERS CROSSED 

1788
01:17:12,228 --> 01:17:14,563
WE HAVE ANOTHER PARTNER THAT 

1789
01:17:14,563 --> 01:17:15,865
WILL BE SUCCESSFUL AS WELL. 

1790
01:17:15,865 --> 01:17:18,234
I SHARE WITH YOU IN HOPE THAT MY

1791
01:17:18,234 --> 01:17:21,437
PERSPECTIVE WILL BE A USEFUL 

1792
01:17:21,437 --> 01:17:22,705
COMPLEMENT TO THE INFORMATION 

1793
01:17:22,705 --> 01:17:25,407
YOU RECEIVE FROM SENIOR STAFF IN

1794
01:17:25,407 --> 01:17:26,342
EARLIER TALKS. 

1795
01:17:26,342 --> 01:17:27,643
I LIKE THE OPPORTUNITY TO TALK 

1796
01:17:27,643 --> 01:17:30,679
ABOUT THE EXCITING AREA OF TECH 

1797
01:17:30,679 --> 01:17:33,315
TRANSFER OR INTERFACE BETWEEN 

1798
01:17:33,315 --> 01:17:35,084
ACADEMIC INNOVATION ON ONE SIDE 

1799
01:17:35,084 --> 01:17:36,418
AND COMMERCIAL DEVELOPMENT THAT 

1800
01:17:36,418 --> 01:17:38,621
IS NECESSARY TO GET A PRODUCT TO

1801
01:17:38,621 --> 01:17:40,723
PATIENTS AND ADDRESS UNMET 

1802
01:17:40,723 --> 01:17:42,591
MEDICAL NEED THAT MICHAEL WAS 

1803
01:17:42,591 --> 01:17:43,826
REFERENCING THAT IS ENOUGH ABOUT

1804
01:17:43,826 --> 01:17:45,661
ME AND I WILL TALK ABOUT 

1805
01:17:45,661 --> 01:17:47,530
SOMETHING OF SUBSTANCE HERE. 

1806
01:17:47,530 --> 01:17:49,231
WHEN I WAS FRAMING TODAY'S TALK 

1807
01:17:49,231 --> 01:17:51,267
OR THINKING ABOUT IT I THOUGHT 

1808
01:17:51,267 --> 01:17:53,602
IT WOULD BE USEFUL TO TALK ABOUT

1809
01:17:53,602 --> 01:17:55,437
THREE MAIN CATEGORIES OF 

1810
01:17:55,437 --> 01:17:55,771
INFORMATION. 

1811
01:17:55,771 --> 01:17:57,873
WHY WOULD YOU WANT TO WORK WITH 

1812
01:17:57,873 --> 01:17:58,374
NIH?  

1813
01:17:58,374 --> 01:18:01,277
THIS IS PERSPECTIVE OUTSIDE 

1814
01:18:01,277 --> 01:18:01,911
PARTY LOOKING IN. 

1815
01:18:01,911 --> 01:18:04,213
WHY WOULD YOU WANT TO WORK WITH 

1816
01:18:04,213 --> 01:18:04,680
NIH?  

1817
01:18:04,680 --> 01:18:07,850
WHAT CAN WE OFFER YOU IF YOU 

1818
01:18:07,850 --> 01:18:10,486
WERE TO WORK WITH US?  SEVERAL 

1819
01:18:10,486 --> 01:18:12,054
THINGS OTHERS MENTIONED THAT I 

1820
01:18:12,054 --> 01:18:15,124
WILL TOUCH ON BRIEFLY HERE. 

1821
01:18:15,124 --> 01:18:16,859
YOU MADE LEAP AND DECIDED WE 

1822
01:18:16,859 --> 01:18:19,628
COULD BE A PARTNER FOR YOU AND 

1823
01:18:19,628 --> 01:18:22,264
INFORMATION ABOUT NIH TECH 

1824
01:18:22,264 --> 01:18:23,032
TRANSFER STRUCTURE AND 

1825
01:18:23,032 --> 01:18:24,400
ORGANIZATION AS LARGE AS OURS 

1826
01:18:24,400 --> 01:18:26,235
HOW DO YOU FIND TECHNOLOGY 

1827
01:18:26,235 --> 01:18:30,306
TRANSFER CONTACT?  THAT COULD BE

1828
01:18:30,306 --> 01:18:32,074
A CHALLENGE WALKING THROUGH IN 

1829
01:18:32,074 --> 01:18:34,310
DETAIL AND WHAT CAN WE DO FOR 

1830
01:18:34,310 --> 01:18:35,778
YOU AND ENABLE SCIENCE AND WHAT 

1831
01:18:35,778 --> 01:18:38,614
WE CAN DO TO ENABLE LICENSE THAT

1832
01:18:38,614 --> 01:18:40,716
WILL HELP YOU GET ACCESS TO 

1833
01:18:40,716 --> 01:18:42,017
CRITICAL TECHNOLOGIES. 

1834
01:18:42,017 --> 01:18:44,720
FINALLY IN SOMETHING THAT I WILL

1835
01:18:44,720 --> 01:18:47,289
HOPEFULLY TEE UP AN INFORMATIVE 

1836
01:18:47,289 --> 01:18:50,359
Q & A ENGAGE IN MYTH BUSTING
AND

1837
01:18:50,359 --> 01:18:53,062
WE WILL ADDRESS WORD ON THE 

1838
01:18:53,062 --> 01:18:54,496
STREET INFORMATION THAT PEOPLE 

1839
01:18:54,496 --> 01:18:57,099
KNOW ABOUT NIH TRANSFER ABOUT 

1840
01:18:57,099 --> 01:19:00,536
THINGS WE CAN AND CAN'T DO AND 

1841
01:19:00,536 --> 01:19:02,371
PARSING FICTION THERE. 

1842
01:19:02,371 --> 01:19:04,139
STARTING I WANTEDED TO CELEBRATE

1843
01:19:04,139 --> 01:19:07,009
OR REMARK ON THE INCREDIBLE 

1844
01:19:07,009 --> 01:19:08,577
BREADTH OF RESEARCH THAT GOES ON

1845
01:19:08,577 --> 01:19:09,645
AT NIH. 

1846
01:19:09,645 --> 01:19:11,614
I THINK THAT PEOPLE ON OUTSIDE 

1847
01:19:11,614 --> 01:19:15,250
LOOKING IN THINK OF NIH AS A 

1848
01:19:15,250 --> 01:19:16,752
MONOLITH THAT IS ONE NIH. 

1849
01:19:16,752 --> 01:19:18,687
IF YOU LOOK CLOSELY YOU REALIZE 

1850
01:19:18,687 --> 01:19:21,924
THAT NIH IS 27 DISCRETE 

1851
01:19:21,924 --> 01:19:24,159
INSTITUTES AND CENTERS THAT IS 

1852
01:19:24,159 --> 01:19:26,128
27 DIFFERENT ORGANIZATIONS EACH 

1853
01:19:26,128 --> 01:19:28,230
WITH THEIR OWN SPECIFIC FOCUSES 

1854
01:19:28,230 --> 01:19:31,367
SUPPORTING BROADER NIH MISSION. 

1855
01:19:31,367 --> 01:19:34,770
YOU HAVE WITHIN INSTITUTES YOU 

1856
01:19:34,770 --> 01:19:37,706
HAVE A WHOLE RANGE OF PARTICULAR

1857
01:19:37,706 --> 01:19:39,975
RESEARCH PROGRAMS THAT FOCUS ON 

1858
01:19:39,975 --> 01:19:42,044
SPECIFIC DISEASES OR PROCESSES 

1859
01:19:42,044 --> 01:19:44,713
NATIONAL CANCER PROCESS THAT 

1860
01:19:44,713 --> 01:19:47,249
EFFECT IHEALTH NATIONAL 

1861
01:19:47,249 --> 01:19:49,118
INSTITUTE AND NATIONAL EYE 

1862
01:19:49,118 --> 01:19:53,389
INSTITUTE NIAD FOR INFECTIOUS 

1863
01:19:53,389 --> 01:19:56,892
DISEASES OR ALLERGIES AND NORMAL

1864
01:19:56,892 --> 01:19:59,261
RESEARCH BIOLOGY TO DISEASE 

1865
01:19:59,261 --> 01:20:01,597
TREATMENT PREVENTION 

1866
01:20:01,597 --> 01:20:02,731
DISSEMINATION OF KNOWLEDGE ELTS 

1867
01:20:02,731 --> 01:20:05,868
AND UPSHOT FOR POTENTIAL PARTNER

1868
01:20:05,868 --> 01:20:07,269
IS WHATEVER YOUR FIELD OF 

1869
01:20:07,269 --> 01:20:09,471
INTEREST I HAVE EXTREMELY HIGH 

1870
01:20:09,471 --> 01:20:11,540
CONFIDENCE THAT SOMEWHERE IN 27 

1871
01:20:11,540 --> 01:20:13,575
INSTITUTES AND CENTERS IS A 

1872
01:20:13,575 --> 01:20:15,244
RESEARCHER THAT KNOWS AND CARES 

1873
01:20:15,244 --> 01:20:19,114
ABOUT YOUR AREA AS MUCH AS YOU 

1874
01:20:19,114 --> 01:20:19,648
DO. 

1875
01:20:19,648 --> 01:20:21,050
RIGHT?  

1876
01:20:21,050 --> 01:20:24,153
SO JUST FOR EXAMPLE SAY YOU ARE 

1877
01:20:24,153 --> 01:20:28,424
A -- SAY YOU ARE A CELL THERAPY 

1878
01:20:28,424 --> 01:20:30,125
START-UP INTERESTED IN 

1879
01:20:30,125 --> 01:20:31,694
DEVELOPING NEXT GENERATION 

1880
01:20:31,694 --> 01:20:34,363
T-CELL THERAPIES FOR COMMON 

1881
01:20:34,363 --> 01:20:37,700
EPITHELIAL CANCERS TOPIC NEAR 

1882
01:20:37,700 --> 01:20:39,835
AND DEAR TO PROFESSIONAL HEART. 

1883
01:20:39,835 --> 01:20:42,237
IF THAT IS YOU YOU WILL BE PROUD

1884
01:20:42,237 --> 01:20:52,147
THAT NIH IS HOME TO SURGERY 

1885
01:20:52,147 --> 01:20:53,749
BRANCH AND UNDERSTATEMENT OF. 

1886
01:20:53,749 --> 01:20:56,618
PERHAPS HIS RESEARCH WOULD BE 

1887
01:20:56,618 --> 01:20:57,453
INTERESTED TO YOU. 

1888
01:20:57,453 --> 01:20:59,021
MAYBE NOT INTERESTED IN CELL 

1889
01:20:59,021 --> 01:21:05,160
THERAPY BUT ALIGNED IN 

1890
01:21:05,160 --> 01:21:06,695
INFECTIOUS DISEASE SPACE AND 

1891
01:21:06,695 --> 01:21:08,397
HUMANITY AND MALARIA AND IF THAT

1892
01:21:08,397 --> 01:21:11,200
IS THE CASELY INTRODUCE YOU TO 

1893
01:21:11,200 --> 01:21:16,371
KAIRO LEANA WHO IS DISTINGUISHED

1894
01:21:16,371 --> 01:21:18,807
INVESTIGATOR AT ANYAD AND WORLD 

1895
01:21:18,807 --> 01:21:20,909
RECOGNIZED EXPERT IN PARASITE 

1896
01:21:20,909 --> 01:21:24,446
INTERACTIONS IN MALARIA. 

1897
01:21:24,446 --> 01:21:25,681
MAYBE NEITHER OF THOSE TICKLE 

1898
01:21:25,681 --> 01:21:28,016
YOUR FANCY AND YOU ARE MORE 

1899
01:21:28,016 --> 01:21:30,419
INTERESTED IN RARE OR FANNED OR 

1900
01:21:30,419 --> 01:21:33,322
GENETIC DISEASES IN AREAS OF 

1901
01:21:33,322 --> 01:21:34,590
METABOLISM AND YOU WOULD PERHAPS

1902
01:21:34,590 --> 01:21:37,292
BE DECIDED TO LEARN ABOUT WORK 

1903
01:21:37,292 --> 01:21:40,496
OF BILL WHO IS A SENIOR 

1904
01:21:40,496 --> 01:21:41,697
INVESTIGATOR AND ANOTHER MEMBER 

1905
01:21:41,697 --> 01:21:44,800
OF NATIONAL ACADEMY OF MEDICINE;

1906
01:21:44,800 --> 01:21:46,001
RIGHT?  

1907
01:21:46,001 --> 01:21:48,470
LONG-TIME LEADER OF UNDIAGNOSED 

1908
01:21:48,470 --> 01:21:50,072
DISEASES PROGRAM AND EXPERT IN 

1909
01:21:50,072 --> 01:21:53,709
RARE GENETIC DISORDERS AND 

1910
01:21:53,709 --> 01:21:55,778
FANTASTIC AND NICE GUY TO BOOT. 

1911
01:21:55,778 --> 01:21:58,380
YOU KNOW, BEYOND FANTASTIC HUMAN

1912
01:21:58,380 --> 01:22:02,418
CAPITAL AVAILABLE AT NIH, THERE 

1913
01:22:02,418 --> 01:22:04,119
IS SOME PARTICULAR RESEARCH 

1914
01:22:04,119 --> 01:22:05,554
RESOURCES THAT REALLY SEPARATE 

1915
01:22:05,554 --> 01:22:06,688
US FROM THE CROWD. 

1916
01:22:06,688 --> 01:22:08,590
I'M SURE THAT OTHERS HAVE 

1917
01:22:08,590 --> 01:22:10,592
REMARKED ON THIS EARLIER AND 

1918
01:22:10,592 --> 01:22:11,894
WILL HIGHLIGHT TWO THAT ARE 

1919
01:22:11,894 --> 01:22:16,298
PARTICULARLY RELEVANT I THINK. 

1920
01:22:16,298 --> 01:22:17,933
FIRST, NANOTECHNOLOGY 

1921
01:22:17,933 --> 01:22:19,001
CHARACTERIZATION LAB THAT IS A 

1922
01:22:19,001 --> 01:22:21,837
FACILITY BASED OUT OF NATIONAL 

1923
01:22:21,837 --> 01:22:25,774
LAB IN FRED ERIC MARYLAND 

1924
01:22:25,774 --> 01:22:27,142
PARTNERSHIP FOOD AND DRUG 

1925
01:22:27,142 --> 01:22:28,410
ADMINISTRATION AND NATIONAL 

1926
01:22:28,410 --> 01:22:30,813
INSTITUTES OF STANDARDS AND 

1927
01:22:30,813 --> 01:22:32,247
TECHNOLOGY AND MISSION TO 

1928
01:22:32,247 --> 01:22:34,249
SUPPORT DEVELOPMENT OF 

1929
01:22:34,249 --> 01:22:36,285
NANOTECHNOLOGIES AND HOW YOU 

1930
01:22:36,285 --> 01:22:37,386
LEVERAGE INCREDIBLE CAPABILITIES

1931
01:22:37,386 --> 01:22:39,988
OF NANOSCALE SCIENCE TO ADDRESS 

1932
01:22:39,988 --> 01:22:41,723
PROBLEMS IN MEDICINE?  

1933
01:22:41,723 --> 01:22:44,126
STAFF AT NANOTECHNOLOGY 

1934
01:22:44,126 --> 01:22:45,727
CHARACTERIZATION LAB DEVELOPED 

1935
01:22:45,727 --> 01:22:48,697
AN INCREDIBLY ROBUST ASSAY 

1936
01:22:48,697 --> 01:22:50,699
CASCADE FOR REVIEW OF NEW 

1937
01:22:50,699 --> 01:22:52,401
NANOMATERIALS AND PURPOSE OF 

1938
01:22:52,401 --> 01:22:54,670
THAT IS TO SUPPORT REGULATORY 

1939
01:22:54,670 --> 01:22:56,538
REVIEW OF NANOMEDICINES AND IF 

1940
01:22:56,538 --> 01:22:58,373
YOU ARE A COMPANY OPERATING THIS

1941
01:22:58,373 --> 01:22:59,608
SPACE AND HAVE A NEW MATERIAL 

1942
01:22:59,608 --> 01:23:02,444
YOU CAN WORK WITH NANOTECHNOLOGY

1943
01:23:02,444 --> 01:23:03,912
CHASHGIZATION LAB SUBMITTING 

1944
01:23:03,912 --> 01:23:05,914
MATERIAL FOR REVIEW THAT WILL 

1945
01:23:05,914 --> 01:23:09,318
RETURN YOU TO A TREASURE TROVE 

1946
01:23:09,318 --> 01:23:12,554
OF VALUABLE DATA A RESOURCE THAT

1947
01:23:12,554 --> 01:23:14,056
NEEDS NO INTRODUCTION AND IF YOU

1948
01:23:14,056 --> 01:23:17,726
HAVE BEEN TO NIH CAMPUS IN BETH 

1949
01:23:17,726 --> 01:23:20,662
ES DAH YOU HAVE SEEN THIS 

1950
01:23:20,662 --> 01:23:21,530
BUILDING WORLD'S LARGEST 

1951
01:23:21,530 --> 01:23:26,401
HOSPITAL DEVELOPED IN CLINICAL 

1952
01:23:26,401 --> 01:23:27,269
RESEARCH. 

1953
01:23:27,269 --> 01:23:29,571
1300 PHYSICIANS AND RESEARCHERS 

1954
01:23:29,571 --> 01:23:32,975
AT ANY ONE TIME 1600 ACTIVE 

1955
01:23:32,975 --> 01:23:34,543
ONGOING CLINICAL STUDIES AND 

1956
01:23:34,543 --> 01:23:36,044
ENGAGED IN CLINICAL RESEARCH OR 

1957
01:23:36,044 --> 01:23:38,413
WANT TO BE ENGAGED IN CLINICAL 

1958
01:23:38,413 --> 01:23:41,650
RESEARCH, THIS IS THE PROMISE 

1959
01:23:41,650 --> 01:23:42,618
LAND. 

1960
01:23:42,618 --> 01:23:46,321
NOW, I GUESS AT NO SURPRISE; 

1961
01:23:46,321 --> 01:23:46,989
RIGHT?  

1962
01:23:46,989 --> 01:23:48,824
COMBINING MISSION-DRIVEN 

1963
01:23:48,824 --> 01:23:51,226
ENVIRONMENT WITH NIH FANTASTIC 

1964
01:23:51,226 --> 01:23:55,264
HUMAN CAPITAL AND RESOURCES YOU 

1965
01:23:55,264 --> 01:23:56,732
DESCRIBED CREATING ENVIRONMENT 

1966
01:23:56,732 --> 01:23:59,301
THAT IS RIGHT FOR INNOVATION AND

1967
01:23:59,301 --> 01:24:00,569
HIGHLIGHT THAT HERE LOOKING AT 

1968
01:24:00,569 --> 01:24:03,639
SUMMARY STATISTICS THAT NIH TECH

1969
01:24:03,639 --> 01:24:06,942
TRANSFER PUT OUT IN RECENT 

1970
01:24:06,942 --> 01:24:09,044
REVIEW PERIOD DECADE BETWEEN 

1971
01:24:09,044 --> 01:24:13,282
2012 AND 2022 AND THOSE 

1972
01:24:13,282 --> 01:24:14,516
INTRAMURAL RESEARCHERS DISCLOSED

1973
01:24:14,516 --> 01:24:18,420
TO OFFICES OVER 3,000 NEW 

1974
01:24:18,420 --> 01:24:19,554
INVENTIONS AND TECH TRANSFER 

1975
01:24:19,554 --> 01:24:21,323
OFFICE REVIEWING THESE AND 

1976
01:24:21,323 --> 01:24:23,692
MAKING DECISIONS TO FILE PATENT 

1977
01:24:23,692 --> 01:24:26,161
PROTECTION OVER 1800 TIMES 

1978
01:24:26,161 --> 01:24:27,396
UNITED STATES AND PATENT 

1979
01:24:27,396 --> 01:24:29,831
PORTFOLIO IN THE UNITED STATES 

1980
01:24:29,831 --> 01:24:33,735
IS GLOBAL AND GOES BEYOND US 

1981
01:24:33,735 --> 01:24:38,840
FILINGS WE ARE REFERENCING OVER 

1982
01:24:38,840 --> 01:24:39,308
HERE. 

1983
01:24:39,308 --> 01:24:40,943
WE DON'T SECURE THESE FOR SAKE 

1984
01:24:40,943 --> 01:24:43,045
OF HOLDING PATENT RIGHTS THAT 

1985
01:24:43,045 --> 01:24:45,414
ARE A TOOL TO INCENTIVIZE 

1986
01:24:45,414 --> 01:24:47,950
COMMERCIAL DEVELOPMENT OF 

1987
01:24:47,950 --> 01:24:49,451
INVENTIONS AND TECH TRANSFER 

1988
01:24:49,451 --> 01:24:50,552
OFFICES WORK WITH OUTSIDE 

1989
01:24:50,552 --> 01:24:54,323
PARTIES TO TRANSFER INTELLECTUAL

1990
01:24:54,323 --> 01:24:55,991
PROPERTY AND THAT SCIENTISTS 

1991
01:24:55,991 --> 01:24:58,093
HAVE GENERATED FOR BENEFIT OF 

1992
01:24:58,093 --> 01:24:59,428
PUBLIC THROUGH COMMERCIALIZATION

1993
01:24:59,428 --> 01:25:01,830
AND RESULT OF PRODUCTS 

1994
01:25:01,830 --> 01:25:03,365
ADDRESSING THAT NEED AND SAME 

1995
01:25:03,365 --> 01:25:06,001
TIME PERIOD TECH TRANSFER 

1996
01:25:06,001 --> 01:25:08,870
PRACTICES EXECUTE OVER 3100 

1997
01:25:08,870 --> 01:25:10,572
LICENSES OVER 1,000 

1998
01:25:10,572 --> 01:25:13,475
[INDISCERNIBLE] AND LISTENING TO

1999
01:25:13,475 --> 01:25:16,411
LAST TALK IT IS AMAZING THING TO

2000
01:25:16,411 --> 01:25:19,014
SUPPORT COLLABORATIVE RESEARCH 

2001
01:25:19,014 --> 01:25:20,949
STUDIES WITH SCIENTISTS AND 

2002
01:25:20,949 --> 01:25:23,251
ORGANIZATIONS AND BEYOND THAT 

2003
01:25:23,251 --> 01:25:24,453
OVER 52,000 TRANSACTIONAL 

2004
01:25:24,453 --> 01:25:26,722
AGREEMENTS IN SUPPORT OF THAT 

2005
01:25:26,722 --> 01:25:26,989
MISSION. 

2006
01:25:26,989 --> 01:25:30,058
AND SO I -- OBVIOUSLY THE NIH 

2007
01:25:30,058 --> 01:25:35,297
HAS A WEALTH OF VALUABLE 

2008
01:25:35,297 --> 01:25:37,065
BIOMEDICAL INVENTIONS THROUGH 

2009
01:25:37,065 --> 01:25:39,468
PARTNERSHIPS WITH OUTSIDE 

2010
01:25:39,468 --> 01:25:41,603
INDUSTRY THAT PRODUCTS REACH THE

2011
01:25:41,603 --> 01:25:41,937
MARKET. 

2012
01:25:41,937 --> 01:25:46,274
WE ARE FORTUNATE THAT OVER 39FDA

2013
01:25:46,274 --> 01:25:48,276
APPROVED THERAPIES OR VACCINES 

2014
01:25:48,276 --> 01:25:50,979
HAVE -- HAVE MADE IT ACROSS THAT

2015
01:25:50,979 --> 01:25:51,980
FINISH LINE. 

2016
01:25:51,980 --> 01:25:55,717
I HYLIEKT A FEW OF THEM HERE; 

2017
01:25:55,717 --> 01:25:56,985
RIGHT?  FROM CELL AND GENE 

2018
01:25:56,985 --> 01:25:59,821
THERAPY SPACE AND THAT IS 50% OF

2019
01:25:59,821 --> 01:26:07,262
ALL FDA APPROVED CAR T PRODUCTS 

2020
01:26:07,262 --> 01:26:09,464
HAVE INVENTIONS COMING OUT OF 

2021
01:26:09,464 --> 01:26:13,402
NIH TO GUARDO SIL AND IT IS AN 

2022
01:26:13,402 --> 01:26:14,202
AMAZING BODY OF WORK. 

2023
01:26:14,202 --> 01:26:21,309
ALL RIGHT.  I KNOW THAT IS AN 

2024
01:26:21,309 --> 01:26:22,678
INCREDIBLY WHIRLWIND BENEFIT TO 

2025
01:26:22,678 --> 01:26:25,247
WORKING AT NIH AND CONVINCED YOU

2026
01:26:25,247 --> 01:26:26,882
SHOULD BE WORKING WITH US AND 

2027
01:26:26,882 --> 01:26:28,383
QUESTION IS HOW SHOULD YOU DO 

2028
01:26:28,383 --> 01:26:28,850
IT?  

2029
01:26:28,850 --> 01:26:29,951
QUESTION IS TIMELY. 

2030
01:26:29,951 --> 01:26:33,422
WE ARE HERE TO ADDRESS JUST 

2031
01:26:33,422 --> 01:26:34,523
THAT. 

2032
01:26:34,523 --> 01:26:36,758
NIH TECH TRANSFER OFFICES ARE 

2033
01:26:36,758 --> 01:26:41,129
GATEWAYS TO COLLABORATIONS AND 

2034
01:26:41,129 --> 01:26:41,396
LICENSES. 

2035
01:26:41,396 --> 01:26:44,132
IF YOU START AT THE TOP, RIGHT? 

2036
01:26:44,132 --> 01:26:46,268
THERE IS NIH OFFICE OF 

2037
01:26:46,268 --> 01:26:47,936
TECHNOLOGY TRANSFER THAT IS AT 

2038
01:26:47,936 --> 01:26:52,874
AN NIH LEVEL ABOVE INDIVIDUAL 

2039
01:26:52,874 --> 01:26:54,142
INSTITUTES THAT IS A CENTRAL 

2040
01:26:54,142 --> 01:26:56,545
OFFICE NOT SO MUCH ENGAGED IN 

2041
01:26:56,545 --> 01:26:58,747
DAY-TO-DAY TRANSACTIONAL WORK OF

2042
01:26:58,747 --> 01:27:01,149
TECH TRANSFER PROVIDING CENTRAL 

2043
01:27:01,149 --> 01:27:03,752
RESOURCES TO LOWER INSTITUTE 

2044
01:27:03,752 --> 01:27:07,055
LEVEL TECH TRANSFER OPS MANAGING

2045
01:27:07,055 --> 01:27:09,224
DATA BASES AND SOME ABSOLUTELY 

2046
01:27:09,224 --> 01:27:11,359
CRITICAL FUNCTIONS ALLOWING 

2047
01:27:11,359 --> 01:27:13,628
PROCESSES TO WORK EFFICIENTLY. 

2048
01:27:13,628 --> 01:27:17,532
REAL MEAT OF IT IS THE FOCUS OF 

2049
01:27:17,532 --> 01:27:19,267
INTEREST FOR AN OUTSIDE PARTY 

2050
01:27:19,267 --> 01:27:21,870
THERE ARE 8 INSTITUTE LEVEL TECH

2051
01:27:21,870 --> 01:27:26,041
TRANSFER OFFICES PROVIDING 

2052
01:27:26,041 --> 01:27:28,510
OFFICES FOR CENTERS FOR DISEASE 

2053
01:27:28,510 --> 01:27:30,745
CONTROL AND PREVENTION THAT IS 

2054
01:27:30,745 --> 01:27:35,283
IN 8 OFFICES WORKING WITH IC 

2055
01:27:35,283 --> 01:27:37,419
INVESTIGATORS PATENT RIGHTS NEW 

2056
01:27:37,419 --> 01:27:38,787
INVENTIONS REPORTED TO US 

2057
01:27:38,787 --> 01:27:40,589
LICENSES AND TRANSACTIONAL 

2058
01:27:40,589 --> 01:27:45,293
AGREEMENTS FOR INVESTIGATORS ON 

2059
01:27:45,293 --> 01:27:45,627
THEIR DOCKET. 

2060
01:27:45,627 --> 01:27:47,963
WE DO MANY THINGS AND WANT TO 

2061
01:27:47,963 --> 01:27:49,931
POINT OUT TWO POPULAR AREAS WE 

2062
01:27:49,931 --> 01:27:51,733
DON'T HAVE MUCH ENGAGEMENT. 

2063
01:27:51,733 --> 01:27:53,668
IF INTERESTED IN COMPETITIVE 

2064
01:27:53,668 --> 01:27:56,471
GRANT FUNDING FOR SCIENTIFIC 

2065
01:27:56,471 --> 01:27:59,875
WORK OR IF INTERESTED IN SBR 

2066
01:27:59,875 --> 01:28:01,576
FUNDING, YOU WILL ENGAGE WITH 

2067
01:28:01,576 --> 01:28:03,879
TECH WILL NOT BE PRODUCTIVE. 

2068
01:28:03,879 --> 01:28:05,780
YOU HAVE TO GO TO ANOTHER SPACE.

2069
01:28:05,780 --> 01:28:09,217
OTHER SPACES FOR LICENSING 

2070
01:28:09,217 --> 01:28:10,285
COLLABORATION AND TRANSACTIONAL 

2071
01:28:10,285 --> 01:28:11,653
[INDISCERNIBLE] WE ARE HOME FOR 

2072
01:28:11,653 --> 01:28:13,155
THAT; RIGHT?  

2073
01:28:13,155 --> 01:28:15,690
I MENTIONED 27 INSTITUTES AND 

2074
01:28:15,690 --> 01:28:18,860
CENTERS IN NIH AND CITING 8 TECH

2075
01:28:18,860 --> 01:28:20,529
TRANSFER OFFICES HERE. 

2076
01:28:20,529 --> 01:28:22,030
DON'T WORRY BALANCE OF 

2077
01:28:22,030 --> 01:28:23,932
INSTITUTES SERVICES ARE STILL 

2078
01:28:23,932 --> 01:28:25,667
MET AND STILL PROVIDED FOR THEM 

2079
01:28:25,667 --> 01:28:28,069
AND SMALLER INSTITUTES CONTRACT 

2080
01:28:28,069 --> 01:28:30,305
WITH SOME OF ONE OR MORE LARGER 

2081
01:28:30,305 --> 01:28:32,207
OFFICES TO HAVE SERVICES 

2082
01:28:32,207 --> 01:28:34,609
FULFILLED THAT I HIGHLIGHT 

2083
01:28:34,609 --> 01:28:35,210
INSTITUTES THAT DON'T HAVE 

2084
01:28:35,210 --> 01:28:38,380
OFFICE OF THEIR OWN BUT TECH 

2085
01:28:38,380 --> 01:28:41,283
TRANSFER SERVICES MET THROUGH A 

2086
01:28:41,283 --> 01:28:44,619
LARGER TECH TRANSFER OFFICE. 

2087
01:28:44,619 --> 01:28:48,490
ALL RIGHT.  IF WE GENERALLY ARE 

2088
01:28:48,490 --> 01:28:49,891
ORIENTED WITH TECH TRANSFER 

2089
01:28:49,891 --> 01:28:51,993
STRUCTURE AT NIH AND TALKING 

2090
01:28:51,993 --> 01:28:53,895
ABOUT COMMON SCENARIOS HOW TO 

2091
01:28:53,895 --> 01:28:55,697
ENGAGE WITH OFFICER AND FIND 

2092
01:28:55,697 --> 01:28:57,065
REALLY THE PERSON YOU NEED TO 

2093
01:28:57,065 --> 01:28:59,301
GET TO TO HAVE THE CONVERSATION 

2094
01:28:59,301 --> 01:29:02,170
ABOUT LICENSING OR COLLABORATIVE

2095
01:29:02,170 --> 01:29:02,871
SCIENCE?  

2096
01:29:02,871 --> 01:29:06,007
IN MY MIND TWO MOST COMMON 

2097
01:29:06,007 --> 01:29:07,709
SCENARIOS; RIGHT?  

2098
01:29:07,709 --> 01:29:11,446
FIRST YOU MADE CONTACT WITH NIH 

2099
01:29:11,446 --> 01:29:13,715
PRINCIPAL INVESTIGATOR AND YOU 

2100
01:29:13,715 --> 01:29:16,184
HAD A GOOD DIALOGUE ABOUT WHAT 

2101
01:29:16,184 --> 01:29:17,219
TO DO TOGETHER AND WHAT IS 

2102
01:29:17,219 --> 01:29:18,987
POSSIBLE AND IS ALIGNMENT OF 

2103
01:29:18,987 --> 01:29:21,556
INTEREST AND IN THAT CASE NIH 

2104
01:29:21,556 --> 01:29:23,592
PRINCIPLE INVESTIGATOR IF THEY 

2105
01:29:23,592 --> 01:29:25,627
BELIEVE BENEFIT FROM ENGAGING 

2106
01:29:25,627 --> 01:29:28,463
TECH TRANSFER OFFICER TOOLS WE 

2107
01:29:28,463 --> 01:29:31,466
HAVE THAT WOULD FACILITATE THAT 

2108
01:29:31,466 --> 01:29:32,367
INTERACTION THEY WILL MAKE 

2109
01:29:32,367 --> 01:29:33,969
DEFERRAL TO US.  YOU DON'T HAVE 

2110
01:29:33,969 --> 01:29:35,870
TO DO NAVIGATING THAT WILL REFER

2111
01:29:35,870 --> 01:29:38,406
COMPANY TO US AND WE WILL REACH 

2112
01:29:38,406 --> 01:29:41,710
OUT TO YOU DIRECTLY. 

2113
01:29:41,710 --> 01:29:45,814
THAT IS FAIRLY STRAIGHTFORWARD. 

2114
01:29:45,814 --> 01:29:48,149
SECOND IS IF YOU START COLD AND 

2115
01:29:48,149 --> 01:29:51,286
PERHAPS DON'T HAVE EXISTING 

2116
01:29:51,286 --> 01:29:55,290
RELATIONSHIP WITH NIH PRINCIPLE 

2117
01:29:55,290 --> 01:29:57,158
INVESTIGATOR THEY LEFT NIH AND 

2118
01:29:57,158 --> 01:29:58,693
ARE AT OTHER INSTITUTE AND 

2119
01:29:58,693 --> 01:30:02,130
LOOKING AT PAPER PUBLISHED SOME 

2120
01:30:02,130 --> 01:30:05,033
YEARS AGO AND PATENT FILING OF 

2121
01:30:05,033 --> 01:30:07,435
INTEREST TO YOU AND EXPLORING 

2122
01:30:07,435 --> 01:30:09,137
OPPORTUNITIES TO COLLABORATE AND

2123
01:30:09,137 --> 01:30:10,672
IMPORTANT TO FIND RIGHT TECH 

2124
01:30:10,672 --> 01:30:12,440
TRANSFER PERSON TO TALK TO 

2125
01:30:12,440 --> 01:30:16,745
DEPENDS ON INSTITUTE OR CENTER 

2126
01:30:16,745 --> 01:30:22,150
PI WORKED FOR GOOGLE OR ONLINE 

2127
01:30:22,150 --> 01:30:27,155
SEARCH TOOL AND NAME + NIH WILL 

2128
01:30:27,155 --> 01:30:28,657
POP UP INSTITUTE THEY WORKED FOR

2129
01:30:28,657 --> 01:30:33,361
AND WHAT I LISTED HERE 

2130
01:30:33,361 --> 01:30:34,796
CONVENIENTLY LISTS TECH 

2131
01:30:34,796 --> 01:30:36,164
TRANSPORT FOR INSTITUTE WITHIN 

2132
01:30:36,164 --> 01:30:38,500
NIH GO THERE E-MAIL US MAKE 

2133
01:30:38,500 --> 01:30:39,901
CONNECTION AND LET'S TALK. 

2134
01:30:39,901 --> 01:30:43,271
I THINK TWO SCENARIOS PROBABLY 

2135
01:30:43,271 --> 01:30:45,974
COVER 99.9% OF HOW YOU WOULD GET

2136
01:30:45,974 --> 01:30:48,410
IN TOUCH WITH TECH TRANSFER 

2137
01:30:48,410 --> 01:30:49,077
OFFICE. 

2138
01:30:49,077 --> 01:30:51,813
I WANT TO BE DEFINITIVE HERE AND

2139
01:30:51,813 --> 01:30:53,348
FOR WHATEVER REASON THOSE TWO 

2140
01:30:53,348 --> 01:30:55,283
THINGS DON'T APPLY YOU TO, I 

2141
01:30:55,283 --> 01:30:59,354
HAVE LISTED TWO CONTACTS. 

2142
01:30:59,354 --> 01:31:01,456
IF YOU NEED TO PICK UP THE RED 

2143
01:31:01,456 --> 01:31:03,525
PHONE AND MAKE CONTACT WITH A 

2144
01:31:03,525 --> 01:31:04,893
LIVE INDIVIDUAL WHO CAN HELP TO 

2145
01:31:04,893 --> 01:31:07,295
GET YOU TO THE RIGHT PLACE, 

2146
01:31:07,295 --> 01:31:11,299
THESE ARE PEOPLE TO DO IT. 

2147
01:31:11,299 --> 01:31:14,436
ALL RIGHT.  HOAR A, YOU 

2148
01:31:14,436 --> 01:31:16,705
NAVIGATED ROUGH WATERS MAKING 

2149
01:31:16,705 --> 01:31:17,906
CONTACT WITH TECH TRANSFER AND 

2150
01:31:17,906 --> 01:31:21,409
QUESTION IS WHAT CAN WE DO FOR 

2151
01:31:21,409 --> 01:31:22,544
YOU NOW?  

2152
01:31:22,544 --> 01:31:24,813
WE UNDERSTAND YOUR TIME IS 

2153
01:31:24,813 --> 01:31:26,314
VALUABLE AND WILL START 

2154
01:31:26,314 --> 01:31:27,649
ENGAGEMENT WITH A NEEDS 

2155
01:31:27,649 --> 01:31:28,817
ASSESSMENT AND WILL UNDERSTAND 

2156
01:31:28,817 --> 01:31:31,753
WHAT YOU ARE SEEKING AND WHAT 

2157
01:31:31,753 --> 01:31:33,455
REQUIREMENTS ARE AND WE WILL 

2158
01:31:33,455 --> 01:31:35,990
CRAFT A WORK PRODUCT AROUND THAT

2159
01:31:35,990 --> 01:31:38,093
THAT MEETS NEEDS AND INTERESTED 

2160
01:31:38,093 --> 01:31:39,961
IN SCIENTIFIC COLLABORATION 

2161
01:31:39,961 --> 01:31:42,897
ENGAGING WITH NIH PRINCIPLE 

2162
01:31:42,897 --> 01:31:44,099
INVESTIGATOR TO MAKE SURE THEY 

2163
01:31:44,099 --> 01:31:46,368
ARE INTERESTED AND ALIGNMENT ON 

2164
01:31:46,368 --> 01:31:48,303
RESEARCH OBJECTIVES AND PUTTING 

2165
01:31:48,303 --> 01:31:50,238
AGREEMENT STRUCTURES IN PLACE TO

2166
01:31:50,238 --> 01:31:51,673
SUPPORT SCIENCE INTENDED AND IF 

2167
01:31:51,673 --> 01:31:54,275
YOU DON'T KNOW OR HAVE NOT MADE 

2168
01:31:54,275 --> 01:31:57,212
CONTACT WITH NIHPI AND 

2169
01:31:57,212 --> 01:31:58,780
COLLABORATION IDENTIFYING 

2170
01:31:58,780 --> 01:32:00,815
INTERNAL CHAMPION TO HAVE 

2171
01:32:00,815 --> 01:32:02,751
CONVERSATION AND SEE IF A 

2172
01:32:02,751 --> 01:32:04,586
COLLABORATIVE PROJECT MAKES 

2173
01:32:04,586 --> 01:32:06,087
SENSE AND INTERESTED IN 

2174
01:32:06,087 --> 01:32:07,689
ACCESSING MATERIAL AND 

2175
01:32:07,689 --> 01:32:11,192
INTELLECTUAL PROPERTY WE HAVE 

2176
01:32:11,192 --> 01:32:15,296
VARIETY OF AMECHANISM GREEMENT 

2177
01:32:15,296 --> 01:32:15,997
MECHANISMS. 

2178
01:32:15,997 --> 01:32:17,565
WE WILL FIND AGREEMENT 

2179
01:32:17,565 --> 01:32:18,600
APPROPRIATE FOR CIRCUMSTANCES 

2180
01:32:18,600 --> 01:32:20,869
AND MAKE SURE THAT WE CAN PUT 

2181
01:32:20,869 --> 01:32:24,072
APPROPRIATE TERMS IN PLACE FOR 

2182
01:32:24,072 --> 01:32:34,616
YOU PRACH YOU ARE THINKING BACK 

2183
01:32:37,052 --> 01:32:40,755
TO CONVERSATION WITH FRIENDS 

2184
01:32:40,755 --> 01:32:42,090
BROTHER'S COUSIN RAISED CONCERN 

2185
01:32:42,090 --> 01:32:44,225
ABOUT NIH CAN'T DO X OR WON'T BE

2186
01:32:44,225 --> 01:32:47,228
ABLE TO DO Y; RIGHT?  I THINK 

2187
01:32:47,228 --> 01:32:48,930
THIS IS A GREAT OPPORTUNITY TO 

2188
01:32:48,930 --> 01:32:52,767
CLEAR THE AIR AND TALKING ABOUT 

2189
01:32:52,767 --> 01:32:54,369
PERVASIVE MYTHS OUT THERE. 

2190
01:32:54,369 --> 01:32:59,641
WHAT IS FACT AND REALLY FICTION;

2191
01:32:59,641 --> 01:32:59,908
RIGHT?  

2192
01:32:59,908 --> 01:33:02,610
COMMON MISCONCEPTIONS ABOUT TECH

2193
01:33:02,610 --> 01:33:04,846
TRANSFER, LET'S START WITH 

2194
01:33:04,846 --> 01:33:05,447
LOW-HANGING FRUIT. 

2195
01:33:05,447 --> 01:33:09,451
FIRST NIH ONLY DOES BASIC 

2196
01:33:09,451 --> 01:33:10,885
RESEARCH; RIGHT?  YOU SEE WHERE 

2197
01:33:10,885 --> 01:33:13,655
THIS MIGHT HAVE COME FROM AND 

2198
01:33:13,655 --> 01:33:15,623
INCREDIBLY LARGE FUNDER OF BASIC

2199
01:33:15,623 --> 01:33:18,293
RESEARCHERS ACADEMIC PARTNERS 

2200
01:33:18,293 --> 01:33:19,694
UNDER GRANTS AND HAS BECOME 

2201
01:33:19,694 --> 01:33:21,162
CLEAR THROUGH TODAY'S 

2202
01:33:21,162 --> 01:33:22,297
PRESENTATIONS WE DO MORE THAN 

2203
01:33:22,297 --> 01:33:25,366
THAT AND 6,000 SCIENTISTS AND 

2204
01:33:25,366 --> 01:33:28,670
CLINICIANS ENGAGED IN SPECTRUM 

2205
01:33:28,670 --> 01:33:31,906
OF BIOLOGICAL RESEARCH INCLUDING

2206
01:33:31,906 --> 01:33:34,042
TRANSLATIONAL WORK NIH CENTER IS

2207
01:33:34,042 --> 01:33:36,978
DOING CLINICAL WORK AND WE ARE 

2208
01:33:36,978 --> 01:33:40,415
DOING MORE THAN JUST BASIC 

2209
01:33:40,415 --> 01:33:40,815
RESEARCH. 

2210
01:33:40,815 --> 01:33:42,450
SECOND ONE COMING UP OFTEN IS 

2211
01:33:42,450 --> 01:33:46,087
THAT NIH WORKS WITH ONLY OR 

2212
01:33:46,087 --> 01:33:47,622
PRIMARILY WORKS WITH ACADEMIC 

2213
01:33:47,622 --> 01:33:50,725
ORGANIZATIONS AND COMES PROBABLY

2214
01:33:50,725 --> 01:33:54,095
FROM HISTORY OF GRANT FUNDING TO

2215
01:33:54,095 --> 01:33:54,429
UNIVERSITIES. 

2216
01:33:54,429 --> 01:33:56,397
I MENTIONED IN THE FAST FEW 

2217
01:33:56,397 --> 01:33:58,867
YEARS WE HAVE DONE THOUSANDS OF 

2218
01:33:58,867 --> 01:34:00,869
KREDAS AND LICENSES AND 

2219
01:34:00,869 --> 01:34:02,537
COLLABORATIONS WITHIN INDUSTRY 

2220
01:34:02,537 --> 01:34:05,006
AND 39FDA APPROVED TREATMENTS 

2221
01:34:05,006 --> 01:34:07,542
THAT ARE IN TREATMENTS AND 

2222
01:34:07,542 --> 01:34:09,477
VACCINES THAT ARE PRODUCT OF 

2223
01:34:09,477 --> 01:34:11,279
COLLABORATIONS AND LICENSES 

2224
01:34:11,279 --> 01:34:14,916
WITHIN INDUSTRY AND WE WORK MORE

2225
01:34:14,916 --> 01:34:16,985
WITH ACADEMIC ORGANIZATIONS AND 

2226
01:34:16,985 --> 01:34:20,255
NIH ONLY WORKS WITH DOMESTIC AND

2227
01:34:20,255 --> 01:34:21,789
US-BASED ORGANIZATIONS AND 

2228
01:34:21,789 --> 01:34:23,157
POTENTIALLY YOU CAN SEE WHERE 

2229
01:34:23,157 --> 01:34:25,293
THIS MIGHT COME FROM AND US 

2230
01:34:25,293 --> 01:34:27,295
FEDERAL AGENCY AND SEE MAYBE WE 

2231
01:34:27,295 --> 01:34:29,898
HAVE LIMITATIONS WHO WE CAN WORK

2232
01:34:29,898 --> 01:34:30,098
WITH. 

2233
01:34:30,098 --> 01:34:32,567
FACT IS THAT NIH IS INTERESTED 

2234
01:34:32,567 --> 01:34:34,536
IN DOING GOOD SCIENCE. 

2235
01:34:34,536 --> 01:34:36,204
GOOD SCIENCE CAN BE DONE 

2236
01:34:36,204 --> 01:34:36,471
GLOBALLY. 

2237
01:34:36,471 --> 01:34:38,806
WE PARTNER INTERNATIONALLY AND 

2238
01:34:38,806 --> 01:34:40,708
ON THE LICENSING SIDE OR 

2239
01:34:40,708 --> 01:34:42,644
COMMERCIAL SIDE THERE IS NO 

2240
01:34:42,644 --> 01:34:44,212
STATUTORY PREFERENCE FOR 

2241
01:34:44,212 --> 01:34:46,314
US-BASED COMPANIES IN LICENSING 

2242
01:34:46,314 --> 01:34:48,049
AND STATUTORY PREFERENCE FOR 

2243
01:34:48,049 --> 01:34:48,883
SMALL BUSINESS BUT PREFERENCE IS

2244
01:34:48,883 --> 01:34:51,286
NOT BASED ON WHAT COUNTRY ARE 

2245
01:34:51,286 --> 01:34:53,488
YOU HEADQUARTERED IN?  

2246
01:34:53,488 --> 01:34:56,758
WHERE RESOURCES ARE AVAILABLE TO

2247
01:34:56,758 --> 01:35:00,562
COMPANIES US-BASED OR 

2248
01:35:00,562 --> 01:35:02,230
NON-US-BASED AND NIH IS 

2249
01:35:02,230 --> 01:35:03,364
INTERESTED IN DEVELOPING 

2250
01:35:03,364 --> 01:35:04,866
INTERNAL IDEAS. 

2251
01:35:04,866 --> 01:35:07,268
NO.  IF WE OR SCIENTISTS ARE 

2252
01:35:07,268 --> 01:35:09,204
APPROACHED BY COMPANY OR OUTSIDE

2253
01:35:09,204 --> 01:35:10,305
COLLABORATOR WITH COMPELLING 

2254
01:35:10,305 --> 01:35:12,140
RESEARCH PLAN, THAT COULD BE 

2255
01:35:12,140 --> 01:35:15,376
BASIS OF COLLABORATION OR BASIS 

2256
01:35:15,376 --> 01:35:16,911
OF JOINT SCIENCE PROGRAM. 

2257
01:35:16,911 --> 01:35:18,546
ALL RIGHT.  LET'S TALK ABOUT 

2258
01:35:18,546 --> 01:35:23,117
SOMETHING A LITTLE MORE WEIGHTY.

2259
01:35:23,117 --> 01:35:26,120
RIGHT?  

2260
01:35:26,120 --> 01:35:28,823
NIH'S TECH TRANSFER PRACTICES 

2261
01:35:28,823 --> 01:35:30,124
ARE CUMBERSOME AND TIME 

2262
01:35:30,124 --> 01:35:32,060
CONSUMING CAN'T ALIGN WITH NEEDS

2263
01:35:32,060 --> 01:35:34,095
OF COMMUNITY BECAUSE TIMELINE IS

2264
01:35:34,095 --> 01:35:36,197
SIMPLY TOO LONG; RIGHT?  

2265
01:35:36,197 --> 01:35:37,365
LET'S BREAK IT DOWN. 

2266
01:35:37,365 --> 01:35:40,168
AS I SAID, WE UNDERSTAND TIME IS

2267
01:35:40,168 --> 01:35:41,436
VALUABLE AND WHY WE START WITH 

2268
01:35:41,436 --> 01:35:43,071
NEEDS ASSESSMENT TO UNDERSTAND 

2269
01:35:43,071 --> 01:35:44,973
WHAT YOU NEED AND WHAT ARE 

2270
01:35:44,973 --> 01:35:46,841
REQUIREMENTS OF ENGAGEMENT AND 

2271
01:35:46,841 --> 01:35:48,943
HOW CAN WE BEST MEET THEM?  

2272
01:35:48,943 --> 01:35:53,214
WE INVOLVE THE NIHPI AS 

2273
01:35:53,214 --> 01:35:54,682
APPROPRIATE PARTICULARLY FOR 

2274
01:35:54,682 --> 01:35:55,650
COLLABORATIVE SCIENCE AND 

2275
01:35:55,650 --> 01:35:57,752
ENSURING WE ARE ALIGNED ON 

2276
01:35:57,752 --> 01:35:59,754
INTEREST AND EXPECTATIONS AND AS

2277
01:35:59,754 --> 01:36:03,291
I SAID 50,000 + AGREEMENTS 

2278
01:36:03,291 --> 01:36:04,158
DIDN'T HAPPEN BECAUSE WE DON'T 

2279
01:36:04,158 --> 01:36:06,728
KNOW WHAT WE ARE DOING AND WE 

2280
01:36:06,728 --> 01:36:09,364
ARE TRANSACTION EXPERTS AND 

2281
01:36:09,364 --> 01:36:11,265
MISSION-DRIVEN PROFESSIONALS WE 

2282
01:36:11,265 --> 01:36:12,567
CAN ABSOLUTELY KNOW WHAT IT 

2283
01:36:12,567 --> 01:36:14,836
TAKES TO GET ACROSS THE FINISH 

2284
01:36:14,836 --> 01:36:16,738
LINE AND GET IT DONE IN TIMELY 

2285
01:36:16,738 --> 01:36:19,474
FASHION AND THIS IS AN 

2286
01:36:19,474 --> 01:36:22,844
OPPORTUNITY TO TALK ABOUT WHAT 

2287
01:36:22,844 --> 01:36:24,679
IS CHARACTERIZED AS BEST 

2288
01:36:24,679 --> 01:36:27,015
PRACTICES FOR SUCCESSFUL 

2289
01:36:27,015 --> 01:36:29,984
OUTCOMES AND NO. 1 ENGAGING WITH

2290
01:36:29,984 --> 01:36:31,285
TECH TRANSFER OFFICE UP FRONT 

2291
01:36:31,285 --> 01:36:33,121
AND STARTING ON RIGHT TRACK AND 

2292
01:36:33,121 --> 01:36:34,856
NOT COMMIT TO AGREEMENT FORM 

2293
01:36:34,856 --> 01:36:36,090
WITHOUT THINKING THROUGH FULL 

2294
01:36:36,090 --> 01:36:38,293
SCOPE OF ENGAGEMENT; RIGHT?  

2295
01:36:38,293 --> 01:36:40,161
MAKE SURE WE HAVE AGREEMENT IN 

2296
01:36:40,161 --> 01:36:42,363
PLACE AND NOT WASTING TIME ON 

2297
01:36:42,363 --> 01:36:43,765
USING A MODEL NOT APPROPRIATE 

2298
01:36:43,765 --> 01:36:45,400
FOR THE CIRCUMSTANCES AND OTHER 

2299
01:36:45,400 --> 01:36:47,302
THING ENGAGING WITH IT UP FRONT 

2300
01:36:47,302 --> 01:36:50,271
IT ALLOWS US TO RUN PROCESSES IN

2301
01:36:50,271 --> 01:36:51,439
PARALLEL NOT SERIES. 

2302
01:36:51,439 --> 01:36:53,841
THERE ARE CERTAIN REQUIREMENTS 

2303
01:36:53,841 --> 01:36:56,244
THAT SIMPLY MUST BE MET THAT WE 

2304
01:36:56,244 --> 01:36:57,679
CAN RUN ON THE SIDE WHILE YOU 

2305
01:36:57,679 --> 01:37:01,549
ARE WORKING WITH A PRINCIPLE 

2306
01:37:01,549 --> 01:37:02,684
INVESTIGATOR ON FINALIZING 

2307
01:37:02,684 --> 01:37:03,418
RESEARCH PLAN. 

2308
01:37:03,418 --> 01:37:05,887
WE CAN ARRIVE AT THE END WITH 

2309
01:37:05,887 --> 01:37:07,822
THE NECESSARY TASKS ACCOMPLISHED

2310
01:37:07,822 --> 01:37:09,791
AND WE HAVE TO POSITION TO 

2311
01:37:09,791 --> 01:37:11,192
EXECUTE IN TIME AND MANNER. 

2312
01:37:11,192 --> 01:37:13,127
NEXT THING IS REALLY THE MINDSET

2313
01:37:13,127 --> 01:37:16,731
THAT THE NIH IS NOT A CONTRACT 

2314
01:37:16,731 --> 01:37:17,565
RESEARCH ORGANIZATION. 

2315
01:37:17,565 --> 01:37:18,032
RIGHT?  

2316
01:37:18,032 --> 01:37:20,334
I THINK THAT WE WILL HAVE A MUCH

2317
01:37:20,334 --> 01:37:22,804
MORE PRODUCTIVE DISCUSSION IF 

2318
01:37:22,804 --> 01:37:26,174
PEOPLE WHEN WE ARE ENGAGING WITH

2319
01:37:26,174 --> 01:37:27,308
COMPANIES AND THERE IS AN 

2320
01:37:27,308 --> 01:37:29,210
UNDERSTANDING THIS WILL BE A 

2321
01:37:29,210 --> 01:37:31,579
PARTNERSHIP AND WE ARE NOT A SET

2322
01:37:31,579 --> 01:37:35,483
OF HANDS ON LAB BENCH AND 

2323
01:37:35,483 --> 01:37:36,718
AWAITING INSTRUCTIONS. 

2324
01:37:36,718 --> 01:37:38,820
IT GOES WITHOUT SAYING PER ALL 

2325
01:37:38,820 --> 01:37:41,089
AGREEMENTS THERE ARE TWO PARTIES

2326
01:37:41,089 --> 01:37:43,157
THAT NEED TO COME TO A CONSENSUS

2327
01:37:43,157 --> 01:37:45,159
WE ARE IN POSITION TO EXECUTE. 

2328
01:37:45,159 --> 01:37:46,961
IT IS RARELY THAT ONE SIDE IS 

2329
01:37:46,961 --> 01:37:48,563
ONE THAT IS RESPONSIBLE FOR 

2330
01:37:48,563 --> 01:37:50,331
DELAY AND OTHER SIDE HAD NO 

2331
01:37:50,331 --> 01:37:51,933
INVOLVEMENT MERELY SITTING THERE

2332
01:37:51,933 --> 01:37:54,402
WITH A PEN WAITING TO SIGN; 

2333
01:37:54,402 --> 01:37:54,802
RIGHT?  

2334
01:37:54,802 --> 01:37:58,306
THAT'S -- ALL RIGHT.  NEXT ONE 

2335
01:37:58,306 --> 01:38:02,543
THAT IS OFTEN RAISED THAT NIH IS

2336
01:38:02,543 --> 01:38:04,445
NOT ABLE TO GRANT EXCLUSIVE 

2337
01:38:04,445 --> 01:38:06,280
RIGHTS TO PATENT RIGHTS. 

2338
01:38:06,280 --> 01:38:07,381
THIS IS FALSE. 

2339
01:38:07,381 --> 01:38:09,383
LAW RECOGNIZES CERTAIN 

2340
01:38:09,383 --> 01:38:11,853
SITUATIONS INTELLECTUAL PROPERTY

2341
01:38:11,853 --> 01:38:14,522
OR EXCLUSIVE RIGHTS PROPERTY 

2342
01:38:14,522 --> 01:38:17,125
COULD BE INCENTIVE TO TIME AND 

2343
01:38:17,125 --> 01:38:20,995
CAPITAL AND LABOR NECESSARY FOR 

2344
01:38:20,995 --> 01:38:24,298
PRACTICAL -- THAT ALLOW US TO 

2345
01:38:24,298 --> 01:38:27,201
GRANT EXCLUSIVE LICENSES IN 

2346
01:38:27,201 --> 01:38:27,702
CERTAIN CIRCUMSTANCES. 

2347
01:38:27,702 --> 01:38:30,671
FIRST IS IF YOU ARE NOT WORKING 

2348
01:38:30,671 --> 01:38:32,473
WITH [INDISCERNIBLE] AND SIMPLY 

2349
01:38:32,473 --> 01:38:35,276
SEEKING A LICENSE TO 

2350
01:38:35,276 --> 01:38:36,010
GOVERNMENT-OWNED INTELLECTUAL 

2351
01:38:36,010 --> 01:38:36,511
PROPERTY. 

2352
01:38:36,511 --> 01:38:38,479
WE HAVE ABILITY TO GRANT 

2353
01:38:38,479 --> 01:38:39,680
EXCLUSIVE LICENSE PROVIDED WE 

2354
01:38:39,680 --> 01:38:41,349
MEET AND ARE ABLE TO DETERMINE 

2355
01:38:41,349 --> 01:38:43,518
CERTAIN THINGS PUBLIC BENEFIT 

2356
01:38:43,518 --> 01:38:46,154
RESULTING FROM LICENSE AND 

2357
01:38:46,154 --> 01:38:48,156
EXCLUSIVITY AND REASONABLE 

2358
01:38:48,156 --> 01:38:50,191
INCENTIVE AND SCOPE GRANTING NOT

2359
01:38:50,191 --> 01:38:52,627
MORE REASONABLY NECESSARY AND 

2360
01:38:52,627 --> 01:38:54,495
CREATE ANTITRUST LAW AND ABILITY

2361
01:38:54,495 --> 01:38:56,197
TO DETERMINE THIS WILL COME FROM

2362
01:38:56,197 --> 01:38:58,666
INFORMATION PROVIDED IN LICENSE 

2363
01:38:58,666 --> 01:39:00,168
APPLICATION AND WOULD SAY IN 

2364
01:39:00,168 --> 01:39:03,004
GENERAL THAT THESE CRITERIA ARE 

2365
01:39:03,004 --> 01:39:04,772
OFTEN THAT WHEN INTERESTED OR 

2366
01:39:04,772 --> 01:39:09,277
COMPANY IS DEVELOPING A PRODUCT 

2367
01:39:09,277 --> 01:39:11,245
THAT REQUIRES EXTENSIVE 

2368
01:39:11,245 --> 01:39:13,881
REGULATORY REVIEW OF TREATMENT 

2369
01:39:13,881 --> 01:39:16,851
OR THERAPY OR REGULATED DEVICE 

2370
01:39:16,851 --> 01:39:18,186
AND TIMELINES ARE EXTENDED AND 

2371
01:39:18,186 --> 01:39:20,054
COSTS OF DEVELOPING IT ARE HIGH 

2372
01:39:20,054 --> 01:39:22,423
AND ODDS OF SUCCESS ARE LOW, 

2373
01:39:22,423 --> 01:39:25,159
THERE IS REASONABLE BASIS FOR 

2374
01:39:25,159 --> 01:39:28,930
GRANT OF EXCLUSIVITY IN CASES 

2375
01:39:28,930 --> 01:39:29,864
AND CAN BE. 

2376
01:39:29,864 --> 01:39:33,935
SECOND WORKING IN KREDA AND 

2377
01:39:33,935 --> 01:39:35,703
ALLOWING OPTION LICENSE 

2378
01:39:35,703 --> 01:39:38,172
INVENTIONED DEVELOPED IN KREDA 

2379
01:39:38,172 --> 01:39:40,675
AND TWO STRAIGHTFORWARD 

2380
01:39:40,675 --> 01:39:42,610
MECHANISMS TO OBTAINING 

2381
01:39:42,610 --> 01:39:43,377
EXCLUSIVE LICENSE. 

2382
01:39:43,377 --> 01:39:44,612
>> IF YOU DON'T HAVE
OPPORTUNITY

2383
01:39:44,612 --> 01:39:46,781
TO GO OVER THIS IN DETAIL I WANT

2384
01:39:46,781 --> 01:39:49,917
TO PROVIDE A LIST THAT IS 

2385
01:39:49,917 --> 01:39:50,918
SOMETHING THAT YOU COULD 

2386
01:39:50,918 --> 01:39:57,258
CONSIDER IN SLIDES AT A LATER 

2387
01:39:57,258 --> 01:39:57,558
DATE. 

2388
01:39:57,558 --> 01:40:01,062
I LIST THESE PARTNERS HERE. 

2389
01:40:01,062 --> 01:40:03,464
WOULD BE FANTASTIC TO GO INTO IN

2390
01:40:03,464 --> 01:40:05,066
MORE DETAIL AND IF YOU HAVE 

2391
01:40:05,066 --> 01:40:09,370
QUESTIONS WE CAN ADDRESS IT IN 

2392
01:40:09,370 --> 01:40:14,308
MORE Q & A PORTION AND
FANTASTIC

2393
01:40:14,308 --> 01:40:16,444
ORGANIZATION AND LOVED IT PAST 

2394
01:40:16,444 --> 01:40:19,180
10 YEARS WE HAVE BEEN HERE AND 

2395
01:40:19,180 --> 01:40:21,215
WE ARE A MISSION DRIVEN 

2396
01:40:21,215 --> 01:40:22,283
ORGANIZATION AND SUPPORT BROADER

2397
01:40:22,283 --> 01:40:24,719
MISSION OF NIH BY ALLOWING 

2398
01:40:24,719 --> 01:40:27,288
RESEARCH TO PARTNER WITH 

2399
01:40:27,288 --> 01:40:28,789
EXTERNAL INDUSTRY TO 

2400
01:40:28,789 --> 01:40:30,458
COMMERCIALIZE CUTTING-EDGE 

2401
01:40:30,458 --> 01:40:31,759
MEDICAL RESEARCH THAT WE ASK YOU

2402
01:40:31,759 --> 01:40:33,895
TO REALLY JOIN US ON THIS 

2403
01:40:33,895 --> 01:40:34,428
MISSION. 

2404
01:40:34,428 --> 01:40:35,162
RIGHT?  

2405
01:40:35,162 --> 01:40:37,665
WE WOULD LOVE TO WORK WITH YOU 

2406
01:40:37,665 --> 01:40:40,167
AND I EMPHASIZE TO GET IN TOUCH 

2407
01:40:40,167 --> 01:40:42,003
WITH US.  WE WOULD LOVE TO HEAR 

2408
01:40:42,003 --> 01:40:44,005
FROM YOU AND WEBSITES I LIST 

2409
01:40:44,005 --> 01:40:46,941
HERE SHOW NIH TECHNOLOGIES 

2410
01:40:46,941 --> 01:40:48,109
AVAILABLE FOR LICENSE AND 

2411
01:40:48,109 --> 01:40:51,279
WEBSITE SHOWS AND BRINGS YOU TO 

2412
01:40:51,279 --> 01:40:53,981
NIH INTRAMURAL RESEARCH PAGE 

2413
01:40:53,981 --> 01:40:55,116
LOOKING AT DESCRIPTION OF 

2414
01:40:55,116 --> 01:40:57,385
DIFFERENT SCIENTIFIC RESEARCH 

2415
01:40:57,385 --> 01:40:59,787
PROGRAMS ONGOING IN NIH RESEARCH

2416
01:40:59,787 --> 01:41:01,255
COMMUNITY THAT COULD BE OF 

2417
01:41:01,255 --> 01:41:03,190
INTEREST TO YOU FOR POTENTIAL 

2418
01:41:03,190 --> 01:41:03,557
PARTNERING. 

2419
01:41:03,557 --> 01:41:06,127
WITH THAT, I KNOW WE ARE TIGHT 

2420
01:41:06,127 --> 01:41:08,296
ON TIME AND I'M HAPPY TO STOP 

2421
01:41:08,296 --> 01:41:12,133
AND PROVIDE AN OPPORTUNITY FOR 

2422
01:41:12,133 --> 01:41:20,207
QUESTIONS. 

2423
01:41:20,207 --> 01:41:22,176
>> THIS IS NOT A LOT OF 

2424
01:41:22,176 --> 01:41:23,477
QUESTIONS THAT I PUT A COUPLE IN

2425
01:41:23,477 --> 01:41:25,179
THE CHAT AND NOT SURE IF YOU CAN

2426
01:41:25,179 --> 01:41:25,846
SEE THAT. 

2427
01:41:25,846 --> 01:41:29,317
>> OKAY.  LET'S SEE.  NIH
ACCEPT

2428
01:41:29,317 --> 01:41:32,353
SPONSORED RESEARCH PROGRAMS IF 

2429
01:41:32,353 --> 01:41:32,820
INDUSTRY?  

2430
01:41:32,820 --> 01:41:35,156
WE HAVE A -- IT DEPENDS HOW YOU 

2431
01:41:35,156 --> 01:41:37,158
ARE DEFINING A SPONSORED 

2432
01:41:37,158 --> 01:41:38,359
RESEARCH PROGRAM. 

2433
01:41:38,359 --> 01:41:41,462
WE HAVE A CREATIVE PROGRAM AND 

2434
01:41:41,462 --> 01:41:43,264
HAVE MECHANISMS BY WHICH WE CAN 

2435
01:41:43,264 --> 01:41:44,699
COLLABORATE WITH INDUSTRY AND 

2436
01:41:44,699 --> 01:41:48,302
KREDA ALLOWS US TO DO A 

2437
01:41:48,302 --> 01:41:50,037
COLLABORATIVE PROGRAM AND 

2438
01:41:50,037 --> 01:41:51,472
COLLABORATIVE SCIENTIFIC PROGRAM

2439
01:41:51,472 --> 01:41:53,774
AND ALLOWS US TO RECEIVE FUNDING

2440
01:41:53,774 --> 01:41:56,110
FROM OUTSIDE PARTY IF NECESSARY 

2441
01:41:56,110 --> 01:41:58,412
TO CONDUCT SCIENCE AND OFFER US 

2442
01:41:58,412 --> 01:42:01,449
TO EXCLUSIVE LICENSE THAT IS 

2443
01:42:01,449 --> 01:42:04,852
DEVELOPED UNDER THAT RESEARCH 

2444
01:42:04,852 --> 01:42:05,786
PROGRAM. 

2445
01:42:05,786 --> 01:42:08,856
POTENTIALLY THAT ADDRESSES THE 

2446
01:42:08,856 --> 01:42:10,358
QUESTION THAT IS THRUST THERE. 

2447
01:42:10,358 --> 01:42:12,360
WE HAVE OTHER MECHANISMS 

2448
01:42:12,360 --> 01:42:14,695
ENGAGING WITH INDUSTRY THAT 

2449
01:42:14,695 --> 01:42:16,364
DON'T OFFER SAME BENEFITS YOU 

2450
01:42:16,364 --> 01:42:18,232
WILL SAY; RIGHT?  

2451
01:42:18,232 --> 01:42:19,867
WE CAN SET UP COLLABORATION 

2452
01:42:19,867 --> 01:42:22,570
AGREEMENT ALLOWING TWO-WAY 

2453
01:42:22,570 --> 01:42:23,504
EXCHANGE OF INFORMATION AND 

2454
01:42:23,504 --> 01:42:25,573
MATERIALS ALLOWING PARTIES TO 

2455
01:42:25,573 --> 01:42:27,641
ENGAGE IN COLLABORATIVE SCIENCE.

2456
01:42:27,641 --> 01:42:30,811
LAW DOESN'T ALLOW US TO OFFER 

2457
01:42:30,811 --> 01:42:33,047
EXCLUSIVE LICENSE OPTION AND 

2458
01:42:33,047 --> 01:42:35,116
CAN'T ACCEPT FUNDING UNDER THAT 

2459
01:42:35,116 --> 01:42:37,718
MECHANISM AND PARTIES TO 

2460
01:42:37,718 --> 01:42:38,819
DETERMINE WHICH IS MOST 

2461
01:42:38,819 --> 01:42:40,121
APPROPRIATE FOR CIRCUMSTANCES. 

2462
01:42:40,121 --> 01:42:43,190
>> IF I CAN STEP IN FOR A 

2463
01:42:43,190 --> 01:42:43,424
SECOND. 

2464
01:42:43,424 --> 01:42:43,724
>> PLEASE. 

2465
01:42:43,724 --> 01:42:45,760
>> SPONSORED RESEARCH
AGREEMENTS

2466
01:42:45,760 --> 01:42:47,828
EXIST IN ACADEMIA. 

2467
01:42:47,828 --> 01:42:48,896
NIH DOESN'T DO THAT. 

2468
01:42:48,896 --> 01:42:50,698
WE HAVE TO BE DRIVEN BY OWN 

2469
01:42:50,698 --> 01:42:52,199
MISSION AND DESIRE TO DO 

2470
01:42:52,199 --> 01:42:53,367
RESEARCH PROJECTS. 

2471
01:42:53,367 --> 01:42:54,235
>> YEAH. 

2472
01:42:54,235 --> 01:42:56,971
>> WE WON'T DO
FEE-FOR-SERVICE 

2473
01:42:56,971 --> 01:42:57,204
STUFF. 

2474
01:42:57,204 --> 01:42:59,774
IT IS WHAT OFTEN, YOU KNOW, 

2475
01:42:59,774 --> 01:43:02,910
SPONSORED RESEARCH REFERS TO IN 

2476
01:43:02,910 --> 01:43:03,277
ACADEMIA. 

2477
01:43:03,277 --> 01:43:03,577
>> RIGHT. 

2478
01:43:03,577 --> 01:43:04,378
>> MAKING DISTINCTION. 

2479
01:43:04,378 --> 01:43:06,147
>> THAT IS GOOD.  I
MENTIONED 

2480
01:43:06,147 --> 01:43:08,482
EARLIER WE ARE NOT C ARE.  O.  

2481
01:43:08,482 --> 01:43:10,384
WE ARE LOOKING FOR A PARTNERSHIP

2482
01:43:10,384 --> 01:43:12,319
THIS IS NOT PAY TO PLAY 

2483
01:43:12,319 --> 01:43:13,721
SITUATION YOU ARE PAYING FOR 

2484
01:43:13,721 --> 01:43:15,456
SPECIFIC RESEARCH TO BE DONE AND

2485
01:43:15,456 --> 01:43:17,658
WE SEND YOU RESULTS FROM THE 

2486
01:43:17,658 --> 01:43:18,526
OTHER SIDE.  

2487
01:43:18,526 --> 01:43:19,994
DOESN'T WORK LIKE THAT. 

2488
01:43:19,994 --> 01:43:22,029
>> QUICK COMMENT ON ANDY'S

2489
01:43:22,029 --> 01:43:23,764
REMARK IT IS A MECHANISM THAT 

2490
01:43:23,764 --> 01:43:26,500
SOME RELATIONSHIPS WE CAN'T TAKE

2491
01:43:26,500 --> 01:43:28,903
IN FUNDING WHEN NEEDED.  

2492
01:43:28,903 --> 01:43:30,771
IT IS IMPORTANT TO MENTION THAT 

2493
01:43:30,771 --> 01:43:34,108
WE HAVE AN OVERHEAD RATE THAT IS

2494
01:43:34,108 --> 01:43:35,376
CAPPING 15%. 

2495
01:43:35,376 --> 01:43:36,644
>> UH-HUH. 

2496
01:43:36,644 --> 01:43:42,183
>> 26 TO THE 27 INSTITUTES
HAVE 

2497
01:43:42,183 --> 01:43:46,287
0% OVERHEAD RATE AND INSTANCES 

2498
01:43:46,287 --> 01:43:48,189
REQUESTING FUNDS FROM PARTNERS 

2499
01:43:48,189 --> 01:43:49,824
TO MENTION ALL OR A SIGNIFICANT 

2500
01:43:49,824 --> 01:43:52,460
PORTION OF THE FUNDS WILL GO TO 

2501
01:43:52,460 --> 01:43:54,995
MOVING YOUR PRODUCT FORWARD 

2502
01:43:54,995 --> 01:43:57,364
RATHER THAN OTHER USES. 

2503
01:43:57,364 --> 01:43:57,965
>> SURE. 

2504
01:43:57,965 --> 01:44:00,067
>> IN INTEREST OF TIME WE
ARE A 

2505
01:44:00,067 --> 01:44:00,434
LITTLE OVER. 

2506
01:44:00,434 --> 01:44:02,002
>> OKAY. 

2507
01:44:02,002 --> 01:44:03,904
>> I THINK WE CAN CLOSE
YOUR -- 

2508
01:44:03,904 --> 01:44:06,674
I WANT TO REMIND EVERYBODY THAT 

2509
01:44:06,674 --> 01:44:09,443
WE WILL TAKE A BREAK FOR 30 -- A

2510
01:44:09,443 --> 01:44:10,978
LITTLE LESS THAN 30 MINUTES. 

2511
01:44:10,978 --> 01:44:13,514
WHEN YOU COME BACK YOU WILL 

2512
01:44:13,514 --> 01:44:15,282
ENTER ONE OF THE THREE PANELS 

2513
01:44:15,282 --> 01:44:18,419
THAT ARE CONCURRENT AND START AT

2514
01:44:18,419 --> 01:44:19,019
3:15. 

2515
01:44:19,019 --> 01:44:20,287
PLEASE PICK ONE OF THEM. 

2516
01:44:20,287 --> 01:44:21,956
SOMETIMES YOU MIGHT WANT TO 

2517
01:44:21,956 --> 01:44:22,890
LISTEN TO MORE THAN ONE. 

2518
01:44:22,890 --> 01:44:24,625
YOU CAN DO IT AFTER THE FACT 

2519
01:44:24,625 --> 01:44:28,662
THAT WILL BE AVAILABLE AS VIDEO 

2520
01:44:28,662 --> 01:44:30,664
AND ON DEMAND SAME PLATFORM UP
TO FOUR WEEKS AFTER THIS 

2521
01:44:30,664 --> 01:44:33,934
CONFERENCE COMING BACK PICK A
PANEL AND THEY WILL BE ONE OF 

2522
01:44:33,934 --> 01:44:39,373
THE LAST SESSIONS FOR THE DAY.
THANK YOU, ANDY AND MICHAEL. 

2523
01:44:39,373 --> 01:44:39,874
>> THANK YOU.